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ABSTRACT 
The preamble to this thesis describes the outline of a 
randomized trial which was performed to compare the incidence of 
adverse reactions to ionic high-osmolar and nonionic low-osmolar 
radiographic contrast media given by intravenous injection or 
during cardiac catheterization. The objective of the thesis 
itself is to describe the design, performance and analysis of 
this trial, while discussing methodologic issues that arose and 
flaws that occurred. The thesis will explore the consequences of 
the flaws and will seek to indicate how these might have been 
avoided or how they may be best dealt with now that they have 
occurred. 
Chapter 1 provides a background description of 
radiocontrast media, the history of their development, and an 
explanation of some terms which are used in relation to contrast 
throughout the text. 
Chapter 2 describes the scientific rationale for the study 
to compare the toxicity of ionic high-osmolar and non ionic 
contrast media. The literature review which forms the basis of 
this chapter was performed after the study had been completed. 
However, it is meant to indicate the sort of review which should 
precede the design of any substantial scientific research. 
Chapter 3 describes the research questions which were 
posed. This chapter also outlines the relationship .between the 
questions, existing knowledge about the toxicity of contrast 
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media, and a proposed strategy for the future use of these 
media. 
Chapter 4 deals with the overall design of the trial and 
discusses the rationale for the choice of study population and 
interventions. 
Chapter 5 is concerned with the processes of randomization 
and blinding that were employed in the trial. There were several 
deficiencies in the methods of the trial at this point. These 
are described, along with their possible consequences. Reference 
is made to methods which would have been more appropriate. 
Chapter 6 discusses the choice of outcomes for the trial. 
Once again there were flaws in the methods. These are explored 
in this chapter. The handling of events is also discussed. The 
analysis and statistical methods used in the trial are discussed 
in Chapter 7. 
Chapter 8 prov;ides a general review of the methods of 
economic analyses of health programs. The chapter also discusses 
some existing economic analyses of the use of contrast media and 
outlines a proposed economic analysis which will use data from 
the trial described here. Chapter 9 discusses some ethical 
issues which arose in relation to the current study. 
Chapter 10 summarizes the major methodological issues which 
were considered in the thesis. 
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PREAMBLE 
The objective of this thesis is to discuss methodologic 
issues which arose during the design, performance and analysis 
of a study to compare the adverse effects of two classes of 
radiographic contrast media. The thesis will describe the 
methods of the trial and will indicate flaws therein. The 
possible consequences of these flaws will be discussed. The 
thesis will then outline how these flaws might have been avoided 
and how their effects can be dealt with after the fact. 
Reference will be made to methodology which might have been more 
appropriate. · 
The study upon which this thesis is based was performed 
between 1987 and 1991 at the General Hospital, Health Sciences 
Centre, in St. John's, Newfoundland. The study had the overall 
goal of establishing whether the nonionic low-osmolar 
radiographic contrast media were associated with a lower 
incidence of clinically important adverse events after contrast 
injection than ionic high-osmolar contrast media. 
Since the low-osmolar media are ten times more expensive 
than the high-osmolar media in Canada, there was also interest 
in exploring the cost-effectiveness of the low-osmolar media. 
One question which arose was whether one could limit the 
increase in expenditure on contrast media in a radiology 
department by selecting only high risk individuals to receive 
the low-osmolar media if they were effective in preventing 
adverse events. 
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The reports of the results of the study are attached as 
Appendices A to c, but I will outline the study and it's major 
findings at this stage in order to orient the reader. 
The study was designed as a randomized trial to compare the 
toxic effects of low-osmolar nonionic and high-osmolar ionic 
contrast media during cardiac angiography and intravenous 
injection. All patients having cardiac angiography were eligible 
for the study. Only those with one or more specified "high risk" 
characteristics having intravenous contrast were eligible. The 
study was performed in one hospital over a four year period. The 
randomization was performed separately in the patients having 
intracardiac and intravenous contrast. 
Patients were excluded from the study if no suitable low-
osmolar contrast was available, or at their own request. 
Furthermore the radiologists and cardiologists performing the 
imaging tests excluded others, whom they felt would be at 
excessive risk if given high-osmolar contrast. These patients 
were all followed in the same fashion as those who were 
randomized. 
Simple randomization was employed and most of the outcomes 
of the trial were determined by individuals who were blind to 
the nature of the contrast given. Nevertheless there were flaws 
in the randomization scheme used and complete blinding was not 
achieved. 
At the start of the study it was intended that the primary 
outcome would be the occurrence of a systemic reaction which was 
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severe enough to require therapy. It was intended that those 
having cardiac angiography and those having intravenous contrast 
would be combined for analysis of this outcome. The overall 
sample size estimate was based on this proposed analysis. As the 
trial progressed it became clear that it would be difficult, and 
probably unwise, to combine the patients having cardiac 
angiography with those having intravenous contrast. A separate 
primary outcome was then proposed for those having cardiac 
imaging. This was the occurrence of an adverse event (not 
necessarily systemic) which required therapy. The data upon 
which this outcome was based had been collected prospectively. 
The decision as to whether an outcome of this type had occurred 
was subsequently made by the investigators while blind to the 
type of contrast received. 
As the trial progressed it became apparent that clinically 
important adverse hemodynamic events were occurring with a high 
frequency among those having cardiac angiography. This led to 
the analysis and subsequent termination of that arm of the 
study, while the intravenous arm continued. 
Serial measurement of serum creatinine was employed to 
diagnose cases of contrast-induced renal failure in those with 
pre-existing renal impairment. The patients having intracardiac 
and intravenous contrast were analysed separately and then 
combined for this outcome. The frequency of significant acute 
renal failure after both high and low-osmolar contrast was low. 
The degree of pre-existing renal impairment and the presence of 
12 
diabetes were confirmed as risk factors for the development of 
a deterioration in renal function after contrast. There were 
insufficient patients in the study to allow definitive 
statements about the relative nephrotoxicity of the two classes 
of contrast media. 
The findings of the trial indicated that low-osmolar 
contrast was significantly less likely to cause adverse events 
which led to therapeutic intervention after either intravenous 
or intracardiac injection. For those having cardiac angiography 
the low-osmolar contrast was also associated with a lower 
frequency of arrythmia requiring therapy and a lower frequency 
of significant hypotension. A retrospectively defined 
heterogenous category of prolonged or severe adverse events was 
also less commonly seen after the intracardiac injection of low-
osmolar contrast. Most of the adverse events seen during cardiac 
angiography were cardiovascular in nature and some of these were 
severe enough to require a change in the level of care for the 
patient. The adverse events following intravenous contrast were 
mainly anaphylactoid in type and none were severe enough to 
require intensive treatment or hospitalization. 
The study indicated that severe coronary disease and 
unstable angina were the best independent predictors of risk for 
an adverse event in those having cardiac angiography. A high 
risk group was identified retrospectively among those having 
cardiac imaging using these factors together with risk f~ctors 
for a systemic adverse event. This grouping was then used for a 
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preliminary economic analysis of the selective use of low-
osmolar contrast for cardiac catheterization. 
Risk factors identified for the predominantly anaphylactoid 
adverse events seen in the patients given intravenous contrast 
included a history of prior adverse reaction to contrast, a 
history of allergy, and to a lesser degree cardiac disease, 
severe illness, renal impairment, anxiety, diabetes mellitus and 
asthma. A preliminary economic analysis of the selective use of 
low-osmolar contrast in high risk subgroups defined by some of 
these risk factors was performed. 
I became involved in this study during it's design phase. 
This was soon after commencing my training in Nephrology at the 
Health Sciences Centre in 1987. I had not received any training 
r 
in Clinical Epidemiology or in research design at that point. My 
involvement in this study was one of the factors which 
stimulated me to pursue training in clinical research methods, 
which I began in 1989. Dr. Patrick Parfrey was the coordinator 
of the study and my supervisor throughout this period. Following 
completion of my training in Nephrology in June 1990, I received 
a Fellowship from the Kidney Foundation of Canada, during the 
tenure of which, I played a major role in the analysis and 
reporting of the trial. Almost all of the data were collected 
and entered on computer for analysis by a dedicated group of 
research nurses and assistants without which the study would not 
have been possible. These personnel included Hilary Vavasour, 
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Gloria Kent, Jackie McDonald, Donna Hefferton, Frank O'Dea, and 
Roxanne Corbett. 
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CHAPTER 1 - INTRODUCTION 
Modern radiology is highly dependent on agents known as 
radiographic contrast media. These compounds contain elements of 
high atomic weight which impede the passage of x-rays through 
otherwise radiolucent soft tissues. The contrast media can be 
given in a number of ways. Oral contrast, which may contain 
barium as the radiopaque element, can be used to outline the 
upper two thirds of the gastro-intestinal tract. Contrast media 
may also be given directly into body fluid compartments (as in 
myelography, where contrast is injected into the cerebro-spinal 
fluid), or into blood vessels by bolus injection or infusion. 
For parenteral use iodine usually serves as the radiopaque 
element. The iodine is incorporated into a variety of organic 
chemicals in order to reduce toxicity, improve iodine 
concentration (and thus diagnostic efficacy), and to provide 
diagnostic images with functional significance as the contrast 
is being excreted. An example of the latter use is intravenous 
pyelography. For this procedure the radiocontrast is injected 
intravenously and is then concentrated in the kidney producing 
an image known as a nephrogram. Subsequent excretion of contrast 
in the urine outlines the urinary collecting system, ureters and 
bladder. 
The intravenous pyelogram ( IVP) was one of the first 
successful examinations performed with intravenous contrast. By 
1929 several compounds had been tested in Germany, one of the 
leading countries in organic chemistry at that time. Since then, 
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contrast media have been improved by the addition of more iodine 
atoms per molecule and by alterations in side chains to reduce 
toxicity. The basic pyridine ring was superseded by the benzene 
ring as an iodine carrier, and this feature is found in even the 
most recently developed contrast media. In 1954 sodium 
diatrizoate was introduced (Fig la). Along with its derivatives, 
iothalamate and metrizoate, this compound served as the standard 
medium for intravascular use prior to the advent of the low-
osmolar media in the 1980's. 
One of the problems with sodium diatrizoate and similar 
media is their very high osmolality in solution. This can be as 
high as 2200 mOsmjkg, over 7 times that of human extracellular 
fluid. This results from the requirement to deliver a threshold 
concentration of iodine to achieve opacification and the 
tendency of the compound to undergo ionic dissociation in body 
fluids. The dissociation yields a sodium ion and a diatrizoate 
ion, both of which contribute equally to the osmolality, even 
though the sodium does not enhance opacification. 
Although sodium diatrizoate is relatively non-toxic it can 
cause some adverse reactions when injected into humans. It is 
felt that the toxicity of diatrizoate results from two 
mechanisms. One is an effect of the hyperosmolali ty of the 
solution - so called "osmotoxicity", while the other is an 
intrinsic effect of the chemical structure and its interaction 
with body systems - so called "chemotoxicity". 
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In 1968 Torsten Almen proposed that replacement of the 
ionizing carboxyl group of diatrizoate by a nonionizing group, 
such as an amide, would halve the osmolality of the resulting 
solution without affecting the iodine content. He has recently 
summarized the development of the resulting low-osmolar media 
[Almen (1985)]. The high-osmolar media are also known as 
"ionics" because of their ionization property, and as ratio 1.5 
media because there are 1. 5 iodine atoms per particle in 
solution. The newer low-osmolar media have either a nonionic 
group replacing the carboxyl of diatrizoate (e.g Iopamidol and 
Iohexol Fig 1b and 1c) or are dimers of tri-iodinated benzoic 
acid derivatives, such as Ioxaglic acid (Fig 1d). All of these 
media are ratio 3.0 media and have osmolalities ranging from 600 
mosmjKg (Ioxaglate) to 709 mOsmjKg (Iohexol) [King (1989)]. 
Iohexol, Iopamidol and Ioxaglate were licensed for use by 
the FDA in the United States at the end of 1985, having been 
used in Europe for several years. Development continues, and 
many other compounds, including ratio 6.0 nonionic dimers such 
as Iotrolan, are undergoing preliminary testing [McClennan 
(1987)]. 
FIGURE 1 
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CHAPTER 2 
RATIONALE FOR A STUDY TO COMPARE THE TOXICITY OF IONIC HIGH-
OSMOLAR AND NONIONIC LOW-OSMOLAR RADIOCONTRAST DURING 
INTRAVASCULAR USE 
It is important to review the existing literature about a 
topic carefully and critically prior to planning any scientific 
research. This review process helps to identify which research 
questions need to be answered. Analysis of how others have 
attempted to answer similar questions can also be helpful in 
deciding how to proceed with further research. This chapter will 
review the literature pertaining to the relative toxicity of 
ionic high-osmolar and nonionic low-osmolar radiocontrast agents 
during intravascular use. This particular review was performed 
after the trial which forms the basis for this thesis was 
underway. However, it is meant to represent the sort of review 
which should precede the planning of such a study. 
2.1 The toxicity of ionic high-osmolar media; 
These media have been in widespread clinical use for over 
30 years and considerable experience of their efficacy and 
toxicity has accumulated. These media provide good diagnostic 
images in cases where the patient has been given a full dose and 
cooperates with the examination. 
The toxic effects of these media can be classified in 
several ways. One method, widely used in surveys, is to classify 
reactions to the media in terms of severity. The classes are 
usually designated "mild", "moderate" or "intermediate", 
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"severe", "very severe" and "fatal". These terms lack precision 
and are defined differently in different studies. Comparison of 
event rates between studies is therefore difficult. Another 
disadvantage of such a classification scheme is that it does not 
specify the nature of the adverse event. This is an important 
disadvantage, as different adverse reactions probably have 
different pathogenetic mechanisms, and may be more or less 
likely to be improved by the newer contrast media. 
Contrast related adverse events may also be divided into 
organ-specific and systemic or generalized ~eactions. This is 
more useful as it more clearly reflects the underlying 
pathogenesis and it allows a more accurate description of the 
nature of the adverse reaction. A severity classification can be 
superimposed on this form of classification if desired. 
The route of administration of contrast is important and 
can best be considered in relation to the organ-specific and 
systemic generalized classificatipn scheme. It appears that 
direct exposure of sensitive organs such as the kidney or the 
heart to large doses of radiocontrast will produce specific 
toxic effects in a predictable fashion. An adverse event might 
reasonably seem more likely to occur if the exposed organ is 
already diseased and thus less able to withstand the adverse 
effects of contrast media. Some individuals may also be 
idiosyncratically predisposed to organ specific toxicity, 
although this has not been proven. 
The generalized 
radiocontrast may be 
or systemic 
equally likely 
adverse effects 
regardless of 
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of 
the 
intravascular route of administration chosen. However, these 
effects can generally be divided into those that are at least 
partly predictable and those which are idiosyncratic, 
unpredictable, and possibly severe or fatal. 
Our interest in the general question of contrast toxicity 
arose from the effects of contrast on the kidney. There had been 
considerable controversy in the literature regarding the 
incidence of contrast nephropathy and thus we performed a 
prospective controlled cohort study on this subject [Parfrey 
(1989)]. We studied hospital inpatients with a serum creatinine 
greater than 150 ~mol/1, diabetes mellitus, or both. The study 
group were having intravascular radiocontrast while the control 
group were having abdominal ultrasound or CT scanning without 
contrast. The patients were examined before imaging and the 
serum creatinine was followed for three days to diagnose cases 
of contrast nephropathy. If the serum creatinine rose the 
patients were re-examined, without knowledge of whether contrast 
had been given, to determine whether definite precipitating 
factors for renal failure, other than contrast, were present. 
Using this data we were able to determine the risk for acute 
renal failure attributable to contrast in patients with various 
characteristics. The only group to have an excess of cases with 
an unexplained rise in serum creatinine of greater than 50% 
above baseline after contrast was the group with diabetes and 
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renal impairment. The incidence of such an event in this 
subgroup was 8.8% (95% confidence interval 1.9 to 23.7%). This 
was considerably less than the rates quoted in the literature 
for such patients prior to that. We also found that less severe 
changes in renal function after contrast were uncommon in 
patients with renal impairment alone and in patients with 
diabetes mellitus and normal renal function. After that study 
our interest generalized to the specific effect of contrast on 
other organs, such as the heart, and to the systemic adverse 
effects of contrast media. This interest was timely because of 
the growing controversy about the appropriate use of the new 
nonionic and low-osmolar contrast media. 
2. 2. The pathophysiology of contrast media induced adverse 
events: 
Much work has been done to elucidate the mechanisms of 
contrast toxicity, but in many cases the data are incomplete. 
Based on the proposed mechanisms there are several situations 
where low-osmolar media might have advantages. In-vitro work has 
often shown that low-osmolar media have lesser effects on 
various biochemical and _physiological processes as outlined 
below. Sometimes this work has been extended to animal models 
and even to humans. I will now briefly review what is known 
about the mechanisms of contrast toxicity. I will concentrate on 
systemic toxicity, cardiovascular toxicity, and nephrotoxicity 
as these represent our areas of interest. 
2.2.1. Systemic idiosyncratic reactions: 
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The clinical features of these reactions may include rash, 
urticaria, bronchospasm, facial and laryngeal edema, 
hypotension, shock and death. These features suggest anaphylaxis 
as a mechanism. Anaphylaxis requires sensitization of the body 
to a foreign substance with the formation of IgE antibodies. On 
rechallenge, an IgE mediated release of histamine, serotonin, 
leukotrienes, and other mediators occurs and causes the clinical 
features mentioned above. There is 1 i ttle evidence of IgE 
antibody formation to contrast related antigens in humans 
[Lasser (1968), Lasser (1985), Brasch (1980)]. Recently it has 
been found that patients given both ionic contrast and 
interleukin 2 frequently develop rather severe, but delayed, 
reactions on re-exposure to the contrast [ Zukiwski ( 1990) , 
Oldham (1990)]. It may be that the contrast acts as a hapten and 
the IL-2 promotes an immune response which mediates the later 
reaction in an amnestic fashion. However, this does not 
necessarily indicate that more usual contrast reactions have an 
immunological basis. Nevertheless it is possible that the 
adverse reactions could still· be caused by the mediators of 
anaphylaxis which are being triggered in a non-immunological 
fashion. 
It is known that contrast media can release histamine 
directly [Lasser (1974), Rice (1983), Assem (1983)]. However, 
this occurs only with exposure of basophils to high 
concentrations of contrast in-vitro. Histamine release may be 
more pronounced in patients who have had a prior reaction to 
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contrast but this is not always so [Lasser (1985)]. Hemodynamic 
changes have not correlated with contrast induced increases in 
histamine levels in-vivo [Cogen (1979)]. Nonionic low-osmolar 
media have been shown to release less histamine from basophils 
in-vitro and this might indicate an advantage for these agents 
if histamine is an important mediator of contrast reactions 
[Amon (1989), Salem (1986), Da wson (1985)]. 
Contrast media can activate the complement system in-vitro 
and in-vivo. Direct activation occurs only with higher 
concentrations than occur in-vivo [Lasser (1985)]. It is also 
possible that contrast induced activation of complement is 
indirect, via damage to vascular endothelium [Lasser (1985), 
Grabowski (1989)]. Again, patients who have a history of prior 
reaction to contrast may have unstable complement systems, and 
thus be predisposed to contrast reactions [Greenberger (1984)]. 
However, complement levels may be increased by contrast without 
apparent clinical effect [Greenberger (1984)]. Nonionic low-
osmolar agents appear to have less complement activating effect 
than ionic high-osmolar agents, which may relate to their lower 
osmolarity [Eaton (1990)]. Low-osmolar agents are also less 
toxic to endothelium [Laerum (1985)]. 
Endothelial damage may also activate Factor XII of the 
coagulation system [Lasser (1985), Cohan (1987)]. This in turn 
can activate pre-kallikrein which subsequently produces 
bradykinin. There is some evidence for more rapid pre-kallikrein 
activation in those with a history of prior reaction to contrast 
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but technical problems make this data suspect [Lasser (1985)]. 
The relevance of bradykinin to clinical events, and the effect 
of low-osmolar media have not been explored. 
Lalli has suggested that contrast media, by gaining access 
to the central nervous system, stimulate a neurogenic response, 
which underlies contrast related adverse events [Lalli (1980)]. 
However, the evidence for this hypothesis is only 
circumstantial. Lalli had previously suggested that anxiety 
increased the frequency of reactions to contrast, and that this 
was mediated by higher centres augmenting the supposed contrast 
induced stimulation of the limbic system [Lalli (1974)]. In that 
study he tried to prevent contrast reactions by diazepam or 
hypnosis. Diazepam was ineffective but hypnosis appeared to 
reduce the frequency of contrast induced nausea and vomiting. 
The treatment groups were not randomly assigned, their baseline 
status was not measured, anxiety levels were not assessed and 
outcome assessment was not blind. These flaws in study design 
make interpretation of the results difficult. Whether nonionic 
low-osmolar media could reduce this type of effect has not been 
directly tested. 
In summary, the mechanism of most idiosyncratic 
"anaphylactoid" reactions remains unclear. Even though nonionic 
low-osmolar contrast media do seem to have fewer deleterious 
effects on various physiological systems, it is not clear that 
this actually leads to, a lower frequency, or severity, of 
idiosyncratic reactions when these media are used. 
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2.2.2. Cardiovascular toxicity; 
Although intravenous contrast may have effects on the heart 
[Berg (1973), Pfister (1980), Mancini (1983), Heron (1984)], and 
cardiovascular collapse is a feature of some severe 
idiosyncratic systemic reactions, the direct cardiotoxicity of 
contrast is of most concern during cardiac angiography. Not only 
is the heart exposed to high local concentrations of the drug, 
but these patients are also likely to have cardiac disease and 
are thus less tolerant to a further cardiac insult. The 
cardiovascular effects of contrast media depend upon the site of 
injection, the osmolarity and inherent chemotoxici ty of the 
media in solution, and also on the presence of additives, such 
as sodium, calcium or calcium binding compounds, in the contrast 
formulations [Hirshfeld (1990)]. 
The high osmolarity of ionic media may cause an acute rise 
in plasma volume by up to 20% after intravenous injection [Iseri 
(1965), Huet (1982)]. This, together with the effects of some 
contrast formulations on ventricular contractility as discussed 
below, might be enough to precipitate pulmonary edema during 
ventriculography in those with a predisposition to cardiac 
failure. Low-osmolar agents only increase plasma volume by about 
8% [Dawson (1989)]. 
Hyperosmolar solutions may cause a concentration dependent 
decrease in myocardial contractile force [Kozeny (1985)]. 
However, the degree and direction of the change in contractility 
has varied in studies using nonionic solutions of mannitol or 
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glucose [Newell (1980), Atkins (1973), Wildenthal (1969)]. 
Exposure of the heart to solutions which contain sodium at 
concentrations higher than plasma depresses ventricular 
contractility [Kozeny (1985), Wolf (1973)], but the addition of 
small amounts of sodium to solutions of nonionic contrast media 
attenuated the depression of myocardial contractility that was 
otherwise observed in one study [Baath (1990)]. Solutions which 
bind calcium have negative inotropic activity [Drop (1981)]. 
These facts have to be considered when the cardiac effects of 
different contrast media are being compared. 
All available formulations of ionic contrast media contain 
sodium at a concentration at or above that of plasma whereas 
there is virtually no sodium in the available formulations of 
nonionic media [Hirshfeld (1990)]. Some formulations of high-
osmolar ionic contrast (Renografin-76 and MD-76) contain calcium 
binding additives [Hirshfeld (1990)]. These factors complicate 
interpretation of the literature comparing the cardiovascular 
effects of various contrast media. 
In general» studies have shown that intracoronary injection 
of ionic high-osmolar contrast reduces the contractility of the 
left ventricle. Fleetwood has studied the cardiac effects of 
contrast in an isolated rat heart model [Fleetwood (1990)]. High 
ionic strength was associated with the fall in myocardial 
contractility. Nonionic low-osmolar media had little effect on 
ventricular contractility. The difference between the effect of 
high and low-osmolar contrast on ventricular function is 
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somewhat less evident when non-calcium binding formulations of 
high osmolar contrast are used [Murdock (1984}]. In fact it is 
hard to distinguish between an ionic medium which does not bind 
calcium and a nonionic medium such as metrizamide in terms of 
their effect on ventricular systolic function [Higgins (1978)]. 
Similarly in another study there was little difference between 
the effect of Renografin with added calcium and iohexol 
[Bourdillon (1985)]. Fleetwood et al. did find that coronary 
perfus ion by an ionic medium without calcium binding additives 
(Angiovist 282) caused a greater fall in ventricular 
contractility than did perfusion with nonionic media in the 
Langendorff rat heart model [Fleetwood (1990)]. Klow et al. have 
studied the effects of various contrast media in the dog using 
an acute ischemic heart failure model [Klow (1990)]. They found 
that intracoronary injection of iohexol caused no change, 
i oxaglate a minor change and diatrizoate (as Renografin) a major 
depression in sys tolic contractile function. They did not 
comment on the po$sible role of calcium binding additives in 
relation to their result. 
Relatively few studies comparing intr acoronary injection of 
high and low-osmolar contrast measure the effects on coronary 
tone or blood flow. High osmolarity seemed to be responsible for 
reductions in coronary resistance seen with contrast injection 
in the study by Fleetwood [Fleetwood (1990)]. It is known that 
hypertonic saline may cause coronary vasodilation after 
intracoronary injection [Wolf (1973)]. High-osmolar contrast 
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media exert a similar effect but the degree of vasodilation is 
much l ess marked with nonionic agents [Tragardh (1976), Gerber 
(1982)]. Reductions in coronary tone could shunt blood away from 
areas with fixed stenoses, and thus precipitate distal ischemia. 
The overall hemodynamic response to bolus injection of 
contrast is complex. It depends on the site and rate of 
injection and the interaction of the effects of contrast on 
intravascular volume, myocardial contractility and systemic 
vascular resistance. The cardiac output may rise during coronary 
angiography. This increase in cardiac output is partly due to 
peripheral vasodilation. This in turn may be largely due to 
direct effects of hyperosmolar solutions on blood vessels 
[Marshall (1959), Dawson (1989)], and partly to the release of 
histamine [Dawson (1989)]. The vasodilation is generally 
associated with a fall in blood pressure which tends to return 
to baseline or above in 60 to 90 seconds [Hirshfeld (1983)]. 
These effects are generally less marked when low-osmolar media 
are used [Partridge (1981), steiner (1980), Bettmann (1984), 
Hirshfeld (1989)]. The relative effects of calcium-binding and 
noncalcium-binding formulations of high-os molar media on 
arterial pressure have not been well studied. 
If contrast is injected at moderate rates and volumes into 
the left ventricle the immediate effect is usually a slight 
increase in ventricular volume and stroke volume [Hammermeister 
( 1973)]. The major hemodynamic effect of ventriculography is not 
seen ' until the contrast -reaches the peripheral circulation and 
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causes vasodilation as discussed above. At that point the blood 
pressure usually declines although the cardiac output remains 
high. If significant amounts of contrast reach the coronary 
circulation, and particularly if severe coronary disease is also 
present, the cardiac output may fall due to myocardial 
depression and bradycardia [Hamby (1977)]. 
Intracoronary injection of contrast has been noted to have 
direct and reflex mediated effects on sinoatrial nodal 
automaticity and AV nodal conduction [Higgins (1976), Higgins 
(1977)]. Calcium-binding ionic contrast media cause the most 
severe bradycardia, noncalcium-binding ionic media are 
intermediate in their effects, while nonionic agents cause the 
least slowing of the heart [Piao ( 1990)]. The tendency to 
bradycardia is much more profound following right than left 
coronary artery injections [Piao (1990)]. This is probably due 
to the fact that the blood supply to the sinus and AV nodes is 
from the right coronary artery in the majority of cases. 
Although the resulting bradycardia is usually transient and not 
accompanied by serious hemodynamic change, complete heart block 
and ventricular fibrillation may ensue [Piao (1990)]. 
The repolarization time of the myocardium is prolonged by 
contrast injection, and if this is not homogenous, there is a 
potential for tachyarrythmia and ventricular fibrillation 
[Hayward (1984), Hirshfeld (1990)]. Some of this effect may be 
due to hyperosmolarity [Hayward (1984)]. However, the calcium 
chelating effect of additives in some formulations of high-
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osmolar contrast may also play a role [Murdock (1985), Zukerman 
(1987)]. While excess calcium in coronary blood tends to reduce 
fibrillation threshold, the addition of controlled amounts of 
calcium to calcium-binding formulations of ionic contrast media 
may reduce their tendency to lower the fibrillation threshold 
[Wolf (1980)]. Nonionic contrast may lower the threshold for 
fibrillation to a lesser extent than ionic media [Higgins 
(1985)]. This may translate into a lowered frequency of 
ventricular fibrillation during clinical use [Bashore (1988), 
Missri (1990)]. It should be noted that some of the potentially 
lethal arrythmias seen during angiocardiography may be related 
to procedural factors rather than contrast [Armstrong (1989)]. 
Nonionic media have been found to cause less ECG change 
than ionic media during intracoronary injection in some [Mancini 
(1983), Sullivan (1984)] but not all studies [Salem (1986)]. 
Similarly divergent findings have occurred with intravenous 
injections [Heron (1984), Foster (1987)]. 
In summary there is fairly strong experimental evidence 
that nonionic low-osmolar agents are less cardiotoxic than ionic 
high-osmolar media. The interpretation of much of the existing 
research is difficult given the disparate effects of the 
calcium-binding and noncalcium-binding formulations of high-
osmolar media. The evidence that the lesser perturbation of 
cardiac physiology with nonionic contrast media translates into 
better tolerance in clinical practice will be reviewed in a 
later section. 
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2.2.3. The effects of contrast media on blood components; 
Contrast media are not inert molecules and are capable of 
interaction with many biological structural proteins and 
enzymes. Such interaction may disturb the fine balance of 
integrated physiological processes and this has been termed a 
"chemotoxic effect" of the contrast media [Dawson (1985)]. 
Contrast media cause changes in red cell shape and 
deformability. Hyperosmolar contrast solutions with high ratios 
of contrast to blood induce the formation of "dessicocytes" 
which are similar to those produced by hyperosmolar saline and 
probably result from cellular dehydration [Aspelin (1978)]. Such 
changes are not seen with nonionic agents like metrizamide which 
have lower osmolarity [Aspelin (1978)]. Red cells with 
reversibly changed shape, called echinocytes, are seen even with 
iso-osmolar solutions of contrast media and are more prominent 
with metrizamide than with diatrizoate [Aspelin (1978)]. It has 
been suggested that the alterations in red cell shape result 
from an interaction of the contrast molecules with the surface 
membrane of the red cells [Aspelin (1978)]. The interaction of 
contrast with the surface of red cells may also be responsible 
for the formation of red cell aggregates when contrast is added 
to static blood. This has been observed particularly but not 
exclusively with nonionic media [Dawson (1988), Kimball (1988), 
Zucker (1988), Aspelin (1988)]. The resulting aggregates are 
easily disrupted by shear forces, such as that resulting from 
the injection of the mixture by syringe [Aspelin (1988)]. The 
34 
aggregates do not indicate coagulation and they can be prevented 
by the addition of low concentrations of saline to the blood/ 
contrast mixture [Kimball (1988), Zucker (1988)]. These 
aggregates may not have any clinical relevance. 
Thromboembolism during coronary arteriography is rare but 
can have serious consequences [Davidson (1990)]. Concern has 
been expressed that this complication may be more common when 
nonionic contrast media are used [Grollman (1988)]. It has also 
been suggested that the effect of contr ast media on the 
coagulation system, given it's complexity, may be a good way to 
assess the intrinsic chemotoxicity of contrast molecules 
[Stormorken (1986)]. 
Contrast solutions inhibit the coagulation system in vitro. 
Using global tests of the intrinsic and extrinsic pathways, the 
degree of inhibition has been found to be greater with the ionic 
high-osmolar than with nonionic media [Stormorken (1986)]. Much 
of the inhibition is not explained by either the i onic or 
osmolar strengths of the solutions and has been attributed to a 
direct effect of the contrast molecules [Stormorken (1986)]. 
However, it is uncle ar how blood samples were handled after 
collection in the study by Stormorken [Stormorken (1986)]. It 
has been suggested that when citrate is added to blood before 
contrast, the apparent anticoagulant effect of the contrast only 
reflects an inhibition of fibrin polymerization [Fareed (1990), 
Dawson (1990)]. Alterations in clot structure in the pres ence of 
ionic media indicate that these agents disturb fibrin 
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polymerization [Verebely (1969)]. However, others have shown 
that contrast media do not markedly alter fibrinogen structure 
but that they do block the conversion of fibrinogen to fibrin 
[Andes ( 1988)]. This effect is most marked with ionic media 
[Andes (1988)]. 
Binding of calcium must also be considered as a potential 
explanation for some of the apparent anticoagulant properties of 
ionic high-osmolar media [Morris ( 1982)]. Ionic media have 
actually been shown to be capable of activating the coagulation 
system by contact [Dawson (1989a)]. Nonionic media have been 
shown to allow thrombin generation while still displaying an 
overall anticoagulant effect in vitro [Kopko (1990)]. In 
experimental systems simulating cardiac catheterization nonionic 
media have been found to have less anticoagulant effect than 
ionic media [Hwang (1989), Hwang (1990)]. There seems to be 
agreement from several sources that in vitro nonionic media have 
less net anticoagulant effect than ionic media. However, the 
evidence available from in vivo work does not suggest that the 
coagulation system is disturbed systemically after the injection 
of either ionic or nonionic contrast [Stormorken (1986)]. 
Similarly the evidence is not firm that the lesser effect of 
nonionic media on the coagulation pathway translates into a 
clinically important risk for thromboembolism in patients 
treated with these agents [Davidson (1990)]. 
Contrast media inhibit collagen induced platelet 
aggregation in vitro [Stormorken (1986)]. While ionic and 
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osmolar strength may be more important in determining the degree 
of platelet inhibition than the degree of anticoagulation, there 
are still differences between agents which cannot be explained 
by these factors [Stormorken (1986)]. Grabowski has shown that 
platelet adhesion and aggregation are not inhibited by iohexol 
at a site of endothelial injury [Grabowski (1988)]. However, 
platelet aggregates do not form in the presence of contrast 
without endothelial injury and iohexol causes less alteration in 
endothelial mono layers than does either ioxaglate or diatrizoate 
[Grabowski (1989)]. The available evidence does not directly 
link these effects of contrast observed in vitro to clinical 
thrombotic events. 
2.2.4. Contrast nephropathy; 
This is usually defined as acute renal failure occurring 
after the administration of contrast in the absence of other 
causes of acute renal dysfunction. This definition, together 
with the difficulty in establishing a suitable animal model for 
contrast nephropathy, has hampered study of the frequency and 
pathogenesis of this disorder. Some have even questioned the 
existence of the condition [Katzberg (1989)]. Clinical 
experience does indicate the occurrence of otherwise unexplained 
renal impairment after contrast. The frequency of this event may 
be low, and it may only occur in the presence of other 
contributory factors, but there seems little doubt that the 
condition does exist [Parfrey (1989)]. 
37 
It has been proposed that contrast could damage the kidney 
by: reducing renal blood flow and causing ischemia, a direct 
toxic effect on tubular or glomerular cells, obstruction of the 
tubular lumen by precipitating protein, or a combination of 
these mechanisms [Berns (1989)]. 
Vari studied rabbits in a sodium deplete state [Vari 
(1988)]. Acute renal failure consistently occurred when ionic 
contrast was given together with indomethacin. Neither contrast 
nor indomethacin alone were associated with renal failure in 
this setting. When the sodium deplete state was not present, 
even the combination of contrast and indomethacin was 
insufficient to produce renal failure. Acute saline or mannitol 
infusion was not sufficient to prevent the renal failure in 
sodium deplete animals. These results would seem to indicate 
that, in the rabbit at least, contrast may only be toxic when 
the kidney is exposed to a vasoconstrictive influence and its 
natural compensatory vasodilatory mechanisms are also impaired. 
These authors were unable to identi~y any histological 
correlates of the reduced renal function. Renal blood flow was 
normal even during the. renal failure and there was no evidence 
for tubular obstruction. They found that the fall in glomerular 
filtration rate was due to a fall in the glomerular 
ultrafiltration coefficient. 
Heyman performed a similar study in Sabra rats [Heyman 
( 1988)]. These animals also developed acute renal impairment 
when salt depletion, indomethacin and ionic contrast were 
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combined. Necrosis of the medullary thick ascending limbs, 
tubular collapse and casts, and extensive vacuolization of 
proximal tubular epithelium accompanied the renal failure in 
these animals. There is no obvious explanation of why rats and 
not rabbits display these histological changes. 
Vaamonde sought to induce contrast nephropathy in Sprague-
Dawley rats [Vaamonde ( 1989) ] • They studied rats rendered 
diabetic by streptozotocin and non-diabetic control rats under 
a variety of conditions designed to mimic the risk factors 
associated with contrast nephropathy in humans. They were unable 
to produce acute or delayed renal function changes with ionic 
contrast despite dehydration, partial renal ablation, and 
insulin use [Vaamonde (1989)]. The renal lesion in the rats 
differed from that seen in human diabetic nephropathy however, 
and it is the presence of this condition in patients which is 
associated with the greatest risk of contrast nephropathy 
[Parfrey (1989)]. 
It has been shown that contrast and other hyperosmolar 
solutions can cause a reduction in renal blood flow [Morris 
( 1978)]. This vasoconstrictive response to contrast is only seen 
in the renal vessels. The change is maximal when the contrast is 
given directly into the renal artery. Similar changes of a 
lesser magnitude have been observed with intravenous contrast 
and may be absent with low-osmolar contrast [Russo ( 1990)]. 
Other mechanisms for contrast induced renal ischemia have been 
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reviewed but the relevance of these changes to contrast 
nephropathy remains unclear [Barrett (1991)]. 
The occurrence of enzymuria or tubular proteinuria after 
contrast injection has been taken as evidence of tubular injury 
[Kunin (1978)]. Several studies have compared the high and low-
osmolar media in terms of their tendency to induce such 
enzymuria [Gale (1984), Albrechtsson (1985), Cavaliere (1987), 
Stacul (1987), Skovgaard (1989)]. These have not consistently 
indicated that the low-osmolar media are less toxic and the 
enzymuria did not usually indicate the occurrence of a 
clinically important renal injury. Other evidence for tubular 
toxicity includes the histological demonstration of tubular 
vacuolization associated with contrast in subjects with prior 
renal disease [Moreau (1986)]. This lesion can also be seen with 
low-osmolar contrast and with hyperosmolar solutions other than 
contrast [Allen (1962), Moreau (1986)]. The mechanism of 
production of the lesion is unknown and it does not correlate 
with renal functional impairment. Rabbit proximal tubular cells 
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in-vitro display an impairment in cellular metabolism on 
exposure to diatrizoate, which is aggravated by hypoxia [Humes 
(1987)]. Iopamidol, a low-osmolar agent, was less toxic in this 
system. 
Intratubular precipitation of urinary protein and uric acid 
have been suggested as mechanisms of contrast induced renal 
injury. Contrast media have been shown to precipitate Tamm-
Horsfall protein in-vitro but it is unknown whether this occurs 
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in-vivo [Dawson and Freedman (1984), Dawnay (1985)]. Contrast 
media (especially those used for ch9langiography) are uricosuric 
[Mudge (1971), Postlethwaite (1971)]. However only one case of 
contrast associated renal impairment has been described with the 
pathological changes of acute uric acid nephropathy [Harkonen 
( 1981)]. Allopurinol prophylaxis did prevent the uricosuria, but 
was ineffective in preventing recurrent contrast nephropathy, in 
at least one patient with diabetic nephropathy [Feldman ( 1974)]. 
Thus it remains unclear how contrast may lead to renal 
injury and what other circumstances must prevail for contrast 
nephrotoxicity to be expressed. Although nonionic low-osmolar 
agents have shown some evidence of decreased toxicity when 
compared to high-osmolar media in experimental situations, there 
is insufficient evidence to state that they should be less toxic 
in routine clinical use. 
2.3. The results of surveys of the toxicity of ionic high-
osmolar media: 
Following the initial introduction of sodium diatrizoate 
and related compounds, there were continuing concerns about the 
toxic effects of the then new contrast. There was also concern 
that no adequate means existed to measure the frequency of 
contrast related adverse events in practice. There had been 
several surveys of reactions to previously used media 
[Pendergrass (1942), Pendergrass (1955), Shehadi (1966)]. These 
surveys had been conducted by sending questionnaires to 
radiologists and asking them to describe their previous 
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experience with reactions to contrast. The response rate was low 
in this already selected group. In one study only 38.5% of those 
surveyed supplied useful information [Pendergrass 1955]. Thus 
these surveys were particularly liable to nonrespondent bias 
[Sackett {1979)], and it is possible that severe under-reporting 
could have occurred for minor or moderate level toxicity. An 
under or overestimate of fatalities could have occurred, because 
of inaccuracy in the estimate of either the number of deaths 
recorde d or the number of injections ·performed in the same 
period. 
Table 1 shows data derived from prospective studies of the 
toxicity of ionic contrast published between 1970 and 1990. The 
surveys were multi-institutional except for the two series from 
the Mayo clinic [Witten { 1973), Hartman ( 1982)]. There were 
differing definitions of mild, moderate and severe reactions 
used in the various studies. Mild or minor adverse reactions 
were generally defined as events not requiring therapy but the 
nature of the events was almost never described. Moderate 
reactions were generally treated but seem to include very 
different types of events in the different studies. Severe 
adverse events were similarly diverse but generally required 
intensive treatment in a hospital setting. Some surveys grouped 
the adverse events seen after intravenous and intraarterial 
injections. 
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TABLE 1. THE FREQUENCY OF VARIOUS ADVERSE REACTIONS TO 
HIGH-OSMOLAR CONTRAST IN THE LITERATURE. 
study 
(year) 
Design 
Pendergrass Retro-
(1955) 
Ansell 
(1970) 
spective 
Prospective 
Witten Single 
(1973) institution 
series 
Shehadi Prospective 
(1975) survey 
Investigation 
IVP 
IVP,angio-
graphy 
Outpatient 
IVP 
IVP 
Angiogram 
Reaction class Incidence 
95% CI (%) 
Death 
Moderate 
Severe 
Death 
Minor 
Severe 
Death 
Mild 
Moderate 
Severe 
Death 
Mild 
Moderate 
Severe 
Death 
0.0005-0.001 
0.04-0.05 
0.004-0.01 
0.0008-0.004 
4.9-5.3 
0.06-0.12 
0-0.009 
3.6-3.9 
1.7-1.9 
0.01-0.03 
0.001-0.01 
1.2-1.5 
0.7-0.9 
0.02-0.07 
0.003-0.03 
TABLE 1. contd. 
study 
(year) 
Design Investigation 
Shehadi Prospective · IVP 
(1980) survey 
Ansell Prospective 
(1980) survey 
Hartman Single 
(1982) institution 
series 
Cardiac 
angiography 
IV contrast 
Sample weeks 
Nonsample 
weeks 
IVP 
Reaction class 
Mild 
Moderate 
Severe 
Death 
Mild 
Moderate 
Severe 
Death 
Mild 
Moderate 
Severe 
Moderate 
Severe 
Death 
Death 
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Incidence 
95% CI (%) 
3.3-3.4 
1.3-1.4 
0.04-0.06 
0.002-0.009 
0.7-1.1 
0.8-1.2 
0.2-0.4 
0-0.06 
6.8-8.2 
1.2-1.8 
0.04-0.02 
0.1-0.2 
0.01-0.03 
0.00005-0.005 
0.00003-0.003 
TABLE 1 contd. 
Study 
(year) 
Design 
Lasser RCT steroid 
(1987) prophylaxis 
-placebo 
groups 
Palmer Prospective 
RACR survey 
(1988) 
Investigation Reaction class 
IV contrast 
IV contrast 
"High risk" 
"Low risk" 
Grade 1 
Grade 2 
Grade 3 
Treated reaction 
Mild 
Moderate 
Severe 
Mild 
Moderate 
Severe 
Death 
Wolf Prospective IV contrast Mild 
Moderate 
Severe 
(1989) series 
All treated 
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Incidence 
95% CI (%) 
4.1-5.9 
3.1-4.7 
0.3-0.9 
1.6-2.7 
5.9-8.7 
1.9-3.7 
0.1-0.8 
3.1-3.4 
0.27-0.35 
0.06-0.1 
0-0.006 
2.1-2.9 
0.9-1.5 
0.24-0.56 
1.0-1.6 
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The study reported by Ansell in 1980 is interesting in that it 
discloses one of the problems with the survey type of study 
design [Ansell (1980)]. In that British survey of reactions to 
intravenous contrast over a one year period, the participating 
institutions were asked to report on all examinations and all 
reactions for two randomly selected weeks during the year. For 
the remaining 50 weeks the centres only reported reactions which 
were classified as being at least of moderate severity. As can 
be seen, the event rates were about 10 times higher during the 
two sample weeks as during the 50 non-sample weeks. This could 
either be due to severe under-reporting during the non-sample 
weeks or to over-reporting during the sample weeks. This kind of 
discrepancy throws considerable doubt on the accuracy of such 
survey results. 
Shehadi reported a u.s. survey in 1975 and a further survey, 
including a large cohort of Italian patients, with Toniolo in 
1980 [Shehadi (1975), Shehadi (1980)]. The definitions of 
reactions were the same in both studies and all patients having 
contrast were supposed to be reported. Intravenous and 
intraarterial contrast were studied separately. The event rates 
after IV contrast are very similar in both surveys. However, the 
frequency of mild and moderate reactions after cardiac 
catheterization may have been seriously underestimated, as such 
events occurred much more frequently during our randomized 
trial. The frequency of severe reactions, after cardiac 
catheterization more than tripled from the first to the second 
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survey, while death rates declined. The event rates were low in 
both cases however, and this could represent a chance 
occurrence, a flaw in data reporting, or improved treatment for 
severe reactions. 
The single institution series from the Mayo Clinic, reported 
by Witten and by Hartman, offer the advantages of more 
consistent reporting and the use of consecutive patients [Witten 
(1973), Hartman (1982)]. However, the definitions o~ reactions 
in the paper by Witten are rather diffuse, and I have attempted 
to draw information from the paper in order to make reasonably 
valid comparisons to the rest of the literature. The series 
reported by Hartman extends over an 18 year period and thus the 
effect of changes in practice on the likelihood of a fatal 
outcome to a contrast reaction, as well as changing diagnostic 
definitions, need to be considered. 
In 1987 Lasser reported a randomized trial of steroid 
prophylaxis against reactions to ionic contrast [Lasser (1987)]. 
The rates of reaction quoted in table 1 are derived from all 
placebo patients. The reaction grading system is sensible and 
reflects the largely idiosyncratic, non-organ specific toxicity 
usually associated with intravenous contrast. Some patients with 
a history of prior reaction to contrast were excluded from the 
trial because they would receive steroid prophylaxis anyway. 
This might have reduced the incidence of reactions in the trial 
a little. Given that this trial extended over at least 6 years 
in 27 centres, it is surprising that only 6763 patients were 
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enroled. The baseline characteristics of the study population 
were not described. This leads to some doubts about the 
generalizability of the results. The comparability of the two 
randomized groups at baseline was not established either, which 
leads to questions about the internal validity of the study. 
Nevertheless, the incidence rates for various reactions in the 
placebo groups are largely in keeping with the rest of the 
literature quoted in Table 1. 
The surveys by the Royal Australian College of Radiology 
[Palmer (1988)] and the Japa nese Committee on the Safety of 
Contrast Media [Katayama (1990)] appeared after our own study 
was underway and have been very influential in determining the 
use of nonionic contrast media. Both were prospective surveys 
which sought to compare the incidence of adverse reactions to 
high and low-osmolar contrast. 
Neither of these surveys showed that low-osmolar media 
significantly reduced deaths attributable to contrast. There 
were two deaths following ionic contrast and none following 
nonionic contrast during the RACR survey of 109, 546 
examinations. The Japanese reported one death after both high 
and low-osmolar contrast. Each medium had -been given to about 
150,000 persons. Neither of these deaths were thought to have 
been due to cont rast. Given that death is so infrequently 
attributed to any kind of contrast medium, it would require a 
trial with millions of participants to show conclusively that 
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low-osmolar contrast significantly reduced the incidence of 
contrast related death. 
The RACR and Japanese studies did suggest that the incidence 
of severe reactions was reduced by the use of low-osmolar 
contrast. However there are concerns about how patients were 
selected for entry into these studies and about whether bias 
could have influenced the reporting of adverse events. 
2.4. A review of the evidence that low-osmolar contrast is safer 
than high-osmolar contrast; 
The previous section has given some idea of the scope of the 
problem concerning toxicity of ionic contrast media. The 
nonionic media were first tested for safety in animals. It was 
found that a significantly higher dose {the so called LD 50) of 
nonionic than ionic contrast had to be given to kill 50% of a 
group of mice [Shaw {1985), Felder {1984)]. The in-vitro and 
animal studies cited above, in relation to the mechanisms of 
contrast toxicity, also provided some reasons to expect that 
nonionic media would be less toxic in humans. 
Following the successful animal toxicology stud ies, the 
nonionic media were subjected to study in humans. Much of the 
initial work was carried out in Europe. The nonionic media were 
studied in small open-label studie s and later in blinded 
randomized trials during various applications. I will limit my 
analysis to those studies which dealt with intravascular 
applications. 
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Two large international symposia were held in the United 
states in 1983 and 1984 to review cumulated experience with the 
nonionic agents iohexol and iopamidol. The proceedings were 
published as supplements to Investigative Radiology [Invest 
Radiol 1984;19(5) suppl , Invest Radiol 1985;20(1) suppl]. Both 
ioparnidol and iohexol caused significantly less pain during 
peripheral angiography than ionic high-osmolar media [Bonati 
(1984), Newman (1984), Reidy (1984), Mills (1984), Wolf (1985), 
Dotter (1985)]. Ioxaglate has also been found to reduce pain 
during peripheral angiography [Murphy ( 1988)]. The nonionic 
agents caused smaller changes in heart rate, blood pressure, and 
pulmonary capillary wedge pressure than conventional ionic 
agents during cardiac angiography [ Bettmann ( 1985) , Newman 
(1984), Ciuffo (1984)]. These trials were small however, and did 
not show a significant reduction in clinically important events 
with nonionic media. Patients with severe or unstable cardiac 
disease had generally not been studied to see whether nonionic 
agents provided advantages in such cases. Intravenous iohexol 
for CT scanning or IVP was associated with some reduction in 
mild adverse reactions when compared to high-osmolar media 
[Holtas (1985), Rankin (1985)]. There were similar findings when 
iopamidol was evaluated for CT or digital subtraction 
angiography [Robbins (1984), Ford (1984)]. None of these studies 
established that nonionic contrast could reduce the incidence of 
clinically important reactions to intravenous contrast. 
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Many further studies of the relative toxicity of high and low-
osmolar contrast were performed subsequently. Kinnison, Powe and 
co-workers performed an extensive literature search and reviewed 
all of the randomized trials, comparing high and low-osmolar 
media during intravascular use, which had been published between 
1980 and 1987 [Kinnison (1989)]. Such randomized trials provide 
the strongest evidence by which to compare the clinical toxicity 
of contrast media. 
The studies of contrast toxicity in humans which use non-
experimental designs such as surveys, consecutive series and 
prospective cohort studies, may provide some data on the 
relative toxicity of high and low-osmolar contrast media, but by 
the nature of their design are open to several sources of bias 
[Sackett (1979)]. Sackett defines many such biases in his paper. 
For the sake of brevity I will not define them again but I will 
indicate how a few of them may apply to studies of contrast 
media. 
Centripetal and referral filter biases could have l,ed to 
patients who were at higher than average risk of an adverse 
event being over represented in the study cohorts. This would 
tend to exaggerate the incidence of adverse events reported. 
Diagnostic suspicion bias would be particularly important in 
unblinded comparisons of the incidence of reactions between 
"high risk" groups and others, or between ionic and nonionic 
contrast media. If this bias were operative the degree of risk 
associated with the risk factor, or t,he efficacy of the nonionic 
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contrast, would tend to be exaggerated. Procedure selection bias 
could operate if those patients at the highest risk for a 
contrast reaction were not given contrast or were given 
effective prophylactic therapy. This would tend to reduce the 
apparent incidence of contrast reactions. Missing clinical data 
bias would probably be important in the case of "risk factors". 
An accurate history of allergy, prior contrast reaction etc. may 
not have been taken in all cases, and may well have been 
collected after it was known whether a contrast reaction had 
occurred or not. This would tend to exaggerate the increase in 
risk associated with ·these factors. 
Noncontemporaneous control bias is operative in the surveys by 
the RACR and the Japanese Committee on the Safety of Contrast 
Media [Palmer (1988), Katayama (1990)]. In these surveys the 
patients enroled early were more likely to have received ionic 
contrast, while those enroled later were more likely to have 
received nonionic contrast. Changes in factors other than 
contrast could have been at least partly responsible for the 
apparently lower incidence of adverse events seen with nonionic 
contrast. Therapeutic personality bias would be particularly 
likely to occur in the case of Lalli's work using hypnosis to · 
prevent contrast related adverse events and might well be 
responsible for the apparent efficacy of that intervention 
[Lalli (1974)]. Data dredging bias probably applies to several 
of the surveys, where the influence of dose, speed and route of 
administration of contrast, along with numerous other factors, 
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were tested for association with contrast reactions and may have 
generated some spurious associations between these factors and 
adverse events. 
Thus the results of the non-experimental studies have to be 
treated with caution, as the results can be greatly influenced 
by biases which are unpredictable in the rnagni tude of their 
effects and cannot be controlled for by any post-hoc form of 
analysis. 
While performing a randomized trial does eliminate several 
sources of bias, there are several aspects of trial design that 
need to be considered when interpreting results. In particular, 
for the trials to be valid, subjects should have been truly 
randomly assigned, randomization and outcome assessment should 
have been performed blindly, the randomized groups should have 
been shown to be comparable apart from the intervention being 
tested, patients entered in the trial should all be properly 
handled in the analysis, and the clinical and statistical 
significance of the results should have been considered [Sackett 
(1981}]. For the results to be useful in practice, all 
clinically important outcomes should have been considered, 
patients included in the study should have been representative 
of the type of patients likely to require the intervention in 
practice, and the experimental therapy should have been applied 
in a way whlch is suitable for subsequent use [Sackett (1981)]. 
Chalmers has suggested criteria for evaluation of published 
randomized trials [Chalmers (1981}]. Powe et al. used these 
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criteria to evaluate the randomized trials of low and high-
osmolar contrast media [Powe (1989)]. The instrument developed 
by Chalmers has been widely used but could be criticized as it's 
construct -validity has not been fully established. The 
instrument weights some aspects of study design and analysis in 
arriving at a composite "quality" or "merit" score. The relative 
importance of these various aspects of study design needs to be 
established before the empirically assigned weights can be 
accepted. Nevertheless, the instrument does provide an overall 
assessment of the quality of randomized trials and can certainly 
be useful to point out gross deficiencies of trial design. There 
are two other factors to consider before a discussion of the 
results of the trials of contrast media. The first is that Powe 
et al. limited their analysis to trials which were reported in 
English at some point in time. This might have led to bias in 
their review since most of the early work on the toxicity of 
nonionic contrast was carried out in Europe. However, it is 
significant that no review in English has mentioned landmark 
studies which were only published in other languages. The second 
factor to consider is the general bias which exists against 
publishing negative studies. Many of the published trials 
included only small numbers of patients and it is possible that 
similar studies which had "true", or indeed "false", negative 
results were not published (Detsky {1985)]. This would bias the 
published literature in favour, of nonionic contrast and make 
performance of an adequate meta-analysis of the data difficult. 
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Kinnison et al. identified 100 trials for inclusion in their 
analysis [Kinnison ( 1989) ] . A total of 6 398 patients were 
studied in the 100 trials. The number in each study ranged from 
5 to 435. Thirty two trials used a crossover design. If one 
considers that reactions requiring therapy after ionic contrast 
occur with a frequency of about 2% [Lasser (1987)], then in 
order to exclude a 50% reduction in this incidence with nonionic 
contrast, negative trials would have to include more than 561 
patients per group [Detsky (1985)]. Thus these trials were not 
ne arly large enough to adequately examine such outcomes. This is 
not to say that a positive outcome would be invalid, but rather 
that it would be very unlikely, and a negative outcome would not 
carry much weight. Other adverse events (including those 
measured as continuous variables), which occurred with greater 
frequency, might well be adequately studied by some of the 
trials included in the analysis by Powe. 
Powe found that the larger trials were more likely to have 
been rigorously performed. Recommendations were made by the 
authors of the trials irrespective of their quality. The 
attributes which were most often deficient in the studies were: 
documentation of exclusions, blinding of randomization, blinding 
observers to study results, tests of blinding, prior estimation 
of sample size, use of confidence intervals or mention of power 
post-hoc, assessment of subjective end points by more than one 
observer, documentation of study performance dates, and 
regression analysis of prognostic risk factors. Powe assessed 
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trials as being of "high quality", if they achieved a score of 
forty or more out of a possible 100, using the Chalmers grading 
system. This was close to the mean score of 39 achieved by the 
trials reviewed by Powe and also close to the mean of 42 for 376 
randomized trials of various treatments reviewed by Lam [Lam 
(1987)]. 
Forty one of the trials compared intravenous injection of high 
and low-osmolar media. None of the trials, irrespective of 
quality, demonstrated an advantage with low-osmolar media in 
terms of clinically important renal, cardiovascular or 
laboratory test outcomes. Several studies did document less 
subjective heat, nausea and pain with low-osmolar media. No 
reduction in the incidence of urticaria was demonstrated. 
Thirty four trials evaluated noncardiac intraarterial 
injections. Again these studies did not identify any advantage 
with low-osmolar media in terms of clinically significant renal 
dysfunction, cardiovascular disturbance, laboratory tests or 
urticaria. Low-osmolar media did seem to reduce the frequency of 
pain and warmth. 
There were 25 trials evaluating the media during intracardiac 
injection. The high-osmolar media seemed to be more likely to 
reduce blood pressure, increase heart rate, increase left 
ventricular end diastolic pressure and prolong the QT interval. 
Most of these changes were minor however, and were not of real 
clinical importance. No clear advantage to low-osmolar media was 
identified in terms of arrythmia or renal dysfunction. There was 
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sometimes a reduction in heat, pain, and headache with low-
osmolar contrast. 
In all cases where it was examined, the image quality was as 
good, or better, with low-osmolar as with high-osmolar contrast. 
The trials did not comment on the relationship between patient 
variables (or so called "risk factors") and the incidence of 
adverse events. In fact, very few trials included many patients 
with characteristics which would traditionally have been 
associated with increased risk. Thus this body of data did not 
allow a sound identification of high risk subjects to be made. 
The relative advantage of the low-osmolar media, in subjects at 
higher than average risk, could not be deduced either. 
Powe, Kinnison et al. conclude (as we had in 1987) that 
larger, properly performed, trials were indicated to clarify 
whether low-osmolar media could reduce the frequency of 
clinically important contrast related adverse events. 
CHAPTER 3 
DECIDING THE RESEARCH QUESTIONS 
3.1. The primary guestion: 
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Following a literature review similar to that in the preceding 
chapter, the investigators who performed the trial which is 
discussed in this thesis felt that there was insufficient 
evidence available to indicate that low-osmolar agents were 
safer in many situations. Pursuit of the answer to this question 
would have had scientific merit on its own, but it might not 
have been easy to convince the medical community, or funding 
agencies, of the need for a further study of contrast safety. 
McClennan, in a "state of the art" paper in Radiology in 1987, 
took the view that enough evidence had been accumulated to 
warrant the use of low-osmolar contrast, at least in certain 
subgroups of patients [McClennan (1987)]. Apart from the 
literature to which I have alluded previously, a paper had been 
published describing experience with the use of iohexol for 
intravenous pyelography in a series of 50,660 patients [Schrott 
(1986)]. Fifty two percent of the patients in this series had 
one or more poorly described "risk factors" for an adverse 
reaction to contrast. Despite that, mild reactions occurred in 
2.1%, moderate reactions in 0.9%, severe reactions in 0.01%, and 
there were no fatalities. There was no control group, but these 
figures were substantially lower than those quoted for high-
osmolar contrast (Table 1). Although this study is open to many 
of the biases which I have mentioned above, it does at least 
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suggest that nonionic media might be safer in practice. Based on 
all this evidence, McClennan advised physicians to act as 
advocates for their patients and to encourage more widespread 
use of the nonionic media. 
The major problem preventing widespread use of the new 
contrast media was their high cost. The nonionic media cost 
about 3 to 5 times as much as the ionic high-osmolar media in 
Great Britain and up to twenty times as much as ionic media in 
the United States [Fischer (1986)]. It has been estimated that 
complete replacement of high by low-osmolar media would cost 
about $1 billion per year in the United States alone [Jacobson 
( 1988)]. This price differential caused some authors to question 
the wisdom of universal use of the new media [White ( 1986), 
Parfrey (1988), Evens (1988)]. It was argued that the limited 
resources available might be better spent on other needed forms 
of health care, such as radiological equipment and personnel 
[Grainger (1987)]. This aspect of the introduction of the new 
contrast media threw the question of the relative safety of 
nonionic and ionic contrast into sharp relief and made the need 
for a properly designed trial of the comparative toxicity of the 
contrast agents even more urgent. While several authors were 
sufficiently convinced of the lower toxicity of the nonionic 
agents to recommend their use in at least some situations 
[Dawson (1984), Grainger (1987), McClennan (1987)], there was 
widespread support in the literature for further studies of the 
toxicity of the new media [White (1986), Thompson (1986), 
59 
aettmann (1987), Evens (1988)]. This interest in further 
research has continued during the performance of our trial 
[Bettmann (1990), King (1989)] despite the publication of large 
surveys by the RACR and the Japanese [Palmer (1988), Katayama 
( 1990)]. Some authors now feel that there will be a gradual 
replacement of high-osmolar media by low-osmolar contrast 
despite the high cost [Grainger (1990)]. 
The primary research question is stated in questions 1 and 2 
of section 3.3 below. 
3. 2. Evaluating strategies for selective use of low-osmolar 
contrast; 
Because of the substantial financial implications of universal 
use of the new contrast media several groups have suggested that 
the low-osmolar agents be reserved for certain patients and 
examinations [Grainger (1984), Grainger (1987), Lasser (1987), 
Thompson (1986), Bettmann (1989), Fischer (1986), Dawson 
( 1984)]. Grainger developed a comprehensive set of guidelines on 
behalf of the Royal College of Radiologists in the U.K. 
[Grainger (1984)]. These guidelines suggested that low-osmolar 
contrast be given to all patients who were to undergo 
arteriography which might be painful, and also to patients who 
were at increased risk of adverse reactions to the high-osmolar 
media. It was stated that the "high risk" patients were those 
with a history of prior severe reactions to contrast media, 
allergic subjects, and those with asthma, all of whom were at 
increased risk of an anaphylactoid reaction. Other "high risk" 
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groups were composed of infants and small children, patients 
with renal or cardiac impairment, diabetes, myelomatosis, sickle 
cell anemia or poor hydration, all of whom were felt to be at 
increased risk of an adverse reaction because of the high 
osmolality of the ionic media. In a 1987 article, Grainger also 
mentioned that "elderly" patients were considered to be at 
increased risk and thus should also be given low-osmolar media 
[Grainger (1987)]. Fischer concurred with Grainger's guidelines 
but also added very ill patients to the "high risk" group 
[Fischer (1986)]. McClennan used similar definitions of 
increased risk but specifically defined elderly as being aged 
over 50-60 years [McClennan (1987)]. Bettmann suggested using 
low-osmolar media in those with marked anxiety, and those in 
whom the side effects of pain, nausea and vomiting might be 
dangerous because of underlying cardiac, pulmonary, or nervous 
system disease [ Bettmann ( 1987)]. He suggested low-osmolar 
agents for those with a history of reaction to contrast, asthma, 
or allergies only if time did not permit steroid prophylaxis. He 
also recommended that those with marked cardiac or pulmonary 
disease be given low-osmolar agents, while recognizing that such 
a recommendation was based largely on evidence other than trials 
in humans. Dawson stated that it was his policy to give the low-
osmolar media to infants, elderly, frail, allergic or asthmatic 
patients and to those with cardiac disease [Dawson (1984)]. More 
recently the American College of Radiology have been reported as 
recommending nonionic contrast for painful examinations, those 
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where patient movement is undesirable, and in those with prior 
severe reactions to contrast, strong allergic history, asthma or 
defined severe cardiac disease [King (1989)]. 
There are problems with all of the guidelines however. Several 
questions need to be addressed before guidelines can be accepted 
as useful in practice. I will now discuss each of these 
questions in turn. 
(a) Are patients with the specified characteristics actually 
at increased risk of an adverse event? 
Table 2 shows the relative risk of various types of adverse 
reactions to contrast associated with several characteristics 
that have come to be called "risk factors". These data are 
derived from much of the same literature which was cited in 
Table 1. In most cases the relative risks were calculated by 
dividing the incidence of the specified adverse event in the 
subgroup with the risk factor by the incidence in the remaining 
subjects. The figure quoted from the case control study by 
Enright is actually an odds ratio rather than a relative risk 
[Enright (1989)], 
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TABLE 2. RISK FACTORS FOR VARIOUS ADVERSE REACTIONS TO 
HIGH-OSMOLAR CONTRAST IN THE LITERATURE. 
study Risk factor Type of reaction Relative 
(year) risk 
Ansell Meglumine Bronchospasm 3.5 
(1970) Infusion IVP Moderate 2.5 
n Severe 2.8 
Witten High dose "Acute reaction" 1.6 
(1973) Allergy (incl. asthma " 2.5 
+ prior reaction) 
Asthma 
" 
3.5 
Prior reaction (mild) II 1.04 
Prior reaction (severe) 
" 
20.0 
Shehadi Age > 50 All types 0.8 
(1975) Allergy (incl. " 2.1 
asthma) 
Prior reaction " 3.3 
IVP vs Arteriogram II 2.5 
Slow injection 
" 
1.4 
Ansell Allergy (incl. Mild 1.6 
(1980) asthma) Moderate 2.6 
n Severe 3.9 
Asthma Moderate 2.5 
" 
Severe 5.0 
Prior reaction Mild 6.8 
" 
Moderate 8.7 
TABLE 2 contd. 
study Risk factor 
(year) 
Ansell Prior reaction 
contd. High dose 
Cardiac disease 
" 
" 
" 
Indian race 
Age > 50 
" 
Shehadi IVP vs arteriogram 
(1980) Age > 50 
"Allergy" 
Lasser Prior reaction 
(1987) Allergy 
Youth 
Prior reaction 
Allergy 
High dose 
Enright Allergy 
(1989) 
Moore Diabetes 
(1989) Asthma 
Prior reaction 
Type of reaction 
Severe 
Severe 
Mild 
Moderate 
Severe 
Fatal 
Severe 
Moderate 
severe 
All types 
" 
" 
All reactions 
" 
" 
Treated reactions 
" 
" 
All reactions 
Relative 
risk 
11.0 
2.0 
1.1 
0.9 
4.5 
8.5 
8.0 
0.5 
3.3 
2.1 
0.9 
2.4 
2.4 
1.3 
1.4 
2.5 
1.8 
2.0 
2.0 
Class II/III reaction 2.3 
" 0.6 
" 1.4 
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Assessing a risk factor is in some senses a study of 
prognosis. Such studies should have: assembled an inception 
cohort, described their referral pattern, completed follow up, 
performed objective outcome assessment blindly, and adjusted for 
extraneous prognostic factors [Sackett ( 1985) ] . Most of the 
studies cited in Table 2 are prospective surveys or case series. 
In some ways they represent an inception cohort presenting for 
radiocontrast administration. In almost all cases the referral 
pattern is not described, and indeed we know little about the 
nature of the study population. In some of the studies several 
potential "risk factors" are lumped together, e.g. asthma and 
allergy in the studies by Ansell (1980), Shehadi (1975), and 
Witten (1973). This makes assessment of individual risk factors 
difficult. 
While it is likely that adverse reactions would have occurred 
soon after contrast injection, it is far less likely that 
reporting was consistently complete, and thus follow up cannot 
be said to have been complete. In fact, since the investigators 
almost certainly knew some of the factors which were to be 
examined, they may have been more thorough in their reporting of 
reactions occurring in subjects with "risk factors". This would 
generally exaggerate the apparent strength of the factors as 
predictors of adverse events. In most of the studies rather 
imprecise definitions of adverse events were used. Since these 
often involved some degree of subjective judgement on the part 
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of the investigator, who was generally not blinded, there is 
also a potential for bias in the outcome assessment process. 
It is not clear from most of the reports that the factors of 
interest were identified in advance. This would be important, as 
it would render a type I error more likely in the assessment of 
the statistical significance of the relative risks. Indeed some 
of the studies did not perform any statistical a s sessment of the 
strength of their risk factors at all and none reported 
confidence intervals for the relative risks. It is also clear 
that not all "risk factors" are relevant to all outcomes. In a 
recent study by Moore, one of the outcomes used was a Class 
II/Class III reaction [Moore (1989)]. Such reactions were very 
heterogenous, but were mostly cardiovascular reactions occurring 
during cardiac angiography. Thus it was inappropriate to examine 
IVP's together with cardiac catheterizations and to expect the 
same risk factors to be important in both groups given that they 
had different adverse events. The final problem with the studies 
is that very few used any kind of multi variate technique to 
simultaneously assess the independent strength of the various 
risk factors. Moore used a multiple logistic regression 
technique, but did not identify many risk factors in his study. 
The study population was small however, and no consideration was 
given to power. 
Studies of risk factors can also be thought of as being 
similar to studies of causation in some respects. While the 
contrast exposure is certainly the proximate cause of the 
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contrast reaction, onher characteristics of the examination and 
the patient can be thought of as contributory causes. Although 
some "risk factors" may actually be noncausal associations, the 
guidelines by which a study of causation can be assessed do 
still apply in part [Trout (1981)]. 
The strength of evidence for causation comes in large part 
from the basic study design. The strongest evidence comes from 
randomized trials. There are no trials where ·the supposed "risk 
factors" are randomly assigned. Indeed it would be impossible to 
randomly assign most of them as they represent inherent 
qualities of the subjects being given contrast. Allergy has been 
assessed as a risk factor in a case control study [Enright 
(1989)] and all the other studies are case series or surveys. 
The strength of association is indicated by the relative risk. 
This can be seen to vary depending on the outcome used and the 
risk factor assessed, but there is still some variation between 
studies even when these are taken into account. The strongest 
associations were generally found with allergy, prior reaction 
to contrast, and asthma. Since several of the studies found 
these characteristics to be "risk factors", this supports the 
reality of the associations. Being aged over 50 years was not 
seen to be associated with an increased risk in most studies, 
but was associated with an increased risk of severe adverse 
events [Lasser (1987), Ansell (1980)]. 
The temporal relationship between the "risk factors" and the 
reactions is as would be expected if the "risk factors" were in 
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fact causing the reactions. There are very little data by which 
to assess whether there is a relationship between the severity 
of the "risk factor" and the likelihood of a reaction. Similarly 
it is impossible to say whether the associations make 
epidemiological sense as there are no studies of the relative 
distribution of the "risk factors" and the reactions in 
populations. Several of the associations do make some biological 
sense, as was explained in Chapter 2 when the putative 
mechanisms of contrast toxicity were being discussed. The 
associations are not specific and cannot really be said to be 
analogous to previously proven causal associations. 
Most authors attempt to define risk factors for contrast 
nephropathy separately from those for anaphylactoid reactions. 
Pre-existing renal insufficiency, diabetes, dehydration, old 
age, high dose of contrast, hypertension, congestive heart 
failure, route and site of injection, and myeloma are often 
stated to be risk factors [Berkseth (1984)]. The evidence for 
these is quite weak in most cases. I have previously reviewed 
this topic [Barrett (1991)] and we have studied the effect of 
renal insufficiency and diabetes ourselves [Cramer (1985), 
Parfrey ( 1989)]. It seems that there is an increase in the 
incidence of contrast nephropathy in subjects with pre-existing 
renal insufficiency with or without diabetes. Diabetics with 
normal renal function do not appear to be at increased risk, 
while diabetics with nephropathy probably have the highest risk 
[Parfrey (1989), Manske (1990)]. Dehydration may well be an 
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added risk in some cases, but this is often prevented now by 
hydration of patients before contrast, especially if they have 
other risk factors. The definition of high risk groups for 
contrast nephropathy may be of lesser importance to the strategy 
of selectively giving those at highest risk nonionic contrast 
because there is still little evidence that nonionic contrast is 
les s likely to injure the kidney [Schwab (1989)]. 
(b) Do low-osmolar agents reduce adverse events in selected 
"high risk" patients? 
There have been no studies, other than anecdotal reports, to 
specifically assess the efficacy of nonionic contrast in high 
risk patients. Holtas reported that 17 patients, who had had 
moderate/severe anaphylactoid reactions to ionic contrast in the 
past, received iohexol without adverse effects on up to three 
further occasions each [Holtas (1984)]. This incidence of 0 
events in at least 17 trials yields an upper 95 percent 
confidence limit of about 17 percent for the incidence of 
recurrent anaphylactoid reactions after nonionic contrast in 
this select group with a history of prior reaction to ionic 
contrast [Hanley (1983)]. This is fairly impressive when one 
considers that the incidence of recurrent reactions to ionic 
contrast has been reported to be as high as 35% [Greenberger 
(1985)]. However, Shehadi found that serious reactions may be 
less likely to recur than less severe reactions [Shehadi 
(1982)], while Lalli was able to give a different ionic contrast 
to patients who had a history of prior shock reactions to ionic 
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contrast without any ill effects [Lalli (1975)]. Rapoport also 
found the low-osmolar agent metrizamide to be safe for imaging 
in patients who had a history of severe anaphylactoid reactions 
to ionic contrast [Rapoport (1982)]. All of the patients in this 
study had also received steroid and other prophylaxis. However, 
some of them had had reactions to ionic contrast in the past 
despite similar prophylaxis. These studies only provide weak 
evidence that low-osmolar media are specifically useful in 
patients with previous reactions to contrast. 
After our study had been initiated Feldman et al. demonstrated 
that low-osmolar contrast was beneficial in patients with severe 
or unstable cardiac disease who were undergoing cardiac 
catheterization [Feldman (1988)]. Schrott gave low-osmolar 
contrast to "high risk" subjects of various types and observed 
a low rate of adverse reactions [Schrott (1986)]. This study was 
uncontrolled, however, and therefore relies on historical 
evidence that high-osmolar contrast would have led to more 
adverse reactions. Thus there are very little data available to 
justify the statement that low-osmolar contrast is of particular 
benefit to patients who might be at high risk. 
(c) Can "high risk" patients be identified easily and 
reliably? 
To identify those at high risk before contrast requires that 
the risk can be assessed by a history from the patient if 
possible. Hospital or other records are not always available at 
the time of imaging procedures and, if special tests or 
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examinations are necessary to identify which patients are at 
high risk, it may not be feasible to identify many such 
individuals in practice. While many of the traditionally quoted 
"risk factors" are identifiable by questioning the patient, 
there will almost certainly be differences of opinion as to what 
level of anxiety, what severity of asthma, what sort of allergy 
etc. actually carry a higher risk. This uncertainty must also 
have affected the studies which examined these charac teristics 
as "risk factors" and in most cases there was no attempt to 
clarify what was meant by allergy, asthma etc. This makes it 
virtually impossible to state exactly what degree of risk is 
associated with various levels of most of the existing risk 
factors. 
(d) Does exclusion of a large "low risk" group from the 
receipt of low-osmolar contrast fail to prevent many adverse 
events which continue to occur in the "low risk" group? Is the 
"high risk" group so large that cost savings, due to the use of 
low-osmolar contrast solely in the "high risk" group, are 
minimal? 
The answers to these questions require knowledge of the sort 
of patients being treated in a cardiac catheterization 
laboratory or an X-ray department. This is likely to vary from 
place to place. Goel and colleagues asked their local 
radiologists for estimates of the proportion of the population 
being given contrast who had various "risk factors" [Goel , 
(1989)]. It is not clear how their estimates were made, but it 
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would behove each centre to do a study of their own population 
to assess the likely local cost-effectiveness. 
(e) Can less expensive measures, such as the use of steroid 
prophylaxis, achieve the same result as the use of low-osmolar 
contrast? 
Prior to the trial of steroid prophylaxis reported by Lasser, 
there was no good evidence that any intervention could reduce 
the incidence of contrast related adverse events [Lasser 
(1987)]. Other workers had suggested that prophylaxis with 
medications or by minimization of anxiety could reduce the 
incidence of reactions [Greenberger (1985), Lalli (1975)]. The 
design of these studies precluded confidence in their 
conclusions however. Even though Lasser's study had faults (as 
I have discussed in Chapter 2) it provided reasonable evidence 
that steroid prophylaxis is efficacious. These authors found 
that the incidence of adverse events in their steroid treated 
patients was comparable to that which had been reported by 
Schrott in patients given nonionic contrast [Schrott (1986)]. 
Subsequent! y both Bettmann [ .Bettmann ( 19 8 7 ) ] and Lasser [Lasser 
(1990)] suggested that steroid prophylaxis might be as useful 
as, and cheaper than, the use of non ionic contrast in some 
patients. However there has never been a direct comparison of 
these strategies in any population. 
3.3. A summary of the research questions; 
Based on a review of much of the data discussed above, it was 
felt that several interrelated research questions should be 
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posed. The questions which were specifically addressed by the 
trial being discussed in this thesis were:-
(1) Is nonionic low-osmolar radiocontrast associated with a 
lower incidence of: (a) systemic anaphylactoid adverse reactions 
requiring therapy, (b) contrast nephropathy as defined by an 
unexplained increment in serum creatinine of at least 25% after 
contrast, (c) subjectively severe symptoms as assessed by a 
Likert-like symptom questionnaire completed by the patient 
immediately after imaging and (d) significant changes in heart 
rhythm or blood pressure, when compared to ionic high-osmolar 
radiocontrast given intravenously for CT or IVP in patients 
perceived to be at high risk of an adverse reaction to 
radiocontrast or into the heart during cardiac angiography? 
(2) Is nonionic low-osmolar contrast associated with a lower 
incidence of adverse cardiovascular events which require therapy 
than high-osmolar ionic contrast after intracardiac injection of 
the contrast? 
(3) What is the magnitude of the increased risk associated 
with the characteristics proposed in the literature as risk 
factors for adverse reactions to intravenous or intracardiac 
radiocontrast? 
(4) Are there other demographic or clinical characteristics 
which are associated with an increased risk for the occurrence 
of such adverse reactions to radiocontrast given in~ravenously 
or by intracardiac injection? 
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(5) What is the incremental cost of using nonionic low-osmolar 
contrast rather than ionic high-osmolar contrast for patients of 
the type entered in the trial and, if nonionic contrast is 
effective in preventing adverse events, what does it cost to 
prevent one adverse event of specified type by use of low rather 
than high-osmolar contrast? 
(6) Might the cost-effectiveness of the low-osmolar contrast 
be improved, without risking the occurrence of excessive numbers 
of potentially preventable clini cally important adverse events, 
by the use of low-osmolar contrast only in a selected "high 
risk" population? 
CHAPTER 4 
RESEARCH ARCHITECTURE, INTERVENTIONS AND SUBJECT SELECTION 
4.1. Research architecture: 
74 
The best way to determine if there is a difference between two 
"therapies" in terms of efficacy or toxicity is to administer 
them both to comparable subjects under the same conditions. This 
ensures that any subsequently observed differences between the 
groups are likely to be due to the "therapy" and not some other 
confounding factor. This could be achieved by giving both 
"therapies 11 to the same subject ( s) at one or more different 
times (a crossover design), allowing only chance to determine 
the order of administration. In that situation each subject acts 
as hisjher own control and thus the comparability of the 
subjects receiving each "therapy" is maximized. In trials of 
contrast media each subject is generally treated once and thus 
crossover designs or N-of-one studies [Guyatt (1986)] cannot be 
employed. 
Comparability of the groups receiving ionic high-osmolar and 
nonionic low-osmolar contrast could be achieved by careful and 
extensive matching procedures . .However, it would be difficult to 
arrange that all known prognostically important variables were 
matched and subject selection would become very difficult. It 
would not be possible to arrange matching for unknown 
prognostically important variables at all. To overcome these 
problems random assignment to treatment groups is often 
employed. If large numbers of subjects are randomly assigned to 
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two groups, chance alone should make prognostically important 
variables distribute equally across the groups. The current 
trial was therefore designed as a randomized comparison of low-
osmolar with high-osmolar contrast media. 
4.2. The interventions studied: 
It was decided to compare the toxicity of ionic high-osmolar 
media to that of nonionic low-osmolar media in general. It would 
have been difficult to study specific products separately, as 
the differences between the various nonionic media would almost 
certainly be less than those between nonionic media in general 
and high-osmolar media. In practice the media used were those 
bought under contract by the hospital and the exact compound 
employed varied during the course of the study. 
After the study had been completed we became aware of the 
possible difference between formulations of high-osmolar 
contrast which contain calcium binding additives and those which 
do not, in terms of their tendency to cause ventricular 
fibrillation [Murdock ( 1985), Zukerman ( 1987)]. The high-osmolar 
media used during the trial all contained calcium binding 
additives. However, ventricular fibrillation was only one of the 
clinically significant adverse events occurring less often after 
low-osmolar contrast in the trial. The literature comparing the 
two formulations of high-osmolar media does not contain enough 
data to prove that clinically important adverse reactions, other 
than ventricular fibrillation, are less frequent with 
formulations that do not bind calcium [Murdock (1985), Zukerman 
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( 1987)). The formulations of high-osmolar media which bind 
calcium are still in use for cardiac catheterization. It would 
have been better if the trial had compared non-calcium binding 
formulations of high-osmolar contrast with nonionic agents, but 
the differences that were observed between the high and low-
osmolar media in terms of events other than ventricular 
fibrillation might still have been found. Therefore the 
comparison that was made still has implications for clinical 
practice. 
It was decided not to study ionic low-osmolar media because 
this would have increased the heterogeneity of the interventions 
and there was little reason to suspect that ionic low-osmolar 
media would be less toxic than nonionic media. Ioxaglate, the 
only ionic low-osmolar medium marketed in Canada, is almost as 
expensive as nonionic media and thus there was no financial 
incentive to study it either. 
Patients were randomly assigned to two equal sized groups. One 
group was given whatever ionic high-osmolar agent the doctor 
felt was best suited to the particular examination, while the 
other group was given a nonionic low-osmolar agent. 
4.3. The study sites: 
We were primarily interested in investigating the systemic 
toxicity of the two classes of contrast. We initially intended 
to study patients at the radiology departments of all three 
adult acute care hospitals in the city. This would have had the 
advantage of maximizing the generalizability of the results and 
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our sample size calculations indicated that we needed more 
patients than would be available in the radiology department of 
our own institution alone. It was eventually decided to limit 
the study to the General Hospital radiology department after it 
became clear that we could also study patients having cardiac 
catheterization at that institution and thus achieve our 
projected sample size. 
The decision to study patients having cardiac angiography 
together with those having intravenous contrast was probably not 
sensible. These populations differ substantially in terms of 
their health status and their response to contrast media. The 
difficulties caused by the decision to study these populations 
together are further explored in Chapter 6. 
The site chosen for the trial is the tertiary referral 
university centre for the province. It provided almost all of 
the computed tomographic imaging and all the cardiac angiography 
required by residents of the province during the study period. 
Thus the results in these subgroups at least should be quite 
generalizable. The advantages of a single institution design 
were that the study could be carried out by fewer staff, was 
less costly, and the conduct of the study could be more strictly 
controlled from day to day. All of the cardiologists and 
radiologists working in these departments agreed to participate 
in the study and thus again generalizability was maximized. 
4.4. Selection of the study population; 
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It was decided not to include patients having peripheral 
angiography in the study, as there was already good evidence 
that low-osmolar contrast reduced the pain associated with this 
procedure [Bonati (1984), Newman (1984), Reidy (1984), Mills 
(1984), Wolf (1985), Dotter (1985)]. The same reasoning was 
applied to cerebral angiography. Venography was not excluded 
from the outset, but it was clear from the pilot study that 
relatively few venograms were done and, that as they were often 
arranged as emergencies, it would be difficult for the research 
nurses to enrol patients having this investigation. Furthermore, 
as we did not have facilities to investigate venogram-induced 
thrombosis we felt that our study would be unlikely to influence 
choice of contrast for venography. 
Thus, in the radiology department, eligible subjects were 
drawn from the population presenting for intravenous pyelography 
or for contrast enhanced CT scanning. 
All patients having cardiac angiography without angioplasty 
were eligible. Angioplasty was excluded as it was felt that 
technical factors, rather than contrast, might cause some of the 
adverse events during that procedure and that it would be 
difficult to decide which events were related to contrast and 
which were not. on the rare occasion when subjects were having 
complete angiography prior to a possible angioplasty, they were 
enroled and their involvement terminated prior to the 
commencement of the angioplasty. 
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§.5. Exclusions because of perceived excessive risk with high-
gsroolar contrast. 
Before the trial started it was decided to exclude those with 
a history of severe prior anaphylactoid reaction to contrast. 
This was because the radiologists, and to a lesser extent the 
cardiologists, were uncomfortable with the use of high-osmolar 
agents in such patients. There were some reasons (reviewed in 
chapter 3) to believe that low-osmolar contrast would cause 
fewer subsequent reactions in such patients. The final 
responsibility for deciding whether an individual patient could 
be entered in the randomized trial rested with the radiologist 
or cardiologist performing the imaging. This was necessary to 
allow these doctors to exercise their clinical freedom and to 
use their best judgement when treating an individual patient. 
This meant that the randomized groups were not entirely 
representative of the population presenting for imaging. This 
reduced the generalizability of the trial results. However, the 
internal validity of the trial was not compromised as all 
exclusions were made prior to random assignment of contrast and 
the exclusions could not bias the comparison of the randomized 
groups. 
This selection process operated on a case by case basis and 
was difficult to predict. The participating doctors varied 
between and within themselves with regard to how they decided 
when a patient was sui table for inclusion in the randomized 
trial. There was a tendency to exclude a progressively greater 
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proportion of otherwise eligible patients as the trial 
progressed. This was particularly evident in the intravenous 
stratum where close to 30% of eligible patients were not being 
randomized by the time the trial was stopped. The major reasons 
given for exclusion were: prior reaction to contrast, allergy or 
asthma in the intravenous stratum, and suspected severe cardiac 
disease in the intraarterial stratum. 
The principal investi gators were unable to exert direct 
control over the subject selection process discussed above. 
Every effort was made to ensure that excessive numbers of 
patients were not excluded from randomization. A log was kept of 
all patients approached for primary interview during most of the 
trial. Note was made of how many met the eligibility criteria, 
how many refused randomization, how many were excluded by the 
radiologists and cardiologists, and the reasons for each 
exclusion. This accumulating information was regularly 
communicated to the collaborating physicians. These physicians 
were encouraged to maximize the number of eligible patients 
. 
randomized. Latterly the publication of the results of the 
surveys by the RACR and the Japanese [Palmer (1988), Katayama 
(1990)] were quite influential in determining which patients 
were entered in the intravenous limb of the randomized trial. 
The bias of the participating radiologists in favour of low-
osmolar contrast was strengthened by the results of these 
surveys. This was further augmented by a rather partisan 
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presentation by Professor Palmer of the results of the RACR 
survey during a visit to St. John's. 
The cardiologists also excluded patients from randomization, 
particularly on the basis of suspected severe cardiac disease. 
The proportion of eligible patients not being randomized did not 
seem to increase over time to the same extent in those having 
intracardiac contrast as it did in those having intravenous 
contrast. The emerging evidence favouring low-osmolar contrast 
in subjects with severe cardiac disease [Feldman (1988)] did, 
justifiably, prevent some patients from being randomized. 
4.6. Exclusions because of nonayailability of low-osmolar 
contrast: 
Some patients, who were having CT scans which required a large 
volume of contrast, were not randomized and were given high-
osmolar contrast. This was purely because there was no suitable, 
large volume, vial of low-osmolar contrast available locally 
during the early days of the study. These patients differed in 
some respects from those who were randomly assigned to high-
osmolar contrast. However they appeared to have a similar 
incidence of contrast related adverse events to those who were 
randomized [Appendix B]. 
4.7. Selection of high risk subjects: 
One of the aims of this research was to study the degree of 
increased risk associated with the "high risk" characteristics 
used in the many guidelines proposed by others (see Chapter 3,). 
We wished to know whether it was possible to select a subgroup 
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of patients to preferentially receive nonionic contrast, and 
whether the guidelines suggested by others were optimal in that 
regard. The "risk factors" in the various guidelines included: 
a history of a prior reaction to contrast, a history of allergy, 
asthma, cardiac or renal impairment, diabetes, excessive anxiety 
and severe illness. To study these factors adequately one would 
ideally like to study all those having contrast enhanced imaging 
and then compare the incidence of adverse events in those with 
and without the various "high risk" factors. 
However, the grant for this study did not cover the cost of 
contrast. If all patients attending for x-ray with contrast had 
been included in the study there would have been a substantial 
increase in the use of low-osmolar contrast, with an attendant 
increase in expenditure in the radiology department. It was felt 
that the department would not be able to afford to pay for the 
contrast for all those subjects. Therefore a decision had to be 
made as to how best to limit the use of low-osmolar contrast 
without compromising the major objective of determining the 
relative toxicity of high and low-osmolar contrast. If a 
clinically important benefit was not discernable amongst high 
risk patients, it was felt that it would be quite unlikely that 
such a benefit would be seen in a low risk group. 
The estimated sample size (see Chapter 5) for the trial was 
large. Enrolment could not be limited to a proportion of 
eligible subjects in order to spread the cost of the, low-osmolar 
contrast over a longer period, as to do so would have made the 
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duration of the study too long and would have introduced a 
possibility for bias in subject selection. Since the incidence 
of adverse reactions to contrast was likely to be lower in those 
without any "risk factors" it was decided to exclude &Uch 
subjects. While this increased the likelihood of an event in 
those who entered the trial, and thus tended to reduce the 
required sample size, it complicated the assessment of the 
relative risk associated with various risk factors. 
However, we hypothesized that several of the "risk factors" 
would not turn out to be very important. In particular it seemed 
• likely that subjects who were aged over 50 years, but who had no 
other risk factors, would not have an excessive incidence of 
adverse events. Therefore we reasoned that if the incidence of 
adverse events did turn out to be lower in this subgroup than in 
others, that they could serve as a reasonable population against 
which to judge the effect of the other "risk factors". This 
approach was obviously not ideal as it would be impossible to 
say directly whether the observed incidence of adverse reactions 
in the subgroup aged over 50 was above or below that seen in 
other individuals felt not to be at increased risk. However, 
some information on the av.erage incidence of specific adverse 
outcomes was available from the literature and served to compare 
with the observed incidence in our subgroup aged over 50 years. 
All patients having cardiac angiography were eligible 
irrespective of whether or not they had ~ny of the above "risk 
factors". This was because we were interested to know whether 
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those without cardiac disease at angiography would have as great 
an incidence of cardiovascular side-effects as those who had 
cardiac disease. In this way we could directly verify whether 
cardiac disease increased the risk of an adverse cardiovascular 
event after intraarterial contrast. It would also have been 
impossible to reliably identify those without cardiac disease 
for exclusion before the results of the cardiac catheterization 
were known. 
one of th~ difficulties with deciding the eligibility criteria 
for this trial was deciding how to define each of the so called 
"risk factors". Most of these factors cannot be unambiguously 
defined. For example the decision as to whether someone is more 
than usually anxious is subject to considerable variability. 
Unless a standardized instrument for measuring anxiety is 
employed the decision is also highly subjective. This further 
increases the variability. Some of the factors, such as severe 
illness, are quite heterogenous. 
Ideally the trial should have assessed the relationship of the 
severity of the risk factors with the likelihood of an adverse 
event. This was done in the case of renal impairment. The degree 
of pre-existing impairment, as reflected in the serum 
creatinine, was associated with the risk for contrast 
nephropathy. An attempt was made to assess the severity and 
etiology of prior reactions to contrast. This was necessary to 
allow the radiologists to decide whether patients should be 
randomized or not. Those with the most severe prior reactions to 
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contrast were excluded. However no attempt was made to consider 
the severity of prior reactions during the analysis of patients 
who were entered in the trial. This is a shortcoming that will 
be addressed in future work with this data. 
It is difficult to measure the severity of some risk factors 
reliably. It might have been possible to scale the severity of 
anxiety or cardiac disease, but it would have been more 
difficult to measure the severity of an allergy history. The 
difficulty of these tasks is reflected by the fact that they 
have not generally been undertaken in other studies of contrast 
media. 
Feasibility was also a major factor in deciding how to define 
the risk factors for this trial. The research nurses did not 
have time to perform extensive assessments of the severity of 
potential risk factors along with their other duties. It should 
also be emphasized that the results of the study were meant to 
be applicable in practice. Busy radiologists would not have time 
to perform lengthy or difficult assessments of ' the severity of 
risk factors either. If the factors were to be useful for 
identification of a high risk group for selective use of low-
osmolar contrast, they would have to be identifiable by an 
easily administered screening process. Nevertheless this trial 
would have been enhanced by a formal attempt to measure and 
analyze the severity of at least some of the risk factors. 
An informal attempt was made to prevent the inclusion of 
subjects with minimal degrees of allergy or trivial prior 
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reactions to contrast. The nurses collected details about the 
nature and severity of these factors. If there was doubt as to 
whether a patient should be coded as having the risk factor or 
not, these details were reviewed before a decision was made. It 
would have been better if more detailed explicit criteria as to 
what constituted eligible risk factors for the purposes of this 
trial had been uniformly applied. This would have helped others 
to interpret the results of the study. 
The following operational definitions were used for risk 
factors whi ch made patients eligible for inclusion in the trial 
of intravenous contrast: ( 1) Prior reaction to contrast was 
defined as a history from the patient or the medical record of 
an anaphylactoid or cardiovascular reaction, or severe symptoms 
following past administration of radiocontrast. (2) Allergy was 
defined as a history from the patient or the medical record of 
an adverse reaction to a drug, foodstuff or other contact, which 
was likely to have an immunological basis as determined by 
either the physician supervising the imaging or the principal 
investigator. ( 3) Asthma was defined as a history from the 
patient or the medical record of a respiratory disease with 
symptoms which were reversible either spontaneously or with 
bronchodilator therapy. (4) Cardiac disease was defined as a 
history of active angina, heart failure, myocardial infarction, 
congenital or valvular heart disease, or a history of cardiac 
surgery elicited from the patient or the medical record by the 
research nurse. In the case of patients having cardiac 
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catheterization it was possible to get specific information 
about the nature and severity of any existing cardiac disease 
from the cardiologist. Hisjher opinion was based on clinical 
information and the results of the cardiac catheterization. (5) 
Renal impairment was de~ined as a serum creatinine greater than 
or equal to 120 ~moljl in a sample taken within 24 hours prior 
to contrast administrat:ion. ( 6) Diabetes mellitus was defined as 
a history from the pati~nt or the medical record of having that 
condition. Details of the duration of the condition and its 
therapy were also recorded. {7) Anxiety was recorded as present 
if the research nurse considered that the patient was unusually 
anxious as compared to other patients having that procedure. (8) 
Severe illness was defLned as being confined to bed in hospital 
for acute medical rea:sons on the order of a physician. { 9) 
Whether the patient was aged greater than 50 years was 
determined by asking t b e patient and examining the records. 
Only subjects with o~e or more of the above characteristics, 
who were having intravenous contrast for computed tomography or 
IVP, were eligible for inclusion in the trial. 
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CHAPrER 5 
sTRATIFICATION, RANDOMIZATION, BLINDING AND SAMPLE SIZE 
~.1. stratification before randomization: 
simple randomization does not always ensure that groups are 
completely comparable in all respects. It is possible for two 
randomized groups to end up with different proportions of 
individuals with some important characteristic. Although this is 
unlikely when large numbers are being randomized, the risk of 
imbalance can be minimized by stratification for the variables 
of interest before randomization. This is particularly helpful 
if there is a prognostically important variable which is likely 
to be present in only a small proportion of the population. In 
that situation chance might well give rise to groups imbalanced 
for the variable if simple randomization is used. This is 
avoided by employing a restricted or block randomization within 
the strata with and without the factor of interest. If there is 
more than one such factor present several stratification steps 
can be employed before randomization. The number of strata that 
can be used is limited in practice by the fact that the number 
of groups randomized separately at least doubles with the 
addition of each stratification factor. If imbalance between 
randomized groups occurs despite these precautions it can be 
addressed by stratified analysis. 
Apart from ensuring comparability of randomized groups, 
stratification can also be useful if one expects that the 
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response to a given intervention might be different in quantity 
or even more importantly, quality in different strata. Subgroup 
' . 
analysis within strata can be performed with greatest assurance 
of validity if the subgroups have been specified in advance and 
have been separately randomized with regard to the intervention. 
since there were major differences between patients in the 
intravenous and the intracardiac arms of the current study it 
was clear that patients would have to be stratified into those 
having cardiac catheterization and those having intravenous 
contrast prior to randomization. Within each of these strata 
there were several variables which could have a prognostic link 
to contrast-related adverse reactions. These variables included 
the factors which had been traditionally referred to as "risk 
factors". 
In order to judge whether stratification by the presence of a 
particular "risk factor" would be required, it was necessary to 
know approximately how many patients with each of the "risk 
factors" would be available for study. A pilot study was 
performed before the trial proper was commenced. This indicated 
that there would probably be 1500 patients with a history of 
prior reaction to contrast, allergy, or asthma, 500 patients 
with renal impairment, 750 with diabetes, 750 with anxiety, and 
2500 aged greater than 50 years available for study during the 
projected study period. Given these estimates further 
stratification of patients prior to randomization did not appear 
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warranted. It was hoped that the randomization process would 
generate comparable groups in terms of all of these variables. 
5.2. The randomization process: 
This trial used simple randomization within each of the two 
strata (i.e. cardiac and intravenous injection arms) in order to 
keep the process as straightforward as possible [Zelen (1974)]. 
This was necessary because there was very little time available 
to the research nurses between cases. The nurse was responsible 
for interviewing each patient attending for imaging, deciding 
eligibility, obtaining consent from both patient and doctor, and 
overseeing the randomization. All of this had to be done without 
imposing delays in the schedules of the imaging departments. 
A block randomization scheme should have been used in this 
trial. This would have ensured that the groups remained 
comparable in terms of the number assigned to each treatment 
within the two strata as the trial progressed. However, the fact 
that a blocking scheme was not employed probably does not have 
serious implications for the validity of the randomization. 
There were several more serious limitations and deficiencies to 
the randomization process. In order to illustrate these I will 
first outline how the randomization proceeded in the current 
trial. 
In the cardiac catheterization laboratory the research nurse 
was responsible for both patient recruitment and randomization. 
Randomization was done using a random number table, but a closed 
envelope system was not used. As a result the research nurse was 
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potentially aware of the group to which the prospective study 
patient would be assigned, at a trme when the patient was being 
evaluated with regard to eligibility. The implications of this 
flaw will be discussed in the section on blinding later in this 
chapter. 
. In the radiology department the research nurse was responsible 
for patient recruitment and initially for randomization as well. 
A serious error occurred in the randomization process for this 
stratum during the first few months of the study. The error 
arose from the fact that some of the study staff were 
inexperienced in research methods and had not been adequately 
trained before they started to work on the trial. The error was 
also contributed to by inadequate formal detailed specification 
of how the randomization should be performed. This error could 
have been prevented by proper planning and by better training 
procedures. The error was compounded by the fact that patients 
entered in the trial were not recorded consecutively in a log at 
this stage. Such a record would have made it easier to recognise 
the error when it occurred. It woulq also have made it easier to 
deal with the error after the fact by allowing unambiguous 
identification of the subjects who had been inappropriately 
randomized. 
The error to which I have been referring arose as follows. 
Nonionic contrast was not available in bottles containing more 
than 50 millilitres. Some investigations, such as CT of the 
abdomen or sinuses, routinely required a large volume of 
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contrast. The radiologists had decided that only ionic high-
osmolar contrast would be employed for enhancement during those 
procedures. Thus it was not possible to randomly assign contrast 
to patients having these procedures. However, when such patients 
were otherwise eligible for inclusion in the trial, the nurse 
checked to see what contrast was indicated by the next random 
number to be used. If the random number indicated that high-
osmolar contrast should be given, the patient received this and 
was recorded as having been randomized. If the random number 
indicated that nonionic contrast should be given then the 
patient was excluded from the randomized trial and received 
high-osmolar contrast. The random assignment to nonionic 
contrast was subsequently used for the next patient eligible for 
the randomized trial. This error may have introduced bias. Those 
patients who were having the procedures which required a large 
volume of contrast all received high-osmolar media. They would 
almost certainly have differed systematically from the next 
consecutive patients. These were given the nonionic contrast 
initially selected by the random number table for those having 
the procedure, for which only high-osmolar contrast could be 
employed. The resulting bias might have favoured the nonionic 
group because the patients having the high volume procedures 
tended to be at higher than average risk of an adverse reaction. 
If the patients entered in the trial had been recorded 
consecutively in a log book it would have been possib;I.e to 
identify all those who had been inappropriately randomized. 
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These patients could then have been excluded from the analysis 
of the randomized trial. It was possible to identify the 220 
patients who had investigations requiring a high volume of 
contrast before the error was discovered. These patients were 
removed from the randomized trial. They were analyzed together 
with others who were not randomly assigned a contrast medium. It 
was not possible to identify those who had been given the 
corresponding nonionic assignments and these patients were not 
removed from the randomized trial. This could also bias the 
comparison of the randomized groups because such patients might 
differ systematically in some way from the others in the trial. 
The direction and magnitude of such bias is difficult to judge 
without knowledge of the characteristics of the patients 
inappropriately randomized to the nonionic group. 
An effort was made to determine if bias introduced in this way 
could have influenced the results of the trial. The event rates 
in the high and low-osmolar groups were determined separately 
for those entered in the randomized trial before and after the 
error was discovered. Among those entered in the trial before 
the error, and not subsequently excluded, 1.3% of those given 
high and 0.6% of those given low-osmolar contrast had an adverse 
event which required attention by a doctor. After the error such 
an event occurred in 5.6% of those given high and 1.7% of those 
given low-osmolar contrast. Given these numbers it seems 
unlikely that the adverse event rate was lower than average in 
the patients randomized to high-osmolar and subsequently 
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excluded, or higher than average in those inappropriately 
randomized to low-osmolar and not subsequently removed from the 
trial. ~f these assumptions are true then any resulting biases 
should tend to cancel each other out. In any case the difference 
between the ionic and nonionic groups randomized after the 
randomization was corrected is still highly significantly in 
favour of nonionic. Even if the patients entered before the 
error was discovered are not counted the conclusion of the trial 
remains unchanged. 
A sure way to prevent the error in randomization from biasing 
the results of the trial would have been to exclude all of the 
patients entered in the intravenous limb of the trial before the 
error was corrected at the time that the error was discovered. 
Most of the patients thus excluded would not have been 
inappropriately included in the trial in the first place. 
However, all of these patients would have to be replaced by 
others who were correctly randomized. This would have been very 
costly but might have been worthwhile. Fortunately the analysis 
of the results before and after the error was corrected indicate 
that the potential bias does not invalidate the conclusions of 
the trial. 
After the mistake in randomization was recognized, the whole 
randomization process in the radiology department was reviewed 
and improved. A sealed envelope system of random assignment was 
introduced. The nurse interviewed the potential subjects while 
I 
blind to the next random assignment. She determined whether they 
met the eligibility criteria. 
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She then approached the 
radiologist to obtain permission to enter the subject in the 
randomized trial. If permission was granted, she handed the 
sealed envelope to the radiation technologist who prepared the 
contrast for injection. This randomization procedure should have 
been employed from the beginning of the trial. A log with 
consecutive numbering of the patients interviewed and of those 
entered in the trial was also maintained from this point. 
5.3. Blinding procedures: 
Blinding is an important technique that helps to control bias 
in randomized trials. Blinding can be applied at four stages 
[Chalmers (1981)]. The first stage at which blinding should be 
applied is when random assignments are being made. Chalmers has 
demonstrated that when the person responsible for recruiting 
subjects to a trial is aware of the next randomly determined 
treatment assignment, bias can play a role in .determining the 
likelihood that a particular subject is entered in the study 
[Chalmers (1983)]. The result is generally an imbalance between 
the random groups in terms of some prognostically important 
variable. This complicates interpretation of the trial results 
and may even invalidate the study entirely. 
Randomization was not performed blindly in the cardiac 
catheterization laboratory or during the initial phase of the 
trial in the radiology department. This could have influenced 
the nature of the patients assigned to the treatment groups. The 
problem could easily have been avoided by the use of a sealed 
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envelope system during randomization. The effects of the bias 
can be partially overcome by an analysis which standardizes or 
otherwise adjusts for factors, which are associated with the 
outcome, but which are not evenly distributed in the randomized 
groups. 
The randomized groups appeared well balanced in terms of 
baseline factors among those having cardiac angiography. 
Therefore it seems unlikely that the unblinded randomization 
introduced major bias to this arm of the trial. 
In the intravenous limb of the trial there appeared to be an 
excess of patients with cardiac disease randomly assigned to 
nonionic contrast. Whether this imbalance arose because of 
unblinded randomization is not clear. The results of the trial 
indicated that cardiac disease was associated with a higher 
likelihood of an adverse reaction requiring the attention of a 
doctor among patients receiving intravenous contrast. The excess 
of cardiac disease in the group assigned to intravenous nonionic 
contrast would thus tend to bias the trial against nonionic 
contrast. However, since the result of the trial was in favour 
of nonionic, this bias could only have reduced the apparent 
benefit of non ionic media. The logistic regression analysis 
adjusted for the presence of cardiac disease when it examined 
the relative risk for an adverse event associated with the 
nature of the contrast given [Appendix B]. 
The traditional r use of the term "double blind" refers to the 
blinding of trial staff and subjects to the nature of the 
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assigned therapy. This is to ensure that measurement of outcome 
events is not influenced by bias on the part of the subject or 
others responsible for assessment of outcome. 
In the initial phase of the study of intravenous contrast the 
patient, doctor, and radiation technologist were blind to the 
contrast given whereas the research nurse was not. The major 
outcome was the occ urrence of an event which led to assessment 
or treatment of the patient by a doctor. The decision as to 
which patients should be assessed or treated was not made by the 
nurse and therefore these decisions should have been free from 
bias. Nevertheless it is possible that the nurse could have had 
some unintentional effect on the nature of the decisions taken 
and bias could thus have occurred. This situation could have 
been avoided by the choice of a better outcome measure as 
discussed in Chapter 6. 
The research nurse in the radiology department was responsible 
for both measurement of the pulse rate and blood pressure after 
imaging and for interviewing the patient as to the presence and 
severity of subjective symptoms during the test. Therefore bias 
could have had a major effect in terms of these outcomes. The 
magnitude and direction of this bias cannot be reliably 
estimated and therefore the results of the analyses of these 
outcomes have to be interpreted with caution. 
Blinding of outcome assessment was addressed when the 
randomization process in the radiology department was revised. 
From then on the radiation technologist prepared the contrast 
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and kept it hidden from all those who were responsible for 
assessing outcome. Thus the traditional "double blinding" of 
those who were assessing outcome was assured. 
In the cardiac catheterization laboratory the patient and the 
cardiology staff were blind to the type of contrast given to 
randomly assigned patients throughout the study. The only person 
who knew the nature of the contrast assigned was the research 
nurse, who was not responsible for assessing major outcomes. The 
nurse did administer the subjective symptom questionnaire after 
the procedure and could have introduced bias to the assessment 
of this outcome. This is not critical to the major results of 
the trial, but it could have been avoided by having the 
questionnaire administered by a person who did not know which 
contrast had been given. 
The final kind of blinding is that which appl~~s during the 
analysis (Chalmers (1981)]. The analysis of this trial was not 
performed in a blind fashion. A pre-specified primary outcome 
and significance level were employed and should help to minimize 
bias at this stage in the study. Nevertheless it would have been 
preferable to perform the major analyses while blind to the 
contrast received by the groups being analyzed. It is unclear 
whether the results of this trial were affected in a major way 
by the lack of blinding during data analysis. 
Chalmers has argued that not only should blinding be 
performed, but that a test of blinding should also be done 
[Chalmers (1981)]. This seems reasonable as it may be 
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unrealistic to claim the benefits of blinding when it is quite 
possible that the blinding process was ineffective. The 
effectiveness of blinding was not assessed at any stage in this 
study. A test of blinding could have been done by asking the 
cardiologists to say which contrast had been given at the moment 
they decided t o treat an adverse event. Such events were often 
preceded by minor hemodynamic changes which, since these were 
more common with high-osmolar contrast, might have compromised 
the blinding of the cardiologist. If the cardiologists were 
found not to be blind, then the decision to treat could have 
been influenced by the nature of the contrast given and thus the 
primary outcome biased. 
5.4. Sample size determination; 
The required sample size was calculated separately for a 
number of outcome measures. These wi 11 be discussed in more 
detail in Chapter 6. The overall sample size was dependent on 
the estimated frequency of systemic idiosyncratic reactions 
requiring the intervention of a physician. 
The formula used to calculate sample size was as follows; 
Number per group = 2 [ ( Za +ZS) + ( 2sin-1 / 1r 1 - 2sin-1/ 1r 2 ) ] 2 
Za is the standardized normal deviate of the chosen a level. ZS 
is the standardized normal deviate of the chosen 8 level. 'lr1 is 
the expected incidence of the outcome of interest in the high-
osmolar group. 'lr2 is the expected incidence of the outcome of 
interest in the low-osmolar group. 
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All calculations used a 1-tailed a level of 0.05 and a B level 
of 0.2. 
The likely frequency of an anaphylactoid reaction requiring 
intervention after high-osmolar contrast was estimated at 2%, 
based on the event rates for placebo treated patients in the 
study by Lasser [Lasser (1987)]. To detect a reduction to 1% by 
use of low-osmolar contrast required a sample size of 1779 
randomized subjects per group, or 3558 subjects in total. 
The sample size in relation to contrast nephropathy assumed as 
an outcome a 25% rise in the serum creatinine above baseline 
within 72 hours of contrast exposure. It was estimated that this 
would occur in 10% of patients given high-osmolar contrast from 
the results of a previous study of the incidence of contrast 
nephropathy [Parfrey ( 1989)]. To detect a reduction in incidence 
to 5% by the use of low-osmolar contrast required 335 patients 
per group, or a total of 670 patients with both baseline ~rum 
creatinine greater than 120 Jjmolfl and a follow up value 
available. 
A separate sample size was not calculated for cardiovascular 
outcomes in the stratum having cardiac catheterization as it was 
initially intended to combine these patients with those having 
intravenous contrast and to primarily examine their systemic 
idiosyncratic reactions. This was a major flaw in the design of 
the trial and will be more fully addressed in the following 
chapter. 
CHAPTER 6 
OUTCOMES AND EVENTS 
6.1. The choice of an outcome for a trial of therapy: 
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The choice of an outcome is one of the important tasks faced 
during the design of a study. For a therapeutic trial the ideal 
outcome should provide a valid reflection of the effects of 
therapy. The outcome should be easy to measure. The measurement 
should be reproducible and associated with as few sources of 
variation as possible. This will maximize the probability of 
being able to detect the effects of therapy. The outcome chosen 
should be clinically meaningful if the study results are 
inte nded to influence medical practice or policy. 
It is preferable to use a single outcome if possible. This 
prevents difficulty that may arise with interpretation if the 
analysis of several outcomes suggests several incompatible 
condlusions. Sometimes it is not possible to avoid the use of 
more than one outcome if all important effects of therapy are to 
be captured. In that situation it is important to specify a 
primary outcome before the study starts. Consideration should 
also be given as to how the results of the analysis of multiple 
outcomes will be interpreted. Decision analysis can be used to 
integrate the many good and bad effects of a therapy as measured 
in a trial. Another possible approach when a therapy can have 
many good or bad effects is to use a single composite outcome to 
measure all of the effects. However, care should be taken to 
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ensure that such an outcome is not too heterogenous to prevent 
sensible interpretation of the data. 
6.2. The choice of outcomes for the trial of contrast media: 
There was considerable difficulty in choosing an outcome for 
the trial of contrast media. Part of the difficulty related to 
the many possible adverse effects of contrast. This difficulty 
was compounded by the decision to study patients having both 
intravenous and intracardiac contrast together. Initially the 
focus was on the anaphylactoid systemic adverse effects of 
contrast. The importance of adverse cardiovascular events in 
patients having cardiac catheterization was not adequately 
appreciated. This reflected the fact that it was initially 
decided to study these patients in order to meet the sample size 
requirements for a comparison of the systemic anaphylactoid 
effects of high and low-osmolar contrast. Some of the resulting 
difficulties might have been avoided by a more careful review of 
the literature concerning cardiac catheterization and by more 
extensive involvement of individuals, familiar with the 
performance of this procedure, in the design of the trial. 
Given the heterogeneity of the adverse effects of contrast 
media a decision was taken to use several outcome measures. 
Specific adverse effects were to be measured separately and a 
composite primary outcome was chosen. The primary outcome chosen 
was the occurrence of a systemic adverse event, which might be 
attributable to contrast, and which led to the use of a 
therapeutic intervention. This outcome was far from ideal in 
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many ways. The research nurses made a record of the nature of 
any adverse event which occurred, it's timing in relation to the 
administration of contrast and the details of any medical 
attention or therapy which followed. The decision as to whether 
the event might be attributable to contrast was made by the 
investigators after the fact. The need for this decision and the 
decision to give therapy made it possible for bias to be 
introduced. An attempt was made to control this by requiring 
that these decisions be made while blind to the nature of the 
contrast given. The subjective nature of the decisions to give 
therapy and to attribute an event to contrast tends to reduce 
the reproducibility of the outcome measure. It also makes it 
more difficult for a third party to interpret the results of the 
trial. A further problem was introduced by the lack of a precise 
definition of the term "systemic adverse reaction". This was 
almost certainly responsible for the designation of several 
episodes of chest pain after intravenous contrast as primary 
outcome events. It is not clear to me even now whether these 
events formed part of the intended primary outcome at the time 
when the trial was being designed. 
The decision to study patients having cardiac catheterization 
led to some further difficulties in specifying an outcome for 
the study as a whole. Given the occurrence of many adverse 
cardiovascular events in the group having cardiac angiography, 
and the rather vague definition of the primary outcome for the 
intravenous stratum, it would have been almost impossible to 
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judge whether an adverse event which required therapy in a 
patient having cardiac angiography was one which qualified as a 
primary outcome event as intended for both cardiac and 
intravenous subgroups at the outset of the trial. This, together 
with differences in the nature of the subjects having cardiac 
and intravenous contrast, made it very unwise to even consider 
combining these two populations for analysis. These difficulties 
are discussed more for theoretical than practical reasons, as 
the cardiac and intravenous arms of the study were never 
combined for any analysis other than that dealing with contrast 
nephropathy. 
When it was decided to study patients having cardiac 
angiography provisions were made for recording details of all 
hemodynamic changes during the catheterization. A semi-
structured record was also kept of any serious events which 
occurred during or shortly after the angiography. Note was made 
of any therapy given and whether the cardiologist asked to be 
unbl inded because of an adverse event. A distinct composite 
outcome for the patients having cardiac angiography was not 
specified until the trial ·was well underway. It was then decided 
that the primary outcome for the cardiac angiography patients 
alone would be the occurrence of an adverse event which led to 
the prescription of therapy or a request for un~linding by the 
cardiologist. This did not lead to difficulty in deciding the 
outcome of patients who had been studied before this outcome was 
chosen, because the data which had already been recorded was of 
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sufficient quantity and quality to make it easy to determine 
retrospectively whether such a primary outcome had occurred. 
It is not methodologically correct to specify an outcome after 
a trial has started. This was a fairly major flaw in the current 
trial which could have been avoided by more careful planning. 
The retrospective classification of patients with regard to 
outcome again made it possible for bias to be introduced. An 
attempt was made to control this by keeping the nature of the 
contrast assigned hidden from those who were making the decision 
as to whether a primary outcome event had occurred or not. 
The heterogeneity of the events which constituted a primary 
outcome for those having cardiac angiography also led to 
difficulty in interpretation of the trial results. These events 
varied from trivial angina to life threatening arrythmias. This 
led to the need to develop other categories of outcome, (such as 
that designated as "clinically important adverse events" in 
Appendix A) , during the analysis of the trial to adequately 
describe the nature of the benefits of low-osmolar contrast. 
In summary there were many flaws with the specification of 
major outcomes for this trial of contrast media. It would have 
been better if separate primary outcomes had been specified at 
the outset for the patients having cardiac angiography and 
intravenous contrast. These outcomes should have been precisely 
defined, based on objective events, more homogenous with regard 
to their severity, and more readily interpreted by consumers pf 
the research findings. 
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6.3. Hemodynamic outcomes; 
In addition to the composite primary outcomes already 
discussed, the occurrence of a number of pre-defined objective 
hemodynamic events was recorded routinely throughout the trial, 
both in patients having intravenous and intracardiac contrast. 
The heart rate and arterial blood pressure of all subjects was 
r~corded before and after the imaging procedure. This was done 
by counting the pulse and usin·g a sphygmomanometer in the 
radiology department. Electrocardiographic recording and 
intraarterial pressure monitoring were used in the cardiac 
catheterization laboratory. Continuous monitoring of these 
parameters during contrast administration was only performed in 
the cardiac stratum. 
For the intravenous stratum the pre-specified hemodynamic 
outcomes were the development of a new arrythmia or a change in 
the arterial blood pressure of more than 20 mmHg systolic or 10 
mmHg diastolic. More severe or symptomatic cardiovascular 
disturbance would generally have required the attention of a 
doctor and, as such, would have been fully described. 
For the cardiac stratum a number of specific adverse 
cardiovascular events were defined. These included (a) any new 
arrythmia after the administration of contrast, (b) the 
occurrence of asystole lasting 5 seconds or more, (c) a fall in 
systolic blood pressure of more than 20 mmHg lasting more than 
1 minute or requiring therapy and (d) angina. 
6.4. Symptomatic outcomes; 
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The presence and subjective severity of several symptoms 
occurring with contrast exposure was measured by asking all 
patients to complete a symptom scale after the procedure. The 
scale contained 9 i terns and each was scored separately. The 
items were the symptoms warmth, nausea, vomiting, itch, dyspnea, 
sneezing, pain, chest tightness, and any other symptom. The 
severity of each symptom was measured by using a 10 point 
Likert- like scale {Fig 2). The symptoms were all analysed 
separately as it did not seem sensible to combine them into a 
composite symptom index and there was enough data to analyse 
them individually. 
The measurement of these subjective variables was not tested 
for reliability or validity. Ideally this should have been done. 
The lack of such testing would constitute a major flaw in any 
study which depended primarily on the use of an instrument with 
unknown psychometric properties to measure subjective states. 
Reliability could have been tested by having a number of 
subjects complete the symptom scale on two separate occasions. 
The degree of agreement between the two scores from each subject 
would give an estimate of the test-retest reliability of the 
scale. Alternatively we could have used a different method, 
known as the Discan method, to measure symptom severity [Singh 
(1989)]. This method would have established whether the 
measurement at least demonstrated internal consistency, a minimum 
requirement for any reliable measurement ~nstrument. The method 
would have been too cumbersome to use in the current study. 
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FIGURE 2. The subjective symptom questionnaire. 
put a mark on each. of the following lines to show the severity 
of the following symptoms that may have occurred after you had 
contrast infused into your blood vessels. 
NO PROBLEM VERY SEVERE 
PAIN 
0 1 2 3 4 5 6 7 8 9 10 
WARMTH 
0 1 2 3 4 5 6 7 8 9 10 
NAUSEA 
0 1 2 3 4 5 6 7 8 9 10 
VOMITING 
0 1 2 3 4 5 6 7 8 9 10 
SNEEZING 
0 1 2 3 4 5 6 7 8 9 10 
ITCHING 
0 1 2 3 4 5 6 7 8 9 10 
SHORTNESS OF 
BREATH 0 1 2 3 4 5 6 7 8 9 10 
CHEST 
TIGHTNESS 0 1 2 3 4 5 6 7 8 9 10 
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The symptom scale responses were divided into 2 categories for 
analysis. Symptoms greater than or equal to 5 out of 10 were 
called severe. This cutpoint was arbitrary and led to a loss of 
power, but this was not serious because there were so many 
subjects with symptoms. In a study of smaller size it would be 
more efficient to treat the scale scores as ordinal values and 
to use a nonparametric test such as the Mann-Whitney-U test to 
analyze the data. 
6.5. Contrast nephropathy: 
There is no specific diagnostic test for contrast nephropathy. 
This remains a diagnosis of exclusion when acute renal failure 
occurs after the administration of contrast. Some authors have 
used changes in the level of various proteins and enzymes in the 
urine as indicators of renal damage. While these measures may be 
very sensitive, they are not specific and do not generally 
indicate the occurrence of a clinically significant renal 
injury. Therefore they were not used to diagnose contrast 
nephropathy in the current study. 
Contrast nephropathy was diagnosed in this study by measuring 
serum creatinine before and after contrast. The serum creatinine 
is an indirect indicator of the glomerular filtration rate 
(GFR), and is widely used to assess renal function. Changes in 
the serum creatinine tend to lag behind changes in the GFR. This 
is not a serious problem if one repeats the measure at the 
appropriate time. This was done at 48 to 72 hours after contrast 
in the current study, as this is the time when the creatinine 
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most often reaches its peak with contrast induced renal damage 
[Mudge (1980)]. A more serious problem is posed by the fact that 
the serum creatinine changes less, in absolute terms, with the 
same change in GFR when renal function is nearly normal than it 
does when renal function is more impair~d. Indeed, the serum 
creatinine rises in an exponential fashion as the GFR falls. 
Some authors have used changes in the absolute level of serum 
creatinine to diagnose cases of contrast nephropathy. This is 
not appropriate as the apparent incidence of renal damage is 
then unduly influenced by the baseline renal function of the 
population studied. This hinders the comparison of the incidence 
and severity of renal damage in different populations. 
A proportionate increase in the serum creatinine was used to 
diagnose a case of contrast nephropathy in the current study 
[Appendix C]. This is a more accurate reflection of the 
underlying change in the GFR than is the absolute change in 
serum creatinine. Logarithmic transformation of the serum 
creatinine values prior to further analysis is an even better 
way to compare changes in GFR in patients with varying existing 
renal function. 
It is statistically inefficient to convert continuous data to 
categories for analysis. The change in serum creatinine after 
contrast is an example of a continuous variable. In the analysis 
of this study the mean change in serum creatinine after ionic 
and nonionic contrast was compared using a Student t test. This 
was done both with and without logarithmic transformation of the 
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serum creatinine values [Appendix C]. This method of analysis is 
not only the most statistically efficient, it also avoids the 
use of arbitrary definitions to categorize the occurrence of 
events. 
The results of such parametric analyses are difficult to 
interpret from a clinical point of view. Clinicians are often 
more comfortable when confronted with data that state that a 
particular therapy causes fewer discrete adverse events than 
another. Therefore the number of specified discrete "cases" of 
contrast nephropathy seen with ionic and nonionic contrast was 
also reported for the current study. A "case" was defined by a 
rise in the serum creatinine to at least 125% of the baseline 
value. This makes some adjustment for the difference in the 
expected magnitude of response of the serum creatinine to 
similar changes in GFR in subjects with varying baseline levels 
of serum creatinine. The choice of a 25% change to represent a 
"case" was based on the fact that this degree of change is 
greater than would be expected to occur simply on the basis of 
test/retest variability in the assay for serum creatinine 
(coefficient of variation 3.9% at our own hospital laboratory), 
or even in the day to day variation in the serum creatinine of 
an individual without any real change in GFR (about 5. 5%) [Young 
(1979)]. Of course one could have chosen any arbitrary higher 
cutoff to define a case. In our previous study we had used a 50% 
change to define a case [Parfrey (1989)]. This level of change 
is more clinically meaningful, but is much less frequent, and 
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would have required a vastly larger sample to be able to show a 
statistically significant difference between the contrast 
agents. Differing categorical definitions of "cases" have been 
partly responsible for the variation in the reported incidence 
of contrast nephropathy in the 1 i terature. Therefore care should 
be exercised when such categorically classified continuous data 
is being reported, compared or discussed. 
Since contrast nephropathy remains a diagnosis of exclusion, 
even the documentation of a decline in renal function after 
contrast is not sufficient to diagnose a true case of contrast 
nephropathy. Acute renal failure is often multifactorial in 
origin and the precise role that contrast plays in a specific 
case may be hard to determine. In the initial analysis of this 
trial the incidence of renal function change, irrespective of 
the likely cause, after the two types of contrast agent was 
compared. This analysis is valid but is complicated by "noise" 
which makes it more difficult to discern any true difference 
between the contrast agents. Therefore the case records of all 
subjects who had a deterioration in renal function were 
reviewed. A decision was made as to whether contrast could have 
been at least partly responsible for the change. This decision 
was made by a nephrologist blind to the type of contrast given 
in order prevent bias [Appendix C]. 
6.6. Analysis of events: 
How events are counted in the analysis of a trial can have 
profound effects on the results. There has been controversy as 
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to which events should be included in the analysis of a trial 
(Sackett, Gent (1979)]. There are two poles to the argument. On 
the one hand one would only like to count events that "make 
sense" and charge them to the "appropriate" regimen. However, to 
do so may risk invalidating the results of the trial. This 
happened in the case of the Joint Study of Extracranial Arterial 
Occlusion for example [Fields (1970)]. On the other hand one 
could perform an analysis by "intention to treat" and charge all 
events to the regimen to which the patient is initially 
randomized. Neither view is necessarily always correct (Sackett, 
Gent ( 1979)]. The choice of which events to include in the 
analysis depends on the nature of the research question, the 
perspective from which it is posed, and a concern to avoid 
specific bias [Sackett, Gent (1979)]. We considered these 
factors when deciding how to handle specific groups of events in 
this trial. 
6.6.1. How crossovers were handled; 
A subject in a randomized trial is said to have "crossed over" 
when hejshe is switched from the intervention to which he/she 
was randomly assigned to receive the intervention which has been 
assigned to the members of another randomized group. If this 
happens it is difficult to know whether an outcome, which occurs 
after the cross over, is due to the action of the intervention 
to which the subject was originally assigned or to the 
intervention which was received after the cross over. The most 
robust way of dealing with patients who cross over is to analyze 
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them separately. If the conclusions of the study are not altered 
by assigning all of the events which occur after a cross over td 
any one specific randomized group, then the presence of cross 
overs is of minor importance, at least when interpreting th~ 
direction of the study results. The magnitude of any differenc~ 
between the randomized groups is of course always sensitive td 
the presence of cross overs. 
Cross overs posed a limited problem in the current trial of 
contrast media even though they were not always handled 
correctly in the analysis. None of the randomized subjects in 
the intravenous arm of the trial were switched from high to low-
osmolar contrast or vice versa. In the cardiac catheterization 
arm many subjects randomized to high-osmolar contrast were 
switched to low-osmolar contrast during the procedure. This was 
not a problem in relation to the primary outcome of an adverse 
event which required therapeutic intervention because the 
requirement to switch to low-osmolar contrast was itself taken 
to constitute such an outcome. Therefore this outcome always 
happened before the cross over was made and the adverse event 
was always attributed to the high-osmolar contrast which had 
been given before cross over. This outcome was only counted once 
for each subject and therefore such an outcome could not be 
counted again after the subject had crossed over. 
During th~ analysis of the cardiac catheterization arm of the 
trial a new category of outcome was created. This is designated 
as a "clinically important event" in Appendix A. This category 
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was created by combining events which had been recorded at the 
time of catheterization and counting the number of patients who 
had at least one such event. It was possible for these events to 
occur after a cross over. The effect of such cross overs was not 
initially considered in the analysis. This was an error which 
could have interfered with the interpretation of the results. 
The data were analyzed subsequently to assess the effect of the 
cross overs. Sixty four subjects who had a "clinically 
important" event also crossed over from high to low-osmolar 
contrast. However, none of those patients suffered their initial 
"clinically important adverse event" after the cross over. 
Therefore it was legitimate to attribute this event to the high-
osmolar contrast they had received. The conclusion that high-
osmolar contrast causes more adverse events of "clinical 
importance" is therefore not sensitive to the presence of, or 
the method of dealing with, the cross overs. 
A similar problem exists with regard to the measurement of the 
subjective symptoms after cardiac catheterization. This 
measurement was made after cross over had taken place in some 
subjects. This problem should have been foreseen. The ideal way 
to deal with it would have been to administer the symptom 
questionnaire before the contrast was switched. However this 
would not have been feasible in practice. The subjective symptom 
data from the patients who crossed over should have been 
analyzed separately. This has not been done to date and 
therefore the results of the comparison of the high and low-
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osmolar contrast, in terms of subjective symptoms, in patients 
having cardiac angiography, have to be interpreted with caution. 
Although several patients were given both high and low-osmolar 
contrast for cardiac catheterization, only one such patient 
(nonrandomized) had a rise in serum creatinine after contrast, 
and in that case it was impossible to be sure which agent was 
responsible [Appendix C]. Given the fact that only one 
individual received both types of contrast and had a subsequent 
rise in serum creatinine, cross overs did not cause a major 
problem in the interpretation of the results of this part of the 
study. 
6.6.2. How ineligible randomized patients were handled: 
Events occurring after randomization but before contrast were 
not recorded as outcome events. Since such patients con~inued in 
the study and were given contrast, the exclusion of these events 
should not introduce bias. 
I discussed a problem with the randomization procedure in the 
intravenous stratum in chapter 5. Patients were excluded from 
one group because they had been inappropriately randomized. 
Analysis of the baseline characteristics of all those who were 
nonrandomly given high-osmolar contrast revealed that they did 
differ in some respects from those who had been randomly 
assigned to high-osmolar contrast [Appendix B]. Thus the 
exclusion of the inappropriately randomized patients who 
received high-osmolar contrast could introduce a bias to the 
f 
study results. However, as indicated in chapter 5, the major 
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conclusions of the trial are not altered by the complete 
exclusion of all patients randomized before the randomization 
process was corrected. 
6.6.3. How dropouts were handled: 
Because most adverse events occurred very soon after injection 
of contrast, there were few problems with dropouts or 
noncompliance in regard to the primary outcome. The only outcome 
which was affected by dropouts was contrast nephropathy. A 
second measurement of serum creatinine was obtained in about 80% 
of those who had cardiac catheterization and in about 55% of 
those who had intravenous contrast [Appendix c] • This was 
despite efforts to maximize the follow up of these patients. The 
problem arose largely with outpatients and patients who were 
discharged from hospital soon after their imaging test. Attempts 
were made to contact all such patients by telephone and 
arrangements were made for them to have their serum creatinine 
measurement repeated in a local hospital. Many patients could 
not be contacted or failed to have the test done. There are no 
data to indicate what happened to the renal function of those 
patients who were lost to follow up. It is unlikely that any of 
them required dialysis, as this therapy is only available at 
three institutions in the province and these cases would almost 
certainly have come to the attention of the investigators. There 
was no systematic difference at baseline between those who were 
lost to follow up and those who were not [Appendix C). Those who 
were lost to follow up were derived equally from the groups 
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assigned to low and high-osmolar contrast. Therefore although it 
cannot be proven it seems unlikely that major bias was 
introduced by these dropouts. The occurrence of the drop outs 
seems to have been unavoidable given the nature of the 
population being studied. 
7.1. Data management: 
CHAPTER 7 
ANALYSIS 
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The large number of subjects and variables in this trial 
resulted in an enormous amount of data. The data was stored on 
a database system known as Datatrieve [NMS, Vax Datatrieve V3, 
Digital Equipment Corp., Maynard, Massachusetts, 1984]. Each 
case was assigned a unique code number. Cases were entered as 
units. There were a few aspects of the data storage which could 
have been better organized. The patients in the cardiac and 
intravenous strata were entered in separate computer accounts. 
This was not a problem in itself, as the data could be 
transferred between accounts with little difficulty. However, 
the structure of the data and the names for the same variables 
were different in the two accounts. This was unnecessary and led 
to some difficulties in the analysis. There would have been even 
more problems if the two strata had been analysed together. 
After data entry, and prior to any analysis, the data were 
checked for errors. This was done by looking for variables with 
impossible values and for logical inconsistencies in the data. 
For example a value of 2 ~mol/litre for the serum creatinine 
would almost certainly represent an error. If a value for a 
variable was possible, albeit improbable, and existed on the 
original record it was retained. An example of a logical 
inconsistency would be a subject who was said to be taking an 
oral hypoglycemic agent but who was not diabetic. The data on 
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the computer was checked against the original data recording 
forms for virtually all variables used in the cardiac stratum 
and for all the major outcomes in the intravenous stratum. · 
7.2. Analysis of the strata; 
It was initially intended to combine the results of the 
cardiac angiography and the intravenous strata for analysis of 
systemic reactions requiring therapy and to report the cardiac 
side-effects separately. However, the cardiac stratum was 
analyzed, without examining the event rates by the type of 
contrast assigned, when it appeared that clinically important 
hemodynamic events were occurring with a relatively high 
frequency. This analysis revealed that the incidence of adverse 
hemodynamic events requiring therapy was high enough that the 
trial, which had enroled 1490 randomized subjects having cardiac 
angiography up to that point, should be fully analysed. This 
analysis confirmed that nonionic contrast was significantly less 
likely to be associated with the occurrence of an adverse 
hemodynamic event severe enough to require therapy [Appendix A] • 
As a result it was decided that enrolment in the cardiac stratum 
would cease. Enrolment in the intravenous stratum continued 
until the total number of subjects in the two strata combined 
reached the sample size previously determined as necessary in 
relation to the primary outcome of treated systemic reactions. 
When enrolment in the intravenous stratum was terminated we 
analysed the intravenous stratum alone initially. There was a 
statistically significant difference favouring low-osmolar 
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contrast in terms of systemic adverse events requiring therapy 
[Appendix B]. The tren.d for similar outcomes also favoured low-
osmolar contrast in the cardiac stratum ·[Appendix A]. Therefore 
the two strata were not combined for analysis or reporting. 
7.3. Descriptive statistics: 
An initial step in analysis of the data was to determine the 
frequency distributions of the continuous variables prior to 
their statistical comparison. Counts were performed of the 
nominal variables. This description of the raw data gave a feel 
for its' structure. This was necessary to allow a correct choice 
of statistical techniques and also helped to identify when 
errors made during the more complex subsequent analyses. 
continuous variables were presented as means and standard 
deviations or medians and ranges, depending on the frequency 
distribution of the variable. Nominal variables were presented 
as proportions, such as percentages. 
7.4. Baseline comparisons: 
The next step in the analysis was to examine the baseline 
characteristics of the subjects. A comparison of the randomized 
groups was made for a large number of demographic and clinical 
variables. This analysis included all variables which might have 
been related to the outcome, such as the "risk factors" already 
mentioned in chapter 3. This was to ensure that any difference 
in outcome between the groups was truly due to the contrast. We 
did not 1 rely on the lack of a statistically significant 
difference in baseline variables between the randomized groups 
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to determine whether an important difference existed or not. It 
is an error to do so because a large and important difference 
may not be statistically significant even though it has an 
influence on the results [Altman (1985)]. It is also fallacious 
to test the comparability of properly randomized groups 
statistically as any difference that has arisen must have done 
so by chance [Altman (1985)]. However, statistical comparison 
can be justified in situations where bias might have influenced 
the assignment of subjects to groups. This is most likely to 
occur when the randomization is not performed blindly, as was 
the case in the current trial. 
The analysis did reveal that there was an excess of cardiac 
disease in the patients who were randomized to nonionic contrast 
in the intravenous stratum [Appendix B]. The significance and 
management of this situation has been discussed in section 5.3 
which deals with blinding. 
The baseline characteristics of the subjects who were not 
entered in the randomized trial were compared to those of the 
randomized groups [Appendices A to C]. This was important for 
interpretation of the generalizability of the results. Those who 
had been excluded from randomization by the radiologists or 
cardiologists were predictably different from those who were 
enroled in the randomized trial. However, those who were not 
randomized because of the lack of availability of suitable 
nonionic contrast did not differ much from those who were 
randomized. Therefore one could argue that the exclusion of. 
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these latter patients did not influence the results of the trial 
very much. 
7.5. The choice of significance levels; 
We chose to use a cut-off of 5% as a maximum chance of making 
a type I error in declaring a difference between contrast media 
statistically "significant" (i.e. p < 0.05 implies 
"significant"). The choice of a 5% level of significance is 
purely arbitrary, but this cut-off has now become well 
established in the literature as constituting one way to assess 
whether differences are meaningful or not. We reported the 95% 
confidence intervals for all differences and relative risks. 
We chose to use a power of 80% for our sample size 
calculations so that the sample size would be reasonable, while 
not making a type II error excessively likely if the results of 
the trial failed to show a difference between the groups. 
We planned to use one tailed tests to determine if any 
observed difference between the two media was statistically 
significant. There is controversy about whether one tailed tests 
of significance are appropriate in most situations. It would 
have been more methodologically sound if we had designed this 
trial to allow us to conclude that nonionic contrast was either 
more or less toxic than high-osmolar contrast. This would have 
required us to use a two tailed statistical test of significance 
to evaluate any difference in toxicity between the two media. 
However, there was little evidence in the literature to suggest 
that nonionic contrast was more toxic than high-osmolar 
124 
contrast. Even if nonionic contrast was only slightly less toxic 
than high-osmolar contrast it would not be widely used because 
of it's high cost. Therefore we were mainly interested in 
determining whether nonionic contrast was significantly and 
substantially less toxic than high-osmolar contrast. We were 
less concerned about being wrong if we declared that there was 
no difference between the media when in fact nonionic was more 
toxic than high-osmolar. Choosing to use a one tailed test of 
significance carried the advantage of allowing us to use a 
smaller sized sample, which was perceived as a major advantage 
when the feasibility of the study was being considered. 
We reported the results of a two tailed test of significance 
for the outcome of the cardiac catheterization arm of the study 
[Appendix A]. A sample size had not been calculated in advance 
specifically for this stratum. We had not stated an intention to 
use a one tailed analysis in relation to the cardiac angiography 
patients alone. Therefore it seemed more legitimate to use a two 
tailed signific ance level in that situation. The results of the 
comparisons made in the intravenous arm of the· study were 
analyzed using the one tailed tests of significance which had 
been planned at the outset. 
7.6. Statistical tests; 
Chi-squared tests for 2 by 2 tables were used to compare the 
distribution of binary variables between groups. In situations 
in which the expected values in any cell of the table were less 
than five, Fisher's exact test was used to determine 
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significance. This was because the chi-squared distribution is 
only approximately approached, at best, when being used to 
evaluate discrete data. The approximation becomes too crude in 
situations where there are small expected numbers and therefore 
the chi-squared distribution is an inadequate criterion to 
determine significance in those cases. The Fisher's test 
involves no such approximations and directly calculates the 
exact probability that the observed, or a more extreme 
distribution, occurred by chance, under the assumption that the 
null hypothesis is actually true. 
The distribution of continuous variables in the high and low-
osmolar contrast groups was compared using Student's t-test for 
unpaired data. Over the years this test has been found to be 
fairly robust to violations of the assumption that the frequency 
distributions of the variable in the two groups being compared 
are normal in character. Nevertheless, when there was a high 
degree of skew in the frequency distribution of the variables 
being tested, the Mann-Whitney-U test was employed to determine 
if a difference was statistically significant. The advantage of 
this approach is that the Mann-Whitney test is nonparametric and 
thus makes no assumptions about the distribution of the data. 
The disadvantage of nonparametric tests applied to interval data 
is that they do not use all of the information in the data and 
thus they lack power in comparison to parametric tests. This was 
not of practical concern in most of the analyses because most of 
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the differences were significant with the nonparametric 
analyses. 
7.7. Multivariate analyses; 
We were interested in determining whether it would be possible 
to identify a high risk group to selectively receive nonionic 
contrast. To do so we had to know which characteristics would 
define such a group. We had recorded whether each subject in the 
trial did or did not have each of a large number of 
characteristics, such as a history of prior reaction to 
contrast, allergy etc. We had not studied subjects without any 
apparent increased risk of an adverse event, apart from a few 
people with normal hearts having cardiac angiography. These 
individuals had a low rate of adverse events and served as a 
useful population to compare with others having cardiac 
angiography. Among those having intravenous contrast the 
subjects who were aged over 50 years, but who were otherwise not 
apparently at increas ed risk, had a low incidence of adverse 
events. Thus these individuals were used to gauge whether the 
incidence of adverse events was increased in those with any of 
a number of potential risk factors. Using this approach 
univariate analyses were performed and the relative risk of an 
adverse event in subjects with any given characteristic was 
calculated. These analyses did not simultaneously consider the 
independent effects of the characteristics being studied. When 
subjects had both asthma and a history of prior reaction to , 
contrast it was impossible to determine which factor was most 
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responsible for the observed increase in the incidence of 
adverse events in such subjects. The relative importance of each 
of the factors can be determined in such situations by a 
multivariate analysis if the individual factors are not highly 
correlated. 
The other situation which required a multivariate approach was 
the imbalance in the randomized groups in the intravenous 
stratum with regard to cardiac disease. 
We performed a series of multiple logistic regression analyses 
using the BMDP LR program [BMDP Statistical Software, Dixon WJ 
ed, University of California Press, Berkeley, 1988]. It was 
necessary to use a logistic regression because the dependent 
variable was of binary type in all cases. In the case of the 
cardiac angiography stratum the dependent variable was the 
occurrence in a patient of a defined type of adverse reaction 
which was labelled "clinically important" (Appendix A]. In the 
intravenous stratum the dependant was the occurrence in a 
patient of an adverse event which required the attendance of a 
doctor. This was used instead of an event requiring therapy to 
increase the number of events available for the analysis. We 
analysed separately the randomized patients having cardiac 
angiography or intravenous contrast using the type of contrast, 
severity of cardiac disease, allergy, age etc. as independent 
variables. The exponential of the beta coefficients of the 
independent variables provided the odds ratio for eventjno event 
associated with the presence or absence of the particular 
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characteristic being tested. A 95% confidence interval was 
constructed for the odds ratio using the standard error of the 
beta coefficients. Variables were entered into and removed from 
the models by both manual and automatic methods. In this way 
multicollinearity could be recognized by a change in the 
apparent importance of variables, when other correlated 
variables were entered into the model. Variables which had no 
significant effect were omitted from the "best fit" model. The 
goodness-of-fit chi-squared statistic was used to determine how 
well a given model fitted the data. The odds ratios quoted for 
given variables were those from the "best fit" model [Appendices 
A and B]. 
Within both the cardiac and intravenous groups separate 
analyses were performed for all patients receiving high-osmolar 
or low-osmolar contrast irrespective of whether they had been 
randomized or not [Appendices A and B]. This prevented 
exclusions from the randomized trial from weakening the 
relationship between certain characteristics and the likelihood 
of an adverse event. We were able to do this, as we had 
collected the same data on the cases who were not randomized as 
on those who were, and we did not try to compare contrast media 
in this analysis. These analyses identified those factors which 
were independently associated with the greatest increase in risk 
of an adverse reaction to contrast. 
7.8. Multiple outcomes and comparisons; 
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This trial had several outcomes all of which were intended to 
indicate the relative toxicity of high and low-osmolar contrast. 
If some of the outcomes had indicated a benefit with low-osmolar 
contrast and some had not, it would have made a decision as to 
which contrast was superior more difficult. Such a problem did 
not actually arise because nonionic contrast appeared superior 
by all outcome criteria. There are several ways in which this 
problem can be handled in trials. One is to determine the 
relative importance of the various outcomes and to aim the 
analysis at a predetermined primary outcome. In using this 
approach it is important to be sure that t he correct primary 
outcome has been chosen to avoid problems such as occurred in 
the trials comparing thrombolytic therapies for myocardial 
infarction [Sherry (1991)]. 
Another approach has been to develop mathematical models .to 
describe a group of outcomes, and thus to derive a single global 
index of superiority of one treatment over another. These models 
have to be developed with a clear knowledge of what they are 
describing, and it is often not appropriate to try to arrive at 
a simple answer to a question of efficacy when the answer may 
actually be more complex. One therapy may only offer a limited 
advantage over another and even this may be limited to specific 
types of patients. 
We reported several comparisons of the two types of contrast 
media in our report on the cardiac ,angiography stratum [Appendix 
A]. These comparisons were in terms of various types of adverse 
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events which required therapy. The comparisons were reported 
with statistical significance values. We used the Bonferroni 
procedure to adjust the significance level for the multiplicity 
of the comparisons [Miller (1981)]. This procedure requires that 
the p value associated with each of the individual pairwise 
comparisons of a set of multiple comparisons be multiplied by 
the number of comparisons made. This method of adjustment for 
multiple comparisons was chosen because of it's simplicity of 
calculation. The purpose of this adjustment was to protect 
against a type I error. When many comparisons are made, and 
particularly when they are unplanned and suggested by the 
results, . the probability of a type I error is considerably above 
that implied by the nominal significance level. There are many 
techniques which aim to overcome this problem, but most of them 
suffer from the limitation that, while they protect against type 
I errors, they increase the chances of making a type II error 
[Steel (1980)]. This did not prove to be a problem in the 
present trial as the differences remained significant even after 
allowing for multiple comparisons [Appendix A]. 
7.9. Contrast nephropathy: 
This trial showed a slightly lower frequency of contrast 
nephropathy with nonionic contrast, but the difference between 
the contrast media was not statistically significant [Appendix 
C]. However, the study ended without having enroled sufficient 
subjects to exclude or yonfirm that nonionic contrast can cause 
a 50% reduction in the incidence of contrast nephropathy, as 
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defined by a 25% rise in the serum creatinine. The parametric 
analysis also did not have a very high power. Therefore we are 
unable to either confirm or exclude the possibility that 
nonionic contrast is less nephrotoxic than high-osmolar contrast 
in subjects with renal impairment. The results of the study did 
confirm that the incidence of severe contrast nephropathy is low 
in subjects with moderate renal impairment and that the 
potential absolute benefit with low-osmolar contrast can thus be 
modest at best [Appendix C]. 
CHAPTER 8 
ECONOMIC ANALYSIS 
8.1. The role of economic analysis: 
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There has been increasing interest in health care financing in 
recent years. This has resulted in part from the development, 
and increasing demand for, new and expensive medical programs, 
and also from the limited availability of resources to pay for 
such programs. Economic analysis has a role in aiding the 
decision making process when health program planners are faced 
with choosing to supply some services at the expense of 
competing alternatives. The underlying assumption of all such 
economic analyses is that the aim of the decision maker is to 
provide the maximum aggregate health benefit to the target 
population using the resources available [Detsky (1990)]. In 
practice, factors other than this may be dominant in determining 
the distribution of scarce resources. Therefore economic 
analyses are only one contributory factor in any decision about 
health care delivery [Detsky (1990)]. 
Clinicians, in their relationships with individual patients, 
do not have the same aims as health program managers. In 
clinical practice the role of the clinician is to provide the 
best available care to the patient irrespective of cost. The 
clinician does not generally consider the possible effects of 
therapy for his own patient on the availability of resources to 
treat other patients. Therefore cost-effectiveness is not a 
factor in most decisions that doctors make when treating 
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individual patients. However, cost-effectiveness is relevant to 
doctors who are involved in decisions about how best to use 
available resources in a population setting. 
Because cost-effectiveness is not a major consideration in the 
daily practice of many physicians, it's role in decision making 
has often been misunderstood by practising clinicians. This has 
led to calls for doctors to act as advocates for their patients 
as an unidentified group and not to be influenced by factors 
such as cost-effectiveness, even when they are acting in the 
role of advisors to health policy planners [McClennan (1987)]. 
This is not always appropriate and is more akin to sectional 
political lobbying than responsible medical practice. If doctors 
cannot function differently in their two separate roles as 
clinicians and as potential advisors to health policy planners, 
then they will be ignored in the latter role, probably to the 
ultimate detriment of their individual patients. 
8.2. Classification of economic analyses; 
Economic analysis of a medical program always involves a 
consideration of the costs of the program. However, to be 
considered a complete analysis, there have to be two other 
elements to the analysis as well. The first is a comparison of 
at least two competing programs and the second is a 
consideration of the potential benefits as well as the costs of 
each of the alternatives [Stoddart (1984)]. In situations in 
which the competing programs are not known to be either equally 
effective or equally costly, any less complete form of analysis 
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cannot provide all the economic data necessary to guide a 
decision as to which program provides the best "value" for 
money. 
There are at least three forms of economic analysis which can 
be considered to be complete and useful in the above situation. 
These are cost-effectiveness, cost-utility, and cost-benefit 
analysis [Stoddart (1984)]. The difference between the three 
lies in how they express the non-monetary consequences of the 
competing programs. Cost-effectiveness analysis determines how 
much must be spent to achieve a unit of a given clinical 
outcome, such as a year of life saved, under the operation of 
each of the programs. Cost-utility differs in that peoples' 
preferences for given health states are taken into account and 
act as weighting factors in the calculation of the clinical 
outcomes, or "utilities", which arise from the operation of the 
competing programs. Thus in this form of analysis both quantity 
and quality of life are considered in measuring clinical 
outcomes. Cost-benefit analysis expresses both the costs and the 
outcomes of the competing programs in terms of monetary units, 
and thus leads to a dimensionless cost/benefit ratio. 
Although cost-benefit analyses always involve a comparison 
between at least two program options, one of the options may be 
the implicit one of simply not providing the program being 
evaluated [Torrance (1986)]. In that way cost-benefit analysis 
can be considered to give rise to an estimate of the "absolute" 
value (or net social worth) of a program in terms of the 
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potential resources that it consumes or generates [Stoddart 
( 1984) ] . Therefore a decision might be made to fund only 
programs with a positive net social value [Torrance (1986)]. 
The form of analysis which is most appropriate in any given 
situation depends in part on the viewpoint from which the 
analysis is being undertaken. Cost-effectiveness does not 
necessarily reflect the health state preferences of the 
consumers of the health care programs. Therefore is not the best 
method to use when the analysis is being performed from their 
perspective. The viewpoint of the analysis also determines what 
costs should be included in the analysis. For example, if the 
analysis is being performed from the viewpoint of a health 
provider organization, it may not be relevant to consider 
whether one program is more likely than another to lead to less 
expenses for the patient in travelling to and from the health 
care facility. The same reasoning applies when considering which 
outcomes, or non-monetary benefits, to include in an analysis. 
These issues have been discussed by Drummond et al. [Drummond 
(1987)]. 
In our own situation we were mainly interested in the economic 
consequences of switching from high to low-osmolar contrast from 
the point of view of the health care system. We did, however, 
feel that it was important to consider the effect of the 
contrast-related adverse reactions on the patients quality-of-
life, when determining the clinical consequences of the use of 
the two types of contrast. Therefore we aimed to perform both 
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cost-effectiveness and cost-utility analyses of the use of 
contrast media. 
8.3. Incorporating quality-of-life in outcome measures; 
Judgement of quality-of-life is largely subjective. It is 
often measured by determining the preference of individuals for 
various health states. The degree of preference is inversely 
related to the "quality" of the health state. There are four 
basic steps in determining the quality of a given health state. 
The first is to identify t he state(s) to be rated. The second is 
to decide who will perform the rating. The third is to decide 
how the rating will be done. The final step is to aggregate the 
ratings in some fashion across all the raters to arrive at a 
more universal measure of the quality of the given health state. 
The term "utility" has been used in many senses. In one rather 
broad usage the term is meant to imply a quality adjusted health 
state which results from the operation of a health care program. 
The term is used in this fashion in clinical decision analysis 
and in health program evaluation by cost-utility analyses. In a 
more narrow, but partly related, usage the term refers to von 
Neumann-Morgenstern utilities (vN-M utilities). These are 
specific weights applied to given situations (not necessarily 
health states) by individuals who express their preferences for 
the situations under conditions of uncertainty [Torrance 
( 1989)). Such values are based on a general utility theory 
developed by von Neumann and Morgenstern in the 1940's. This 
theory provides a normative model of how rational individuals 
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should make decisions under conditions of uncertainty [Torrance 
(1989)]. This is not to say that individuals do make decisions 
in such a fashion all the time. However, there is some empirical 
evidence that individuals follow the model in many situations 
[Torrance (1989)]. 
Confusion over the use of the term "utility" arises in part 
because utility theory provides the basis for the "standard 
gamble" approach to the measurement of health state preferences, 
called "utilities", which are subsequently used in the 
calculation of the quality-of-life adjusted outcome measures 
also known as "utilities". 
Since such outcome "utilities" are measures which incorporate 
the preferences of patients for various health states, there is 
a need for a method(s) to measure these preferences in order to 
calculate the "utility" score for any given health state. 
Several such methods now exist. These include the standard 
gamble, time trade off, rating scale, magnitude estimation, 
equivalence, and willingness-to-pay methods [Froberg (1989)]. 
These methods are not all equivalent, often yield very different 
estimates of utility, and several have not been fully evaluated 
with regard to reliability and validity [Froberg (1989)]. 
The standard gamble is one of the better studied methods and 
is often considered to be the gold standard against which the 
other methods should be judged. This is because the standard 
gamble is directly derived from utility theory. It therefore 
provides a direct measure of preferences under conditions of 
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uncertainty. In the standard gamble method a rater is presented 
with a description of a given health state or is asked to 
imagine his own current health state. Suppose that this health 
state is preferred to death. Now the rater is asked to state 
whether he would prefer to stay in the given health state for a 
guaranteed specified period (say t years), or to take a gamble. 
The gamble is that he would live for the same time period in 
full health with probability p or die immediately with 
probability 1-p. The probability p is varied until the point is 
reached where the rater is indifferent to the alternatives of 
the gamble or the certainty of staying in the health state being 
rated. This value for p at indifference is the von Neumann-
Morgenstern utility of the health state. This method can be 
difficult for people to understand, however, and therefore some 
of the other methods may be more feasible in practice. 
The utility of the health states resulting from the occurrence 
of adverse reactions was not measured at the time that they 
occurr ed in the study which is discussed in this thesis. In 
fact, the cost-utility study was only designed after the trial 
proper was well under way. Telephone interviews wer~ performed 
after the study to measure the quality of the health states 
resulting from minor contrast-related side- effects. It was felt 
that it would be impractical to use the standard gamble method 
with a telephone interview. The willingness-to-pay method to 
rate the quality of the health states was used and was found to 
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be feasible in practice. The details of the planned cost-utility 
study will be discussed later in the chapter. 
The results derived with the various scaling methods may be 
influenced by the context in which the measurement is made, as 
well as by characteristics of the population studied [Froberg 
( 1989a)]. For example, experience with an illness tends to 
increase the utility values assigned by raters to states 
associated with that illness. Health professionals ofteh put 
lower values on health states than patients or the general 
public [Froberg (1989a)]. 
Health states are generally quite complex to describe and may 
have many attributes such as pain, loss of function, mood etc. 
Each of the attributes can have a varying number of levels. Such 
complex multi-attribute states can be rated as units or the 
individual elements that make them up can be rated separately 
and then combined. There are advantages to taking the latter 
"decomposed" approach. This increases the number of states that 
can ultimately be rated, and exposes the weighting factors that 
are applied to the various attributes by the rater in arriving 
at the final global assessment of the quality of the state 
[Froberg (1989b)]. It can also (with a functional measurement 
approach to a statistically inferred decomposed model) allow 
simultaneous validation of the derived scale values, along with 
a check for interaction between attributes at various levels 
[Froberg (1989b)]. 
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Following measurement of the vN-M utility values of the 
various health states of interest, this measurement of the 
preference of individuals for the health state has to be 
incorporated in some way into the outcome, when evaluating 
health care programs. Doing so incorporates the concept of the 
quality of the health state in the outcome. One of the original, 
and still the most widely employed, ways to do this is to 
calculat e a measure o f o u t c ome known as a Quality-Adjusted-Life-
Year (QALY) [Torrance (1989)]. This is done by multiplying the 
time spent in a given health state by the quality adjustment 
factor derived from the measurement of the vN-M utility of the 
state. It should be noted that the weighting factor for the 
quality-of-life need not always be derived from empirically 
measured vN-M utilities. However, this is the best way to derive 
the weights if the quality adjustment is meant to reflect the 
true health state preferences of those likely to be in the 
health state [Torranpe (1989)]. 
In calculating QALY's it is assumed that a prolonged but poor 
quality health state has the same "value" as a shorter but good 
quality one. It is also assumed that the gain of a QALY is 
always "worth" the same amount, no matter whether this gain is 
in the form of a minor increment in quality or quantity of life 
for a large number of people, or an equivalent major increment 
for a small number of people. In this sense QALY's are equitable 
measures. Another advantage o,f the QALY is the fact that it 
provides a unit of measure which · allows comparison between 
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widely differing health care programs. This is of major 
importance when the programs are being competitively evaluated. 
A major limitation of the QALY for comparison of various 
health states is the fact that the preference of the raters for 
given health states may not be mirrored by the relative number 
of QALY's assigned to the states. Situations have been 
discovered where raters have expressed a clear preference for 
one health state rather than another, but when the two states 
were compared by using the calculated QALY's, the least 
preferred state seemed superior [Mehrez (1989)]. This situation 
is obviously undesirable, but may not be all that common in 
practice. A more common situation would probably be that, while 
the order of preference for the health states is preserved in 
calculating the QALY's, the absolute value of each state is not 
directly reflected in the number of associated QALY's. This 
would be of importance when these states are being compared with 
others outside of the setting in which they were initially 
evaluated. This problem arises because QALY's are not the same 
thing as the vN-M utilities from which they may be derived. In 
order that the utility be properly reflected by the derived QALY 
value several assumptions have to hold. These are ( 1) that 
quality and quantity are mutually utility-independent (i.e. 
preferences for gambles on quality are independent of quantity 
and vice versa), (2) the trade off of quantity for quality 
exhibits the constant proportional trade off property (i.e. the 
proportion of remaining life that one would trade off for a 
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specified quality improvement is independent of the amount of 
remaining life), and (3) that for a given quality, utility is 
linearly related to quantity [Torrance ( 1989) ] . Since these 
assumptions do not often hold in practice, QALY's are not the 
same as utilities [Loomes (1989)]. 
A further problem with QALY's is that they can only be used to 
rate a single chronic health state unless further assumptions 
are made. One such assumption is that the utility function of 
the individual over his or her lifetime health profile is 
additive in form. This assumption has no empiric basis and, 
since it is often more realistic to imagine that an individual 
will not remain in a given specific health state for a prolonged 
period of time, this constitutes a major limitation to the use 
of QALY's. 
To overcome these problems with QALY's Mehrez and Gafni have 
developed a concept which they call the Healthy-Years 
Equivalents (HYE) [Mehrez ( 1989)]. This health state index 
incorporates elements of quality and quantity, and also allows 
comparisons across programs. Since it is directly derived from 
vN-M utilities and uses the rater's own utility function, it 
always reflects the health state preferences of the rater. The 
index is more difficult to calculate than the QALY, as it 
requires that, either the individual rater's utility function be 
known over the projected lifetime health profile in any 
situation where more than one period of less than full health is 
likely, or that the HYE value be obtained by using a multi-stage 
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lottery approach. In fact the latter approach can be used to 
measure the HYE value of a chronic health state, a particular 
lifetime health profile containing several different health 
states, and even the HYE values for many possible lifetime 
health profiles [Mehrez (1991)]. This approach has been proposed 
in relation to contrast media [Gafni (1990)]. Gafni states that 
the utility of a brief reaction to contrast can be rated using 
the standard gamble approach. Then the trade off of heal thy 
years to eliminate the reaction can be measured in a second 
standard gamble measurement. This yields the Heal thy-Years 
Equivalent of the life with the reaction directly and without 
any of the assumptions inherent in the use of the QALY measure. 
8.4. A review of some existing economic analyses of contrast 
media: 
There is a real dearth of complete economic analyses of the 
use of contrast media in the literature. Early considerations of 
the costs of contrast media were limited to estimates of the 
incremental cost of converting to the use of low-osmolar 
contrast media, generally for all patients. Sometimes this was 
combined with an estimate of the likely benefit of low-osmolar 
agents in reducing contrast related deaths; a benefit which has 
never actually been proven to exist. By this means estimates of 
the marginal cost-effectiveness of low-osmolar contrast, in 
terms of lives saved, were made [Jacobson (1988)]. These studies 
did not attempt to estimate the costs associated with nonfatal 
contrast reactions. Similarly, they did not attempt to view the 
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situation from the viewpoint of the person receiving the 
contrast. Powe et al. did measure the costs to a health provider 
of various nonfatal reactions to high-osmolar media [Powe 
(1988)]. This study did not consider the costs or benefits 
associated with the use of low-osmolar contrast. Thus it could 
not yield an incremental cost-effectiveness ratio of any kind. 
Hlatky et al. recently reported a randomized trial of high 
versus low-osmolar contrast media for cardiac angiography 
[Hlatky (1990)]. This study considered the cost and the 
effectiveness of the two types of contrast. The viewpoint was 
that of the health care provider. However, they did not report 
a specific cost-effectiveness ratio and did not consider the 
option of a policy of selective use of low-osmolar contrast in 
high risk subjects. They did not consider any capital costs and 
only allowed for operating costs in their analysis. They did not 
consider any costs or effects that occurred more than 24 hours 
after the contrast had been given. The sources of the costs, and 
how these were measured, are not stated clearly in the paper. 
They did draw appropriately tentative conclusions and were aware 
of the problems regarding the generalizability of their results. 
Thus it can be seen that none of the published cost-
effectiveness studies of contrast media have been 
methodologically rigorous. 
Appel et al. reported a study in which they attempted to 
compare the 
radiological 
incremental cost of low-osmolar contrast, for 
examinations in general, with the amount that 
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people would pay to achieve specified reductions in the risk of 
contrast-related adverse effects [Appel {1990)]. This was done 
by selecting a group of outpatients, who were not going to have, 
and had not had an examination with contrast in the recent past. 
These raters were asked to state their willingness-to-pay 
specified amounts to be given low rather than high-osmolar 
contrast, while (a) imagining that they were about to be given 
contrast media and (b) while assuming that the low-osmolar media 
were less likely to cause specified adverse events. The low-
osmolar media were stated to provide a specified reduction in 
risk of· various minor and major adverse reactions. The raters 
considered how much they would pay to reduce the risk of each 
specific adverse reaction alone. They also stated how much they 
would pay to reduce the risk of all minor side-effects combined, 
and further, stated how much they would pay to reduce the risk 
of all major and minor side-effects simultaneously. 
This study has several limitations. Firstly it does not 
address the question of the cost-utility of the two types of 
contrast media directly~ Only one aspect of the cost of treating 
such patients with low or high-osmolar contrast is considered. 
The assumptions made with regard to the relative toxicity of the 
two types of media are based on the flawed studies which I have 
reviewed in Chapter 2. No attempt was made to allow for the 
uncertainty of those estimates by presenting the raters with 
more than one set of estimates of risk reduction. The health 
states which they described to the raters were contrived such 
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that none of the adverse reactions were assumed to lead to 
permanent, or even long term disability. Therefore the time 
horizon selected for this study was very short. This is not 
necessarily an accurate reflection of reality. The willingness-
to-pay values derived from this study are probably not the same 
as those that would be derived from people who had recently 
experienced a contrast reaction. Such individuals would probably 
be in a better position to judge the utility of the health state 
related to any given type of contrast reaction. A further 
problem with the study is that the authors suggested possible 
responses to the willingness-to-pay questions to the raters. 
This is very likely to have had an anchoring effect and to have 
played a major role in determining the actual responses observed 
[Froberg {1989a)]. The authors recognized this limitation, but 
they state that they were obliged to use this approach because 
a pilot study had shown that raters had difficulty in providing 
answers to open ended questions about willingness-to-pay. This 
• 
leads to a concern about the adequacy of the method used to 
determine the utilities. Furthermore the interviewer in this 
study perceived that 36% of the raters appeared to have 
difficulty understanding the concept of risks. If this is true 
it is not clear how the observed responses were obtained and 
whether these were true reflections of the incremental "utility" 
of the two kinds of contrast media. It would have been easier to 
measure the absolute utility of each of the states separately, 
and then to have used the published event rates associated with 
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each type of contrast, to derive an index of the utility of the 
two types of contrast. However, this approach would not capture 
the attitude to risk of the raters in making a decision as to 
which type of contrast to employ. 
The most complete economic analysis of the use of contrast 
media was reported by Goel et al. (Goel (1989)]. These authors 
performed a cost-utility analysis of the use of low and high-
osmolar contrast media. They did consider the alternative of 
using the low-osmolar contrast selectively in a high risk 
subgroup. The problem was structured as a decision tree and the 
final utilities associated with each decision option were 
expressed as QALY's. The major limitation of this analysis is 
the fact that it is based on assumptions regarding the relative 
toxicity of the two types of contrast media, and also about the 
quality of life associated with the health states which result 
from the occurrence of various contrast-related adverse 
reactions. No attempt was made to measure the vN-M utilities of 
these states. Reactions to contrast media are generally of very 
short duration in relation to the time horizon chosen in 
economic analysis (30 years in the study of Goel et al.). This 
means that even if they are associated with a major reduction in 
quality of life that they will not reduce by much the total 
number of QALY' s for a person having such a reaction. Gafni 
pointed this out in commentaries on the Goel study and suggested 
that HYE's would be a better way of expressing the outcome of a 
future empirically based cost-utility study of contrast media 
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(Gafni (1990), Gafni (1991)]. The major difficulty was related 
to the relatively common minor adverse effects associated with 
contrast media. These effects should therefore be the ones most 
closely examined in any future empirical utility analysis. Goel 
et al., in their reply to the criticisms of Gafni, do not deny 
the problems associated with the use of QALY's, which I have 
discussed above. They do point out that any analysis that uses 
HYE's as the unit of outcome cannot be readily compared to 
analyses of other programs which were reported in terms of 
QALY's (Goel (1990)]. 
Irrespective of the criticisms of the studies which I have 
discussed above, the results of all of these analyses have 
indicated that the decision to use low-osmolar contrast has 
major cost implications. This is very important from the point 
of view of health care providers and continues to be emphasized 
in the literature. There is no agreement yet about th~ best way 
to use the low-osmolar contrast without causing huge increases 
in expenditure. The strategy of selective use of low-osmolar 
contrast for patients at high risk of a contrast-related adverse 
reaction may well be desirable from a cost-utility point of 
view. There continues to be sufficient uncertainty about the 
true cost-utility ratio associated with the use of low-osmolar 
contrast to justify further research in this area. 
8.5. Economic analysis of our own study; 
We have decided to perform the economic analysis of our study 
I 
largely from the viewpoint of the health care system. This is 
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due to the fact that there is considerable controversy within 
the system as to whether nonionic contrast should be funded 
ahead of other programs, given the existing climate of fiscal 
restraint. Therefore our primary purpose is to provide data that 
might be useful in deciding whether to fund the use of low-
osmolar contrast. It is necessary to perform a cost-utility or 
a cost-benefit analysis to achieve this objective, as the 
outcomes have to be expressed in a form that can be compared 
across disparate programs. A cost-utility analysis is also 
useful as both mortality and morbidity can be consequences of 
contrast-related adverse events [Torrance (1986)]. 
The current study was designed to address the question of 
whether a high risk subgroup could be identified. We aim to 
analyse the potential costs and consequences of a policy of 
selective use of low-osmolar contrast in such a high risk group 
only. Therefore we will perform both cost-effectiveness and 
cost-utility analyses of three competing program choices. The 
first choice is the continued use of high-osmolar contrast for 
all examinations of the type included in the current trial. The 
second is the universal use of low-osmolar contrast for all such 
examinations, while the third is the selective use of low-
osmolar contrast only in those felt to be at high risk of an 
adverse reaction. 
For economic analysis of the data from the trial itself only 
randomized patients can be included. Some patients had been 
excluded from the randomized trial because they were felt to be 
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at high risk of a reaction to high-osmolar contrast, but the 
doctors entering patients in the randomized trial did not only 
exclude individuals whom they felt were at increased risk of a 
reaction to high-osmolar contrast. The decision as to which 
patients were part of a high risk group was made after the study 
for patients in the cardiac catheterization arm. The records of 
all patients were reviewed, blind to whether they had suffered 
an adverse event. Those patients who had specified risk factors 
that could have been identified before contrast administration 
were placed in the high risk group. Since the assignment of high 
risk status was retrospective and the predictive ability of the 
risk factors has not been validated in a second independent 
testing set of patients, a policy of selective use might be more 
or less economically efficient than indicated by the results of 
the current analysis [Appendix A]. To allow for that we will 
perform sensi ti vi ty analyses of the proportion of patients 
included in the high risk group along with the likely incidence 
rates of adverse reactions in each high and low risk group 
combination during further cost-utility analyses. The actual 
costs and consequences of a policy of selective use of low-
osmolar contrast will have to be measured in a further study. 
High risk patients will be selected in advance using specified 
criteria for receipt of low-osmolar contrast. 
For the cost-effectiveness analysis of the current trial the 
incremental health care cost associated with the use of low-
osmolar contrast was estimated. This served as the numerator for 
the cost-effectiveness ratios [Torrance (1986)]. 
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The 
denominators were the incremental numbers of adverse reactions 
of various types which had occurred. Ratios were calculated 
separately for the options of universal use of low-osmolar 
contrast and selective use of low-osmolar in defined risk groups 
only [Appendices A and B). 
Data had not been collected regarding time spent by patients 
in the catheterization laboratory as a result of reactions. This 
made assignment of appropriate related costs difficult. Patients 
had not been followed up after they left the radiology or 
cardiology departments during the study. However the medical 
records of all those who had significant adverse reactions to 
contrast were examined to determine if any extra resources had 
been used in their care after they left those departments. In 
this way at least the hospital based resources consumed were 
identified. Capital and operating costs were included in the 
analysis 1 by using costs for inpatient care 1 which included 
these elements, as provided by the hospital administration. The 
cost figures used were those that were borne by the health care 
provider, as patients do not pay for health care at the point of 
delivery in Canada. Indirect costs or benefits applying to the 
patients as a result of the receipt of low-osmolar contrast were 
not considered. This is reasonable as the viewpoint is that of 
the health care system. Since all of the costs and consequences 
accrued very quickly after the contrast was given, we did not 
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have to allow for differential timing of the costs and benefits, 
or employ discounting [Appendices A and B]. 
The cost-utility analysis will be performed in collaboration 
with Dr. Allan Detsky in Toronto. The problem will be structured 
as a decision tree, much as in the study by Goel (Goel (1989)]. 
The cost-utility of low-osmolar contrast in high risk and low 
risk populations will be examined. Once again, sensi ti vi ty 
analyses will be performed for factors likely to affect the 
cost-utility of a policy of selective use of low-osmolar 
contrast in patients at high risk. The direct costs used in this 
analysis will be the same as those used for the cost-
effectiveness study and will thus reflect costs to the health 
care system. There were no deaths and very few life threatening 
reactions during our study. The study was not designed to 
analyse such outcomes in any case. Therefore we will have to use 
figures from the literature to allow for the possibility of the 
occurrence of such adverse events. 
We did' not measure the vN-M utilities associated with severe 
reactions directly. To do so would have required a proxy 
population of raters and would not have been worth the effort in 
view of the very low frequency of such events and hence their 
limited impact on the final utility of any program chosen. The 
estimates required for the frequency and utility of severe 
reactions or death will be handled in a manner analogous to that 
used by Goel et al. [Goel (1989)]. 
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As has previously been noted it is desirable to empirically 
measure the quality-of -1 if e consequences of minor contrast 
reactions. This is because these reactions are relatively common 
and low-osmolar contrast is effective in reducing their 
incidence. Therefore they could have a considerable influence on 
the results of any cost-utility analysis. 
We felt that those who had experienced the reactions were in 
the best position to judge their quality-of-life implications. 
It would have been best to perform the utility measurement of 
these reactions soon after they had occurred using the standard 
gamble method. Unfortunately we did not have the organization in 
place, or the resources available, to perform that measurement 
at such a time. 
We performed telephone interviews with patients in the cardiac 
stratum who had had minor symptomatic reactions which did not 
necessarily require therapy. These were defined as the 
occurrence of symptoms graded as greater than or equal to 5 on 
the 10 point subjective severity scale (see Figure 3 above) • The 
interviews were performed up to eight months after the cardiac 
catheterization had been performed. The results of these 
interviews are suspect because some patients may have forgotten 
some details of the event being rated. It will be necessary to 
make utility measurements in relation to adverse events by 
interviewing a separate cohort of patients soon after similar 
events have occurred. 
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In our initial telephone interviews we identified 384 subjects 
who had a minor symptomatic adverse reaction to cardiac 
angiography during the last 8 months of the study. We chose this 
time period to maximize the chance that the subjects would 
remember the symptoms and to ensure that we would have a 
sufficient number of raters to give reasonably reliable 
estimates of the quality-of-life implications of the symptoms. 
We arranged for each subject's cardiologist to send them a form 
letter informing them that we would call and of the reason for 
the call. One cardiologist, who had participated in the trial, 
decided not to collaborate in this part of the study. This led 
to the exclusion of about 10% of otherwise eligible subjects. A 
further number were unavailable for inclusion in this portion of 
the study because they had died or were otherwise uncontactable. 
These factors further limit the usefulness of the data because 
they reduce its' representativeness. 
24 patients were contacted in an initial pilot study and were 
thus not used in the final analysis. Overall we were able to 
make contact with 229 of the original 384 subjects identified. 
Of these, 36 were either unable to remember the symptomatic 
adverse reaction or were unable to comprehend the nature of the 
questions asked. Therefore we had responses from 193 patients 
available for analysis. 
Each subject was asked whether they remembered the adverse 
reaction, and if so, they were reminded of how they had rated 
its severity at the time of the trial. They were then asked to 
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imagine that they were about to have contrast again and that 
they were certain to have the same symptomatic reaction as they 
had previously. They were asked if they would pay any amount, 
out of their own pocket, to avoid the occurrence of the symptom. 
Subjects who had difficulty with the question were advised that 
they did not have to pay anything, if that was what they 
preferred, but they were not given any other anchor points in 
order not to limit the maximum possible value. 
We also collected information about the income, education, and 
demographic characteristics of the subjects. These factors, 
together with the subjective severity of the symptom, were 
examined to determine if they had any influence on the amount 
that people were willing to pay. In fact they did not appear to 
do so. 
The amount that someone is willing to pay to avoid the 
occurrence of a symptom is a measure of the net intrinsic 
benefit of avoiding that symptom. This is not exactly the same 
as the vN-M utility that someone would attach to the health 
state resulting from the existence of the symptom. The easiest 
way to handle the willingness-to-pay data in the cost-utility 
model is to consider it as an intangible benefit and to use it 
to offset some of the marginal net cost associated with the use 
of low-osmolar contrast [Torrance (1986)]. In this way the data 
are considered in the numerator of the cost-utility ratio. 
Since we did not measure the utilities associated wit~ more 
serious contrast-related adverse events (including reactions 
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requiring therapy in the cardiac catheterization stratum), we 
will have to make assumptions about the utility values 
associated with these states. This is probably reasonable in the 
case of the most serious reactions, as these are so infrequent 
that they will not influence the overall utility associated with 
any decision tree branch to a major extent. It will be necessary 
to measure the utility values for the states resulting from 
"intermediate" level reactions, as these may have more effect in 
the model. This may be done during a proposed study of the 
selective use of low-osmolar contrast. In the meantime we can 
still construct a cost-utility model by making assumptions about 
the utility of the 11 intermediate" level adverse events which are 
biased against high-osmolar contrast. If such a model still 
shows that selective use of low-osmolar contrast has a lower 
cost-utility ratio than universal use of low-osmolar, then we 
will still have an economic argument justifying the further 
study of that approach. 
The final outcomes of the decision tree branches will be 
expressed in terms of QALY's initially, in order to facilitate 
comparison with similar data on other programs. The results 
could also be expressed in terms of HYE's, but only if further 
assumptions are made, which seems to negate some of the benefits 
of that approach. 
CHAPTER 9 
ETHICAL CONSIDERATIONS 
9.1. Risks and benefits; 
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Before any research on human subjects is initiated there has 
to be a consideration of the risks and benefits of the proposed 
research. The major responsibility for this rests with the 
investigators, but research proposals are now generally subject 
to review by a separate institutional ethics review board before 
they are implemented. I have indicated that the investigators 
felt that there was insufficient evidence to justify the routine 
use of low-osmolar contrast prfor to the commence ment of the 
current trial. Therefore they did not think that it was 
unethical to withhold low-osmolar contrast f r om some subjects 
and to randomly assign them high-osmolar contrast. Furthermore 
high-osmolar contrast was in everyday use at the study 
institution anyway. The existing literature did not provide any 
evidence that low-osmolar contrast was more toxic than high-
osmolar contrast. If anything there was a prevailing opinion 
that low-osmolar contrast should be more widely used in 
radiology. Therefore it was not felt to be unethical to expose 
subjects to the high-osmolar medium, or the low-osmolar medium 
for that matter, given the then prevailing state of knowledge of 
the relative toxicity of the two types of contrast. 
Others did not hold the same views, however. Prior to the 
start of the current study there had been inquests in Ontario 
into the deaths of two young adults after receiving intravenous 
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contrast. The juries in those cases had recommended that there 
should be a substantial increase in government funding to allow 
the replacement of high-osmolar by low-osmolar contrast 
[Grainger (1987)]. This led to the virtual total replacement of 
high by low-osmolar media in that province. In Alberta the 
College of Physicians and Surgeons had reviewed the ethics and 
legalities of using low-osmolar media and concluded that only 
low-osmolar contrast should be used in that province [Parfrey 
(1988)]. These decisions had led to some problems because the 
high cost of the new media, combined with the lack of resources 
to pay for them, had required that expenditure on other forms of 
health care be curtailed [Linton (1990)]. The investigators 
interpreted this to mean that there was an even greater need for 
the study discussed herein to determine whether such policies 
could be justified by facts. 
Such controversies led to an extensive debate over the ethical 
and legal implications of the research proposal for the trial. 
The local ethical review board did not object to the nature of 
the study and eventually the funding agency also agreed that the 
study met with acceptable ethical and legal standards. The 
opinion which was received from the Canadian Medical Protective 
Association assumed that the low-osmolar media were less likely 
to cause death and severe reactions [F. Norman Brown, M.D. 
Personal communication]. There is still no evidence to prove 
that the new media can prevent death and the evidence that they 
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may reduce the incidence of severe side-effects following 
intravenous use is mainly derived from surveys. 
The study consent form did not state that the low-osmolar 
media were known to be less likely to cause death or severe 
reactions, as there was no evidence to say that this was so at 
the start of the study [Appendix D] . Neither was the study 
stopped on learning the results of the RACR and the Japanese 
surveys, as these studies did not provide the level of evidence 
that would demand such an action [Palmer ( 1988) , Katayama 
(1990)]. Individual doctors differed in their interpretation of 
the available evidence. This was accommodated by providing the 
radiologists and cardiologists who took part in the study with 
the opportunity to use their best judgement as to whether a 
patient should be randomized or not. As I have stated in an 
earlier chapter, they did in fact exclude people, whom they felt 
to be at excessive risk of an adverse reaction to high-osmolar 
contrast, and treated them with low-osmolar contrast. This 
approach left the study entry criteria flexible enough that 
emerging evidence of the greater safety of low-osmolar media 
would prevent inappropriate inclusion of subjects in the study. 
Apart from bearing the risk of a reaction to contrast (most of 
which would have existed anyway), the subjects in this study 
were also asked to provide some personal and medical information 
about themselves. This information was not of a sensitive nature 
and it's disclosure did not really constitute much of a material 
risk. The only other imposition was the requirement to have a 
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measurement of serum creatinine performed. The blood for this 
test was almost always taken at the time of insertion of the 
needle for injection of contrast and thus did not involve any 
increase in discomfort. Those with elevated serum creatinine 
were asked to have a second blood test done two days later, but 
this would have been done in some cases anyway and was not 
considered to be unreasonable from an ethical point of view. 
The benefits arising from participation in the study included 
the receipt of low-osmolar contrast, which had been shown to 
reduce discomfort (see Chapter 2), by many subjects who would 
not otherwise have received these agents at our institution 
during the period of the study. The only other benefit to 
participants in the trial was the indirect one of knowing that 
one's participation might provide information leading to better 
health care in the future. 
9.2. Stopping the trial; 
The decision to stop a trial is influenced by many factors 
both internal and external to the trial itself. A trial is 
designed to answer a question and, to be ethically sound, should 
appear to be able to answer that question without exposing 
participants to excessive risk. Statistical considerations play 
a role in deciding how large a study has to be so that it is 
likely to detect a positive answer to the question posed. Such 
calculations are done before the study starts, but they rest on 
assumed ~vent rates in at least one of the randomized groups. 
The ultimate intent is to have a study which is large enough to 
161 
exclude a benefit from the experimental treatment if one does 
not exist, and to be likely to detect such a benefit if it does 
exist. There is also a concern to determine the answer in as 
short a time as possible, so that others may benefit from the 
information. Finally, there is the concern that a minimum number 
of subjects should be enroled, and thus exposed to at least 
inconvenience, to achieve the research goal. 
The ideal way to achieve those competing objectives would be 
to keep constant watch on the results of the study as it 
progresses. This would allow the study to be stopped as soon as 
it provided an answer to the question posed. The problem with 
this approach is that it introduces the "multiple peeks bias". 
This means that it hugely increases the chances of making a type 
I error and declaring a difference between treatments 
"significant" when in fact it is not. This situation is not 
desirable, as there is then the real possibility that patients 
subsequently will be exposed to useless or even harmful therapy. 
To overcome these problems investigators have developed 
"stopping rules". These are prespecified guidelines as to when 
a trial should be stopped because a specific difference between 
treatments has been observed with a specified statistical 
significance level. Such rules need to applied by persons 
external to the trial itself to avoid all of the potential 
effects of the multiple peeks bias. This is generally done by 
' having the results reviewed by a policy and data monitoring 
board. The board will generally include people knowledgeable in 
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the area of trial design and analysis, as well as persons expert 
in the field of the research question. These boards make 
decisions about the need to continue a study using the 
prespecified stopping rules, together with considerations of 
whether the research question has been answered by other 
investigations, whether the treatments under study appear to be 
as safe as expected, and whether the current study is enroling 
patients in the manner predicted. These topics have recently 
been nicely discussed [Browner (1991)]. 
Monitoring the accumulating data in a trial can be done by 
performing analyses at specified intervals or by examining the 
data continuously in a form of sequential analysis [Armitage 
(1975)]. The sequential analysis carries a high risk of making 
a type I error. To protect against that a very conservative 
significance level is used. This then reduces the power of the 
study. The most practical solution is probably to perform a 
limited number of analyses after specified numbers of subjects 
have been entered in the trial. The significance level for each 
of the analyses can be selected so as to maintain the type I 
error rate at a specified level at the projected end of the 
trial. 
The organization of the trial under discussion here was not 
ideal in that a policy and data monitoring board was not set up. 
Repeated analyses of the accumulating data were not performed in 
order to prevent type I error. However, this delayed recognition 
that the low-osmolar media were substantially less likely to 
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cause an adverse hemodynamic event in those having cardiac 
angiography. An analysis of the overall event rate in the 
cardiac stratum was performed, when it was realized that the 
event rates were high. The result of this analysis was reviewed 
by an external advisor and, following the subsequent complete 
analysis of the data by contrast type, the decision was made to 
stop enrolment in the cardiac stratum. Enrolment in the 
intravenous stratum continued until the prespecified overall 
sample size was achieved. The trial was stopped at that point 
and the data were analysed. The results indicated that low-
osmolar contrast was beneficial in reducing the incidence of 
adverse reactions requiring therapy, but the reactions which had 
occurred were not life threatening and the difference between 
high and low-osmolar contrast only just reached statistical 
significance [Appendix B]. Therefore an external data monitoring 
board might not have stopped this arm of the study before the 
point at which it was stopped anyway. 
In summary the trial organization was not ideal in that formal 
processes for review of accumulating -data were not established. 
However, the investigators did keep a close watch on the trial 
generally and were aware of the nature of the events which were 
occurring in the trial. As a result, analyses were performed in 
a timely fashion, and it does not appear that subjects were 
exposed to undue risk of harm. External factors were able to 
influence the trial as the radiologists/cardiologists were able 
to take account of the emerging evidence of the superiority of 
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low-osmolar contrast in the literature when deciding which 
patients to enter in the trial. 
CHAPTER 10 
SUMMARY AND CONCLUSIONS 
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This thesis has reviewed the design, performance and analysis 
of a trial comparing the toxicity of high and low-osmolar 
contrast media. The trial suffered from several flaws which 
mainly arose during it's design and the early phases of patient 
enrolment. ' 
A thorough review of the literature should always be performed 
to determine what is already known about the subject for a 
research proposal. The review performed prior to this study 
should have been more comprehensive and careful in regard to the 
cardiovascular effects of contrast media, especially once it had 
been decided to include patients having cardiac catheterization 
in the trial. Such a review should have highlighted the 
differences between the formulations of high-osmolar contrast 
which bind calcium and those which do not. This might have led 
to the more clinically relevant comparison of nonionic and 
noncalcium-binding ionic high-osmolar media. 
The most important problems with the design of the trial were 
in the areas of choice of major outcomes, randomization 
procedure and blinding. Furthermore it was initially intended to 
combine two fairly different populations to measure a single 
outcome. The initial primary question of whether low-osmolar 
media caused less systemic adverse events than high-osmolar 
media was not the most relevant question for the population 
having cardiac angiography. The fact that other outcomes were 
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more important for this group was not considered sufficiently 
before the trial began. A separate sample size for a relevant 
outcome was not calculated for the group having cardiac 
angiography. The trial was not monitored in a way that allowed 
for external unbiased consideration of the accumulating data. 
Therefore the cardiac angiography trial was terminated only 
after informal monitoring led to the analysis of the data for 
that group. 
The flaws in trial design have implications for the 
interpretation of the results. It was intended that the trial 
would provide information about events of clinical importance so 
that the results might have an impact on clinical practice. The 
chosen major outcome for the cardiac angiography group proved 
too heterogenous in that regard. Fortunately the degree of 
detail in the information collected during the study did allow 
for post hoc construction of other outcomes which were somewhat 
more readily interpreted. It is uncertain whether the results of 
the trial of intravenous contrast will influence practice. Only 
a trial which examined more severe events or deaths would be 
assured of doing so and this type of trial would be a major 
undertaking. The economic analysis of the current trial is 
important however, because it illustrates the sort of trade offs 
that exist when a decision is made as to who should receive low-
osmolar contrast. 
The inadequacy of the randomization and blinding p~ocedures 
employed make it imperative to consider whether bias could have 
167 
had a major influence on the trial results. I have indicated in 
the thesis how comparisons made during the analysis attempted to 
determine whether bias was operative. The results of these 
analyses were reassuring in that they did not provide evidence 
to support a conclusion that bias had been introduced. Neither 
did they suggest that the conclusions of the study would have 
been different if a more optimal design had been used. However 
one cannot be certain after the fact that bias was not at least 
partly responsible for the results obtained and therefore one 
always has to be cautious in the interpretation of the results 
of studies with major design .flaws. It is always better to try 
to prevent bias by using a sound design than to have to consider 
whether it is operative after a study is complete. 
168 
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MSTRACT 
Background: A randomized trial was undertaken to compare the Incidence, risk 
factors and costs of adverse events after Ionic high-osmolar and nonlonic low-
osmolar radlocontrast media during cardiac angiography. 
Methods: We compared the frequency of therapeutic intervention for adverse 
reactions, and the frequency and severity of specified hemodynamic, systemic 
and symptomatic side effects in two groups randomly assigned to Ionic high-
osmolar (N=737) or nonlonlc CN=753) radtocontrast, and also in 366 patients 
who could not be randomized. 
Results: The randomized groups were wei I matched at baseline. Therapeutic 
intervention for adverse events was received by 213 of 737 (28.9 percent) 
patients after high-osmolar contrast, but by only 69 of 753 (9.2 percent) after 
nonlontc contrast (95 percent confidence Interval for the difference 15.8-
23.6 percent). Hemodyn am i c deterioration and symptoms also occurred 
substantially more often after high osmolar contrast, as did severe or 
prolonged reactions (2.9 vs 0.8 percent, p = 0.035>. Such severe reactions 
were virtually confined to those with severe cardiac disease. Multivariate 
analysis showed that severe coronary disease and unstable angina were 
predictors of adverse reactions of clinical Importance. If alI patients In our 
randomized trial had been given nonlonlc contrast, the Incremental cost per 
procedure would have been Can $100. This cost would be higher In the USA. 
Conclusions: Nonionic contrast is better tolerated than calcium binding Ionic 
high-osmolar contrast during cardiac angiography. Should cost constraints 
deter universal use of nonionic contrast, selective use In those with severe 
cardiac disease could be considered. 
I 
Key Words: contrast medl a, 
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INTRODUCTION 
The high osmolal tty of conventional contrast media may contribute to their 
adverse side effects. New Iodinated contrast media have lower osmolal tty and 
some are nonionic. Low-osmolar agents cause less discomfort and may decrease 
objective side effects during cardiac angiography (1). Hypotension, cardiac 
arrhythmias, and pulmonary edema may be reduced in high risk patients such as 
those with recent myocardial infarction, unstable angina, hypotension, or 
severe heart failure (2). Unfortunately few high quality randomized control led 
trials comparing lntracardiac Infusion 
have been undertaken. Furthermore the 
of high-osmolar and low-osmolar media 
number of patients enrol led In these 
studies has been small and some did not use clinically Important outcome 
measures (3,4). Further trials have been recommended to determine whether 
nonlonic media actually perform better than high-osmolar media and, If so, 
whether their benefits exist for alI patients or only for high risk patients 
(5). 
The major problem with the new contrast media Is their cost- 10-20 times 
higher than conventional media In North America. Thus cost, as wei I as 
effectiveness, need to be considered In any decision as to which media should 
be used and for which patients (6). When alI contrast requiring radiological 
procedures were considered and optimistic assumptions about the safety of 
nontonic medta were made, It was found that the marginal cost of nonlonlc media 
was very high (7), amounting to $186 more per cardiac catheterization In a 
recent randomized trial (8). 
Our randomized, control led, double blind, clinical trial was undertaken 
(a) to compare the Incidence of clinically Important side effects following 
tntracardtac Injection of high-osmolar Ionic and low-osmolar nonlonlc 
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contrast media, 
(b) to determine whether it was possible to Identify patients who were at high 
risk of adverse reactions, and 
(c) to determine the cost-effectiveness of the nonionic versus the high-
osmolar media. 
METHODS 
For 17 months prior to August 1990 one thousand eight hundred and fifty 
six consecutive adult patients having cardiac catheterization without anglo-
plasty during the research nurses' working hours were considered for entry to 
the study. The only pre-specified exclusion criteria were (a) history of prior 
anaphylactoid reaction to contrast (N=32) and (b) a cardiac condition severe 
enough for the cardiologist to Insist upon nonlonlc contrast. These conditions 
Included low output left ventricular failure, unstable angina, or myocardial 
Infarction In the previous week (N = 188). It should be noted that notal I 
those with these clinical conditions were excluded from the randomized trial. 
However, refusal by the cardiologist to enter the patient for reasons other 
than (a) or (b) occurred In a further 125 Instances and refusal by the patient 
to enter the stUdy occurred on 21 occasions. 267 of 366 (72.9 percent> non-
randomized patients received nonlonlc contrast, 56 (15.3 percent> received low-
osmolar Tonic contrast and the remainder high-osmolar contrast. All non-
randomized patients were followed In the same manner as the randomized groups. 
737 patients were randomly assigned to receive high-osmolar contrast 
(Renografin 76 or MD 76 In alI cases) and 753 to receive nonionic contrast 
(lohexol N=33, lopamldol N=721). Outcomes were determined by the doctor, 
cardiopulmonary technician and patient, alI of whom were blind to which 
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contrast was prescribed. The research nurse was responsible for the allocation 
of contrast and was also an unbl inded recorder of events that occurred during 
and after the procedure, as reported by the patient, doctor and technician. 
Informed consent was obtained from each patient. A questionnaire containing 
demographic data (age, sex), clinical history (prior reactions to contrast, 
allergies, asthma, cardiac disease, renal impairment, diabetes mellitus, 
anxiety, other II lnesses) and medication history was completed by the research 
nurse before random allocation of contrast. 
Serum creatinine was measured on the day of the procedure. As the risk of 
clinically important contrast nephropathy Is low In patients with normal renal 
function (9) a repeat serum creatinine was obtained 2 days after the procedure, 
only if the pre-contrast level was greater than 120 umol per I iter (1.36 mg per 
deciliter). One hundred and fifty three patients had an elevated serum 
creatinine on the day of the cardiac catheterization and a follow-up level was 
obtained tn 123 (80%> patients. A more detailed analysis than presented in 
this report wll I be provided In another paper where the data from both the 
cardiac and an intravenous contrast trial wl I I be combined. 
Following Insertion of the catheter, arterial blood pressure, cardiac rate 
and rhythm were recorded continuously. The type and dose of contrast was 
recorded, as was the duration of catheterization. Following contrast Infusion 
the development of asystole, hypotension, angina, arrhythmias and other adverse 
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reactions was recorded, as was the type of therapeutic Intervention which 
resulted from these reactions. After the procedure the results of the coronary 
arteriogram and left ventriculogram were obtained. On leaving the cardiac 
catheterization laboratory the patient was asked to complete a short 
questionnaire containing Likert scales {graded from 0 [no symptoms] to 10 [the 
most severe Imaginable]) related to the presence and severity of 9 symptoms: 
pain, warmth, nausea, vomiting, 
tightness and any other symptom. 
sneezing, Itching, shortness of breath, chest 
Any side effect which occurred during the 30 
minute period after the procedure terminated was also recorded. 
The research protocol was approved by the Human Investigation Committee of 
Memorial University of Newfoundland. 
CATEGORY OF REICTIONS 
1. Therapeutic Intervention by a doctor: This was the primary outcome of 
Interest and was assigned If the patient received a medical Intervention 
because of an adverse reaction to contrast. A reaction severe enough to 
necessitate unblindlng of the cardiologist was considered to have been one 
requiring a therapeutic intervention. We did not use standard criteria to 
determine who required medical Intervention. 
2. Clinically Important adverse events: Reactions potentially related to 
contrast, that were either life-threatening themselves, might presage a 
life-threatening event, or were of sufficient severity to be likely to 
Interrupt or delay the completion of the angiography. Such clinically 
important events were defined as follows: {a) angina which was not 
relieved by one nitroglycerine tablet Cb) tachyarrythmias of new onset 
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requiring treatment (c) bradyarrythmlas or conduction system disturbance 
of new onset requiring treatment {d) a fal I In blood pressure to less 
than 80 mmHg systolic for longer than 1 minute or which required therapy. 
3. Subjectively severe symptoms: One or more symptoms rated greater than or 
equal to the arbitrary cutpoint of 5 on the Likert scale. 
4. Severe, prolonged reactions: Unlike categories 1-3 these reactions were 
judged retrospectively by the investigators blind to the type of contrast 
prescribed. They Included angina requiring multiple drugs, ventricular 
fibrillation or severe tachyarrhythmla requiring medical Intervention, 
prolonged hypotension requiring multiple Interventions, prolonged cardiac 
arrest. 
EFFECT OF PATIENT DESCRIPTORS ON INCIDENCE OF REACTIONS 
Potential covarlates were examined to determine whether they Influenced 
the reaction rates. These Included sex and age; history of prior reaction to 
contrast, allergy, asthma, diabetes mel lltus, renal Impairment (serum 
creatinine> 120 umol per I Iter), anxiety, severe II lness, cardiac failure, 
myocardial Infarction, hypertension, intermittent claudication and transient 
Ischemic attacks; presence and severity of coronary artery disease, left 
ventricular dysfunction and valvular disease as determined by the 
catheterization; dose and type of contrast Infusion. Anxiety was recorded as 
present only if the research nurse considered it severe. Severe II lness was 
defined as being bed-bound 
medical reasons. The effect 
examining Incidence rates of 
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In hospital by order of a physician for acute 
of the potential covarlates was analysed by 
therapeutic Intervention in the subgroups with 
each of the covarlates and also by combining them In a multivariate analysts. 
COST ANALYSIS 
The records of alI randomized patients having a significant reaction 
during cardiac catheterization were reviewed to determine what changes in 
medical care occurred as a result. The additional days spent In coronary care 
or on the ward as a result of an adverse reaction to contrast were assessed 
blind to the type of contrast prescribed, as were the many different medica-
tions, balloon pumps and pacemakers. The average cost to the hospital of extra 
days spent in coronary care or on the ward was assigned tor each patient, as 
was the actual cost to the hospital of resources consumed to treat an adverse 
event. The average marginal cost to the hospital of a day spent In coronary 
care rather than on a ward was used when such an event occurred. Thus all 
costs are based on hospital costs In 1991 Canadian dol Jars. 
STATISTICAL ANALYSIS 
Continuous variables are presented as medians or means and standard 
deviations. All statistical tests were 2 tailed with a significance level of 
0.05. The Bonferronl procedure was used to adjust for multiple comparisons 
<Table 3>. 
202 -
lncldence rates and relative risks are presented wlth 95 percent 
confidence Intervals. The effect of nonionic contrast on the rate of reactions 
and the effects of binary covariates were assessed by the chi-squared test or 
Fisher's exact test. Continuous variables were compared by t-tests or Mann-
Whitney U tests depending on distribution. A stepwise multiple logistic 
regression, using the BMDP software {1988 version), was performed to assess the 
effect of several potential predictors on the incidence of clinically Important 
adverse events. The variables were added to and removed from the models 
singly by both automated and deliberate stepping procedures to allow detection 
of multicollnearity. AI I variables of potential cllnclal importance were so 
examined. The interaction of several variables were also assessed in the 
models. The odds ratios presented are those from a final model using alI 
Independent variables previously found to have a predictive effect. 
At the outset It was Intended that the patients In this trial be comblned 
with those In a trial of Intravenous contrast (manuscript submitted for 
pub I !cation) to Investigate the systemic toxicity of the contrast agents. The 
overall required sample size was estimated to be 3543. During enrollment of 
the patients having cardiac angiography It became apparent that there was a 
high frequency of adverse cardiovascular events requiring therapy, noted before 
analysis by contrast assignment. This high frequency in 1490 patients was 
reported to the external advisor CDr. JO Harnett). He advised ful I analysis of 
the data, following which the cardiac catheterization arm of the trial was 
stopped. 
RESULTS 
Patient status at baseline 
Randomized trial: Table shows the demographic data, clinical 
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information, dose and type of contrast, while Table 2 shows the results of the 
cardiac catheterization for patients In the randomized study. The two 
randomized groups were wei I matched for alI demographic and clinical variables, 
drug prescription <Table 1) and for the degree of cardiac disease observed at 
catheterization (Table 2). 
Non-randomized patients: Those patients, who were excl uded from the 
randomized trial for medical reasons, had more severe previous cardiac il loess 
(previous myocardial Infarction 63 percent CN=140); unstable angina 66 percent 
CN=146), were more likely to be severely II I [43 percent (N=95)], or to have a 
history of prior contrast reaction [16.3 percent CN= 36)], than those In the 
randomized trial. 
Effect of nontontc contrast In randomized trtol 
Therapeutic Intervention: The number of patients receiving a therapeutic 
intervention by the cardiologist as a result of adverse reaction to contrast 
was high (28.9 percent> after high-osmolar contrast, and the relative risk for 
such an Intervention was 3.1 times (95~ confidence Intervals: 2.5-4.1) that In 
the nonionic group (Table 3). A switch to a low-osmolar contrast was the only 
Intervention In 29 cases assigned to high-osmolar contrast. In addition, the 
Incidence of clinically Important angina, hypotension and bradycardia was 
substantially higher to the high-osmolar group (Table 3). Urticaria occurred 
In 20 <2.7 percent> and was treated In 9 (1 .2 percent> patients assigned to 
high-osmolar, while only 1 case (0.1 percent p < 0.0001) given noniontc had 
urticaria and this was not treated. Nonlontc contrast was associated with a 
lower Incidence of symptoms particularly palo, chest tightness and nausea 
<Table 4). 
Severe or prolonged reactions: These events (category of reaction 4) 
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occurred In 2.9 percent of the high-osmolar group and In 0.8 percent of the 
nonlonlc group (Table 3). In the former group these severe reactions Included 
angina requiring multiple drugs (N=11), ventricular fibrillation (N=5), 
prolonged hypotension requiring multiple Interventions (N=4) and a prolonged 
cardiac arrest (N=1). In the comparable nonionlc group 4 of the 6 patients had 
ang ina requiring morphine (one of ~ham had an intraprocedural myocardial 
infarct), one had ventricular tachycardia requiring lidocaine, and one atrial 
fibrillation requiring verapami I and digoxin. 
AI I but 3 of those having severe or prolonged reactions had severe 
coronary disease, advanced valvular disease or poor left ventricular function. 
22 of the 27 severe events were In people who could have been Identified as at 
high risk in advance because of unstable angina, current heart failure, 
previous coronary artery bypass grafting or known 3 vessel coronary disease. 
There were no deaths related to the procedure and no episodes of permanent 
disability or damage attributable to contrast administration in the study. 
Procedure time: The average time from Insertion to removal of the 
catheter was not longer In those who received high-osmolar contrast C13.7 + 8.8 
vs 13.6 ± 10.6 minutes). The number of abbreviated procedures was few: three 
patients randomly allocated high-osmolar and one nonlonlc contrast. 
Qontrast nephropathy: Sixty-four patients who received high osmolar 
contrast, had an elevated serum creatinine on the day of the cardiac 
catheterization, and also had a follow-up level taken. 
f 
Three (4.7%> of this 
group developed greater than 25% but less than 50% rise in serum creatinine, 
205 ; 
and a further 3 (4.7%> patients had greater than 50% rise. Of 59 patients, who 
randomly received non-ionic contrast and had pre-serum creatinine greater than 
120 umol/1, 2 (3.4%> patients experienced greater than 25% but less than 50% 
rise in serum creatinine, and 1 (1.7%> patient had greater than 50% rise. 
Given the relatively smal I sample size and low Incidence rates of contrast 
nephropathy these differences were not significant. 
Non-randomized patients: Those who had been excluded from the randomized 
trial for medical reasons had a higher Incidence of most adverse reactions than 
those randomly at located nonlonlc contrast. A therapeutic Intervention was 
required In 17 percent versus 9.2 percent (p=0.002). It should be noted that, 
despite being at higher risk, those excluded for medical reasons had a lower 
Incidence of adverse reactions than those who were randomized to high-osmolar 
contrast. 
Effect of coyarlates 
Univariate analysts of alI the covartates mentioned In the methods 
revealed that the only patients with a higher than average relative benefit 
from nonlonlc contrast, In terms of events requiring therapeutic Intervention, 
were those with diabetes mel I Itus (relative risk 6.6, 95 percent Cl 2.7-16.3) 
and those with a history of prior reaction to contrast (relative risk 7, 95 
percent Cl 1-50). Those who were severely II I had a greater Incidence of 
therapeutic Intervention after both types of contrast (40.5 percent after high-
osmol~r and 12.6 percent after nonionic). There was a gradual Increase In the 
number requiring therapeutic Intervention with Increasing severity of coronary 
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disease In those receiving either high-osmolar or nonionic contrast Cone vessel 
27.1 versus 4.2 percent, 2 vessel 35.7 versus 11.1 percent, 3 vessel 39.1 
versus 17.9 percent, left main 38.2 versus 22 percent). 
Multiple logistic regression was used to further assess the linear 
associations between many subject and investigation related characteristics and 
th e occurrence of an adverse event. The dependent var iable used was the number 
of patients with clinically important adverse events (see category of reactions 
(2) in methods for definition). The type of contrast was one of the 
independent variables In each model. 
The independent variables found not to be associated with adverse events 
of clinical Importance In these models Included age, sex, a history of prior 
reaction to contrast, allergy or asthma, the presence of renal Impairment 
(serum creatinine ~ 120 umol/1>, valvular heart disease, diabetes, the degree 
of left ventricular dysfunction, or dose of contrast. 
Severe Illness was associated with an increase In the risk of a clinically 
important adverse reaction (odds ratio 1.36, 95 percent confidence Interval 1.1 
to 1.7) but this association was no longer significant when the degree of 
coronary disease was taken Into account. The best predictors of an adverse 
reaction of clinical Importance were the presence of severe coronary disease 
Cleft main, three vessel or coronary artery bypass grafts present) (odds ratio 
1.5, 95 percent confidence Interval 1.2 to 1.8) and unstable angina (odds ratio 
1.2, 95 percent confidence Interval 1.03 to 1.5>. The Interaction of these 
variables had I lttle extra association with the occurrence of an adverse 
reaction. 
Qost Qonslderatlons 
The length of hospital stay was the same In those randomly allocated high-
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osmolar contrast as In those given nonlonlc contrast (median stay 5 days In 
each case). The length of stay was significantly longer In those excluded from 
the randomized trial for medical reasons (median 11 days, p <0.0001 relative 
to randomized groups). 
The differences between the high-osmolar and nonlonlc groups In terms of 
medical care for adverse events potentially related to contrast included: 20 
days spent In coronary care rather than on a ward, 1 day on a ward rather than 
as an outpatient, Insertion and maintenance of 2 pacemakers, and many different 
medications. The cost of alI these Interventions was Can $6,742. Contrast for 
the high-osmolar group cost Can $18,352 (Including nontonlc In those crossed-
over), while contrast for the same number of patients In the nonlonlc group 
cost Can $98,700. Thus the Incremental cost of nonlonlc contrast was Can 
$73,606, or Can $100 per patient undergoing the cardiac catheterization 
procedure. Thirty-nine percent of patients In the randomized study had current 
heart failure, myocardial Infarction within previous 2 weeks, unstable angina, 
previous coronary artery bypass grafting, known 3 vessel coronary disease or 
advanced valvular disease. If only patients in this "high risk" group were 
given nonionic contrast the marginal cost would be $128 per "high risk" patient 
having cardiac catheterization. Data on the number of patients needed to treat 
to prevent a reaction and the marginal cost per event prevented, If all 
patients or only "high risk" patients in the trial were given nonionlc 
contrast, are reported in Table 5. 
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DISCUSSION 
There have been consistent requests for trials to provide better 
Information about the benefits of the expensive nonionic contrast media. To 
date few large scale randomized trials have been reported (3) and many did not 
comment on the clinical consequences of the adverse reactions reported 
tol lowing contrast. To our knowledge our study is the largest randomized trial 
yet reported comparing lntracardiac high-osmolar and nonlonic contrast. 
We observed a high frequency of adverse effects requiring therapeutic 
Intervention after high-osmolar contrast. This event rate is higher than that 
reported for a similar population given high-osmolar contrast by Hirshfeld et 
at (5). This may be due to the fact that we Included treatment of anglna 1 
bradycardia and requests for unbllndlng as events. In fact many of the adverse 
effects seen with contrast In our trial were relatively minor and short lived. 
Nevertheless more clinically Important adverse events also occurred (see 
category of reactions 2 in methods). The incidence rates for serious 
arrythmias and prolonged angina seen in our study are similar to those noted by 
others (5, 1 0). Severe prolonged reactions (see category of reactions 4) were 
infrequent but were also more likely to be seen with high-osmolar contrast. 
The particular formulations of high-osmolar contrast used In our trial 
contained calcium chelatlng additives. These media have been associated with a 
significantly greater Incidence of ventricular fibrillation than similar high-
osmolar media which do not chelate calcium (11,12). Although use of a non-
calcium chelatlng formulation of high-osmolar contrast might have prevented 
some of the episodes of ventricular fibril tatlon seen only after high-osmolar 
contrast In our study, there is no evidence that the non-calcium dhelatlng 
I 
high-osmolar media can prevent other adverse reactions to contrast. Neither 
209 
has there been any adequate comparison of nonionic contrast, which we found to 
be associated with a lower Incidence of at I contrast related adverse events, 
and non-calcium chelatlng formulations of high-osmolar agents. 
Virtual Jy all patients having cardiac catheterization were eligible for 
Inclusion in this trial but the cardiologists excluded a sizeable number 
because they felt that they would be at excessive risk with high-osmolar 
contrast. These patients were more II I and did have more adverse events than 
those randomized to the same nonionic contrast. However, they had Jess adverse 
events than those who received high-osmolar contrast In the randomized trial. 
VIrtual Jy all of the most serious adverse reactions, to either contrast, 
occurred In those with advanced cardiac disease, and the multivariate analysts 
of those In the randomized trial identified the severity of coronary disease 
and the tnstabi I tty of angina as risk factors for clinical Jy important adverse 
events in this already selected group. 
We found that universal use of nonionic contrast for the type of patients 
in our randomized trial, who are served by the Canadian health care system, 
would cost an extra Can $100 per patient undergoing the procedure. In the 
United States nontonlc contrast Is up to twice as expensive compared to Canada. 
Therefore the figure of US $186 higher for use of lopamidol rather than 
dlatrizoate In a recent US trial (8) would be comparable to our predictions. 
Of course If nonlonlc contrast were selectively given only to those at higher 
risk for adverse reactions the cost-effectiveness would Improve. 
The results of this trial 1 I lustrate the problem that faces health pol Icy 
decision makers when a new therapy Is found superior to an established one, but 
Is also associated with a substantial Increase In cost. There are no agreed 
formal guidelines to aid a decision as to how much society would be wll 1 ing to 
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pay to achieve a given degree of Improvement In the health status of 
individuals. Cost-effectiveness analyses alone cannot usually be used to 
compare disparate and competing health care programs. Decisions as to which 
programs should be funded are often not influenced solely by even cost-benefit 
considerations (6~7>. 
Thus we conclude that noniontc contrast is better tolerated during cardiac 
angiography than a calcium chelating formulation of high-osmolar contrast~ but 
universal use of nonlontc contrast ls expensive. It may be possible to select 
those at highest risk of serious adverse side-effects on the basts of some 
Therefore selective use of these agents may~ at least, be 
attractive. Should the price of nonlonlc media decrease, 
cltntcal variables. 
more economically 
their universal use would be more attractive In the cardiac catheterization 
laboratory. 
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TMLE I: DESmiPTION OF PATIENTS AT BASELINE 
Randanlzed 
High-Osmolar Non tonic 
N % N % 
Total 737 100 753 100 
Male 520 70.6 514 68.3 
Prior reactor to contrast 33 4.5 21 2.8 
Allergic 171 23.2 170 22.6 
Asthmatic 50 6.8 46 6.1 
Diabetic 115 15.6 115 15.3 
Renal Imp a! rrrent 90 12.2 80 10.6 
Aged >50 years 516 70.0 522 69.3 
Severe II I ness 74 10 95 12.6 
Anxious 300 40.7 313 41.6 
Medical History 
Myocardl al Infarction 310 42.1 322 42.8 
Heart fa I I ure 100 13.6 108 14.3 
Intermittent claudication 219 29.7 236 31.3 
Hypertens Jon 357 48.4 371 49.3 
Tr~nslent Ischemic attacks 41 5.6 42 5.6 
Drugs:Nitrates 429 58.2 412 54.7 
Calcium Channel Blockers 403 54.7 409 54.3 
Antlplatelet Agents 358 48.6 349 46.3 
Beta B I ockers 294 39.9 270 35.9 
TABLE I: D:SCRI PTION OF PATIENTS AT BASELINE CCX>NT'D> 
Premedication given 
Unstable Angina as Indication 
for catheterization 
Volume of contrast (ml) 
Age <years) 
Pulse rate before procedure 
Systolic blood pressure 
before procedure (mmHg) 
Diastolic blood pressure 
before procedure (mmHg) 
681 92.4 
278 37.7 
MEAN ± SO 
122 ± 43 
56± 11 
68 ± 25 
139 ± 25 
71 ± 13 
701 93. 1 
287 38.1 
MEAN± SO 
127 ± 35 
55 ± 11 
69 ± 13 
138 ± 26 
70 ± 14 
212 
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TleLE 2: RESULTS OF CAROtiC CArnETERIZATION 
Randanlzed 
High-Osmolar Nonlontc 
N % N % 
Valvular heart disease 65 8.8 62 8.2 
Left ventricular dysfunction 
-Mild 209 28.4 219 29.1 
-Moderate 90 12.2 99 13.1 
-Severe 26 3.5 30 4.0 
Coronary disease 
-Left main 55 7.5 41 5.4 
-One vessel 170 23.1 167 22.2 
-Two vessel 126 17.1 153 20.3 
-Triple vessel 192 26.1 179 23.8 
-Coronary bypass 
grafts present 31 4.2 24 3.2 
TMLE 3: 
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TiiE Nl.M3ER OF CASES Willi SPECIFIED ADVERSE REACTIONS TO OONTRAST IN 
'THE RAN[XJ41 ZED TR I AI... 
Hlgh-Q~Iar Low-Osmolar P* 95~ Cl RR 95~ Cl 
Adverse Reactions 
leategory 1: Cases 
N=737 ~ N=753 % Dl fference% RR 
who required thera-
peutic Intervention 213 28.9 
leategory 2: Clinically 
important adverse 
69 
events 124 16.8 25 
Angina rei leved by 
2 nitroglycerine 
9.2 <1 o- 7 9 3 15. -2 .6 3. 1 2. 5-4. 1 
3.4 -8 <10 10.5-16.5 5.1 3.3-7.7 
tablets CGTN> 23 3.1 6.0 0.8 0.014 0.9-3.7 3.9 1.6-9.6 
Angina requiring 
more than 2 GTN 
~linical ly important 
31 4.2 
hypotension 40 5.4 
Treated bradycardia 63 8.5 
2Treated Tachyarrythmia 6 0.8 
1eategory 3: Subjectively 
severe symptans, 
12 
3 
6 
2 
excluding warmth 
1eategory 4; 
189 25.6 70 
Prolonged/severe event 21 2.9 6 
1.6 0.028 0.9-4.3 2.6 1.4-5.1 
-7 0.4 <10 3.3-6.7 13.6 4.2-44 
-7 0.8 <10 5.6-9.9 10.7 4.7-25 
0.3 NS -0.1-1.3 3.1 0.6-15 
-8 
9.3 <10 12.6-20.1 2.8 2.1-3.6 
0.8 0.035 0.7-3.4 3. 6 1.5-8. 8 
*The P values were adjusted for multiple comparisons by Bonferronl correction. 
1 These adverse events are defined In the text. 
2 Ventricular fibrillation in all cases after high-osmolar, episode of 
ventricular tachycardia and one of atrial fibrillation after nonionlc. 
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TIBl.E 4: TI-lE INCIDENCE Of SYMPTCMS SlBJECTIVELY RATED AS GREATER THAN OR EQUAL 
TO 5 00 A 1 0 PO I NT SEVERITY SCALE IN TI-lE RAN[)().1 I ZED TRIAL. 
High-osmolar Nonlonlc p Relative 95% 
N J N J Risk Cl RR 
Warmth 527 71 .5 443 58.8 <0.0001 1.2 1.1-1.3 
Pain 79 10.7 34 4.5 <0. 0001 2.4 1 . 6-3.5 
Chest tl ghtness 75 10.2 32 4.2 <0.0001 2.4 1.6-3.6 
Nausea 79 1 o. 7 26 3.5 <0.0001 3.1 2.0-4.8 
Van ttl ng 13 1.8 11 1.5 NS 1.2 0.5-2.7 
Dyspnea 17 2.3 12 1.6 NS 1.4 0.7-3.0 
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T,6Bl.E 5: CX>ST EFFECTIVEt£SS OF NON-IONIC OONTRAST IN RAN[)(J.fiZED TRIAL. 
If alI patients glyen a If high risk patients 
non Ionic only glyen nonlonlc 
Category of Number needed Marginal cost Number needed Marginal cost 
Reaction to treat to tor use of to treat to for use of 
prevent one nonlonlc per prevent one nonlonlc per 
reaction event prevented reaction event prevented 
1. Therapeutic 
Intervention 5. 1 $510 4.2 $541 
2. Cl lnical ly Important 
adverse events 7.4 $740 6.8 $871 
4. Severe, prolonged 
event 50 $5,000 27 $3,464 
a High risk: current heart failure, myocardial Infarction within previous 2 weeks, 
unstable angina, previous coronary artery bypass grafting, known 3 vessel coronary 
disease, or advanced valvular disease. 
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N3STRACT 
Background: Nonlonlc low-osmolar radlocontrast may be better tolerated than 
Ionic high-osmolar radiocontrast following Intravenous Injection but Its cost-
effectiveness has not been examined in a large randomized trial. Selective use 
of expensive noniontc contrast has been advocated In groups perceived to be at 
high risk of an adverse reaction,. but the costs and consequences of various 
strategies need to be examined. 
Methods: We randomly assigned 955 
to receive low-osmolar intravenous 
patients to receive high-osmolar and 1158 
contrast, alI of whom had 1 or more of the 
following perceived "risk factors" for adverse reactions to radiocontrast: 
prior reaction to contrast, al lergles, asthma, diabetes, cardiac or renal 
disease, anxiety, severe illness or age greater than 50 years. Demographic and 
clinical data were collected before contrast was given. The occurrence of any 
adverse event, requirement for therapy and subjective symptoms was assessed in 
a double blind fashion after contrast. 
Results: In the randomized trial an adverse reaction requiring the attention 
of a doctor occurred In 3.9 percent after high-osmolar and 0.9 percent after 
low-osmolar contrast (p < 0.000005). Therapy was given to 1.4 percent and 0.5 
percent respectively Cp = 0.035). The difference was due to a reduction In 
urticaria and other mild anaphylactoid reactions. In those receiving high-
osmolar contrast the following factors Increased the risk relative CRR) to 
those aged over 50 alone: prior reaction CRR = 7.4>, allergy CRR = 4.4>, 
cardiac disease CRR = 3.1>, severe II lness CRR = 3), renal disease CRR = 2.4>, 
anxiety (RR = 2.2), diabetes <RR = 1.9) and asthma CRR = 1.4>. In a 
multivariate analysts only prior reactions and allergy were Independent risk 
factors. The marginal cost of nontontc contrast was Can S 72.77 per patient In 
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the randomized trial. If 81 I patients In the randomized trl81 were given 
nonlonlc contrast It would cost Can $2679 to prevent 1 reaction. If only those 
with prior reactions, allergy or asthma were given nonlonic contrast it would 
cost at most Can $1211 to prevent reaction and at least 67 percent of 
reactions would be prevented. 
Conclusions: The frequency of reactions requiring medical attention and 
therapy, after Intravenous use of high-osmolar contrast, in patients perceived 
to be at high risk, is low. Nonionic contrast significantly reduces this 
incidence, but at high cost. Selective use of nonionlc contrast Is a viable 
strategy. 
Key Words: contrast media, Ionic, nonionlc, toxicity, adverse effects, 
intravenous, risk factors, cost-effectiveness, random allocation, 
comparative study. 
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INTRODUCTION 
The high osmolarity . of conventional radiographic contrast media may 
contribute to their toxicity. This led to the development of nonlontc and 
dimeric-ionic contrast media which have lower osmolarity {1). These new 
compounds have also been shown to have lesser effects on many physiological 
processes and are thus said to be Jess chemotoxic {2). It was expected that 
these advances would Improve on the already good safety profile of conventional 
high-osmolar radiocontrast media. 
The low-osmolar agents have been available for use In North America since 
1986 and in Europe for several years longer. These newer agents were quickly 
shown to be superior in terms of minor adverse effects following Intravenous 
administration (3). Large scale prospective surveys have been published more 
recently and suggest that more serious adverse events may also be less frequent 
with low-osmolar media <4,5). Such surveys are subject to several sources of 
bias because of study design. Adverse events of "intermediate" severity (6) 
have not been very wet I studied in randomized clinical trials (7). Such 
evidence is desirable to confirm or refute the Impression derived from the 
surveys. Death and the most severe adverse events are so Infrequent that It Is 
unl tkely that a large enough randomized trial wll I be conducted to study them. 
The low-osmolar contrast media are between ten and twenty times more 
expensive than high-osmolar media In North America. If low- rather than high-
osmolar media were used for alI radiological procedures In the United States, 
It has been estimated that the extra expenditure would amount to at least $1.1 
btl I ton per annum (8). Partly as a result of these economic considerations, 
some have suggested selective use of the low-osmolar media In patients 
perceived to be at high risk {9). Such a policy of selective use Is much more 
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cost ef feet I ve < 1 0) but depends on accurate I nformat Jon as to what constItutes 
a high-risk subject. . . ... . . 
Thus we performed this randomized, double blind, cl lnlcal trial (a) to 
compare the Incidence of moderately severe adverse events following lntravencus 
Injection of high-osmolar ionic and low-osmolar nonionic contrast media in 
patients perceived to be at high risk (b) to determine the relative risk for 
such events associated with various clinical characteristics and (c) to examine 
the cost-effectiveness of low-osmolar nontonic contrast In a selected "high-
risk" population. 
METiiODS 
Inclusion and Exclusion Criteria: Subjects were considered for entry to the 
randomized trial if they were having Intravenous contrast for computed 
tomography {CT) of the head or body or intravenous pyelography at the Health 
Sciences Centre, St. John's. This is a tertiary referral centre for the 
province. Only those patients who had one or more "high risk" characteristics 
were eligible {6,11). These Included (a) prior mild adverse reaction to 
radlocontrast (b) "allergy" to drugs, foods or other substances (c) asthma (d) 
cardiac disease (angina, heart failure, myocardial or valvular disease) (e) 
diabetes mel I ltus (f) chronic renal failure (g) age greater than 50 years (h) 
severe II lness (bed-bound In hospital for medical reasons) and (I) excessive 
anxiety as Judged by the Interviewing nurse. 
Subjects were excluded from the trial In the absence of any of the above 
characteristics and for three other reasons: (1) patient refusal, (2) non-
availability of low-osmolar contrast In a form suitable for the patient's 
Investigation, (3} at the request of the radiologist because of a perception 
that the patient would be at excessive risk If high-osmolar contrast were 
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given. 
Sub(ects and Contrast Media: In the three years prior to February 1991 three 
thousand one hundred and sixty seven consecutive eligible patients were 
Identified during the research nurses working hours. This represented 49.5 
percent of those having Intravenous contrast for similar Investigations over 
the same time period. Of these 2113 (66. 7 percent) were entered In the 
randomized trl al. 955 were randomly assigned to receive Ionic high-osmolar 
contrast and 1158 to recel ve non ionic I ow-osmo I a r contrast. The contrast used 
was that bought under contract by the hospital. Overall 163 patients were 
given topamldol, 1329 ldhexol, 12 loxaglate, 613 meglumine lothalamate and 1050 
sodium/meglumlne diatrlzoate In various concentrations. In the early months of 
the study some patients, having CT of the body, for which no appropriate 
Infusible formulation of nonlonic contrast was available locally, were 
Inappropriately entered in the randomized trial. Such Individuals CN = 220) 
who had received high-osmolar contrast were subsequently identified and removed 
fran the trial. The corresponding asslgnnents to nonlonic contrast had been 
used for the next available patient. These subjects could not be reliably 
Identified after the error was discovered and remain In the randomized trial. 
58 patients refused to enter the trial, 612 were excluded because of non-
avallabil ity of appropriate nonlonic contrast and 216 were excluded at the 
request of the radiologist because of asthma, allergies and previous reactions 
to contrast. A further 168 were not randomized for miscellaneous reasons. All 
non-randomized patients were followed In the same fashion as the randomized 
groups. The only patients who received steroid prophylaxis were 5 patients 
with a history of prior serious reaction to contrast. All were nonrandomlzed 
and given nonionlc contrast. None had any adverse events with the current 
exan I nat Jon. 
Protocol: The research nurses briefly 
ellglbi I tty. Informed consent was 
demographic data (age, sex), clinical 
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Interviewed 81 I patients to determine 
sought and a questionnaire containing 
history (prior reactions to contrast, 
a II erg I es, asthma, cardIac dl sease, rena I 1 mpa I rment, dl abetes me IIi tus, 
anxiety, other II lnesses) and medication history was completed by the research 
nurse. The nurse then approached the radiologist who made the final decision 
as to whether contrast type could be assigned at randan. A radiation 
technologist prepared the randomly assigned contrast. The research nurse, 
radiologist and patient remained bl lnd to the type of contrast administered. 
The nurse recorded the patient's pulse and blood pressure before and 
immediately after the radiological procedure as wei I as recording any adverse 
events which occurred after contrast and before the patient left the radiology 
departrrent. Whether the radiologist was required to review a patient because 
of an adverse event was also noted, including any therapy prescribed. Before 
leaving the departrrent the patient completed a questionnaire containing llchert 
scales (graded 0 to 10) relating to the presence and severity of 9 symptoms: 
pain, warmth, nausea, vomiting, sneezing, pruritus, dyspnea, chest pain and any 
other symptom. The serum creatinine was measured on the day of the procedure 
and If It exceeded 120 umol per liter (1.36 mg per decl liter) a repeat serum 
creatinine was sought 2 days later. This dat8 wl II be analysed In 8 separate 
paper. 
This research protocol was approved by the Human Investigation Committee 
of Memorial University of Newfoundland. 
Outcomes: 
1. The prImary outcam'e was the occurrence of an adverse event after contrast 
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which was sufficiently severe for the doctor to treat the patient. 
2. Hemo"dynanlc deterioration defined as a change In blood pressure fran 
baseline of greater than 20 mmHg systolic or 10 mmHg diastolic. 
3. The occurrence of symptoms subjectively rated as severe (greater than or 
equal to 5 on a scale of 0 to 10) by the patient. 
Analysis and Statjstjcs; 
Continuous variables are presented as medians and ranges or means and 
standard deviations. AI I statistical tests had a significance level of 0.05 
which was 1-tailed for outcomes. Incidence rates and relative risks are 
presented with 95 percent confidence Intervals. Categorical variables were 
compared by the chi-squared or Fisher's exact test. Continuous variables were 
compared by t-tests or Mann-Whitney-U tests depending on distribution. 
A stepwise multiple logistic regression, using BMDP software (1988 
version) was performed to assess the effect of various risk factors on the 
primary outcome. 
We used a 2 percent Incidence of reactions requiring therapy after high-
osmolar contrast, as found by Lasser (12) to estimate sample size. We wished 
to be able to detect at least 50 percent reduction In risk with low-osmolar 
contrast with a maximum 1-talled Type error rate of 5 percent and a Type 2 
error rate of 20 percent. This suggested that we required 3543 subjects In 
total. We had Intended to canbfne the subjects In this report with a 
previously reported group having cardiac catheterization (13) and we stopped 
patient accrual when the total predicted sample size was achieved. 
RESULTS; 
Baseline Comparison; The randomized groups were wei I matched apart from a 
greater prevalence of previous cardiac disease In the group assigned to low-
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osmolar contrast <Table 1). The volume of high-osmolar contrast given was 
higher, which Is partly due to the lower Iodine content of the high- than the 
low-osmolar contrast (141 versus 300 mg per mil It liter) used for Infusion, and 
partly to the regular use of larger vials of high- than low-osmolar contrast 
(300 versus 100 milliliters) at our Institution. 
Those excluded from the randomized trial by the radiologists, and given 
low-osmolar contrast, had the expected significantly higher proportion of 
prior reactors, -8 al lerglc and asthmatic patients (alI p < 10 relative to the 
randomized group) <Table 2). Eczema, rhinitis, and use of antihistamines or 
bronchodllators were alI more common in these selected patients as wei I. This 
group was significantly younger than the randomized groups (p < 0.0001). 
Table 2 also shows the baseline characteristics of the patients who were 
excluded largely because of non-availability of low-osmolar contrast, and who 
received high-osmolar contrast. The only differences between these patients 
and those who were randomized to high- osmolar contrast were a slightly lower 
prevalence of prior reactors (1 .1 versus 2.7 percent, p = 0.02) and a higher 
prevalence of diabetics (15.6 versus 12 percent, p = 0.03), very II I patients 
(7 versus 3.5 percent, p = 0.001), anxious patients (43.9 versus 26.6 percent, 
-8 p < 10 >, and patients on diuretics and steroids tn the non-randomized group. 
Oytcqmes In the randomized patients: Therapy was given for a contrast reaction 
2.6 times more often In those assigned to high-osmolar contrast (Table 3). 
Adverse events requiring attention by the radiologist were 4.5 times more 
frequent In those randomly assigned to high-osmolar contrast. Table 3 also 
shows that urticaria alone or other mild anaphylactoid reactions accounted for 
most of the difference between the groups. The remainder of the reactions 
were varied but consisted of severe vomiting In 5 (0.5 percent) cases given 
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high- and none glven low-osmolar contrast. There were no life-threatening 
reactions. We dtd not show any difference in hemodynamic responses to 
contrast, with a fall in blood pressure greater than 20/10 mmHg occurring in 97 
of 955 (10.2 percent) of those receiving high-osmolar and In 104 of 1158 (9 
percent, p = NS) receiving low-osmolar contrast. Angina was more frequent (0.5 
percent versus 0.3 percent, p = NS) in those given low-osmolar contrast but 
this may reflect the more severe cardiac history in those patients. Several 
subjectively severe (greater than or equal to 5 on the 10 point scale) symptoms 
were significantly more common in those given high-osmolar contrast (Table 3). 
Outcomes In the non-randomized patients; Despite being at apparently higher 
risk, those excluded from the randomized trial and given low-osmolar contrast 
had a lower frequency of reactions requiring the attention of a doctor than 
those given high-osmolar contrast In the randomized trial (1.5 versus 3.9 
percent, p = 0.05) <Table 4). Predictably, when alI patients given low-
osmolar contrast are considered, those excluded from the randomized trial had 
more such reactions (1.5 versus 0.9 percent, p = NS>. 
The adverse event rates In those receiving high-osmolar contrast were the 
same Irrespective of whether they were randomized, apart from a lower frequency 
of subjectively severe warmth In those not randomly assigned <Table 4). 
Assessment of Risk Factors; We dld not specifically study patients felt to be 
at low risk of adverse events. Thus It Ts not possible to deflne the relatlve 
risk of our "high risk" categorles directly. However the patients who were 
aged more than 50 years and were without any other risk factor had the lowest 
frequency of adverse events requiring a doctor's attention (1.6 percent of 
those given high- and 0.3 percent of those given low-osmolar contrast>. These 
patients thus serve as a useful population against which to assess other rtsk 
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factors. Table 5 shows the results of a univariate analysis of risk factors 
within each contrast group. 
To further assess the Independent effects of these and other potential 
risk factors we performed a series of multiple logistic regression analyses. 
In each case the dependent variable was a reaction requiring attention by a 
doctor. AI 1 3167 patients were included for one analysts and alI those 
receiving high-osmolar contrast were Included In a separate analysis. The 
results are shown In Table 6. As can be seen a history of previous adverse 
reaction to contrast, a history of allergy and cardiac disease Increase the 
risk of an adverse event. A high volume of contrast was also associated with a 
smal I independent Increase In 
made patients eligible for the 
risk. None of the other "risk factors" which 
randomized trial had independent predictive 
power for adverse events requiring the attention of a doctor. 
AI I of those at Increased risk benefited from the use of low-osmolar 
contrast. The relative reduction in the Incidence of an adverse reaction 
requiring the attention of a doctor, by use of low-osmolar contrast, ranged 
from a two-fold reduction in those with cardiac disease, to a 4.1 fold 
reduction In those with a history of prior reaction, to an 8.9 fold reduction 
In those with a history of allergy. 
Cost Considerations; The high-osmolar contrast for the 955 patients In the 
randomized trial would cost at least Can $8,197 at local prices In 1991. The 
cost of the drugs used In treating adverse reactions was negligible. All 
patients who had an adverse event requiring a doctor's attention remained In 
the radiology department for between 10 minutes and 2 hours unti I they were 
Judged stable. None of the patients required admission to hospital or a change 
from a ward to an Intensive care bed as a result of a reaction. None of the 
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reactions required the attendance of an anaesthetist. patient required 
assessment In the emergency department after high-osmolar contrast and 5 
patients were similarly assessed after low-osmolar contrast. Thus the 
marginal cost of treating adverse reactions related to high-osmolar contrast 
was very smal I and can be Ignored for this analysis. 
The cost of providing nontonic low-osmolar contrast to a group of 955 
patients in the randomized trial was Can $77,699. Thus the marginal cost of 
nonlonic contrast for this group was Can $ 69,502 or Can $72.77 per patient on 
average. 
If alI patients In the randomized trial were given nonlonic contrast then 
49.5 percent of those being given intravenous contrast in our X-ray department 
would receive nonlontc. This would Increase the cost of contrast In our 
radiology department by 948 percent over use of only tonic media and It would 
cost Can $2679 to prevent 1 reaction severe enough to require the attendance of 
a doctor. Universal use of nonlonic contrast would further substantially 
increase the cost of preventing 1 reaction. 
If those aged over 50 years, but without other risk factors, were not 
given nontontc contrast, and If this was given to all others eligible for our 
trial, then 38 percent of those getting Intravenous contrast would receive 
nonlonlc contrast. This would Increase contrast cost In our radiology 
department by 244 percent over use of only Ionic contrast and It would cost Can 
$1998 to prevent 1 reaction, whfle 86 percent of preventable reactions would be 
prevented. If only those with a history of prior reaction to contrast, 
al lergtes or asthma were selected to receive nonlonlc contrast then 19 percent 
of those being given Intravenous contrast would receive nontonlc contrast. 
This would Increase the cost of contrast by 183 percent over use of only Ionic 
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medl8, and cost Can $1211 to prevent reaction, while 67 percent of 
preventable reactions would be prevented. 
Because same prior reactors to contrast, al lerglc patients and asthmatics 
were excluded from the randomized trial, the cost to prevent a reaction In this 
type of patient is probably overestimated and the proportion of potentially 
preventable reactions prevented Is probably underestimated. Since nontontc 
contrast Is nearly twice as expensive again relative to tonic contrast In the 
United States the above costs could be doubled in that country. 
OJ SOJSSION 
Our results indicate that noniontc low-osmolar agents are associated with 
a significantly lower frequency of "moderate" or "intermediate" level adverse 
reactions than ionic high-osmolar agents, when given Intravenously to a 
selected "high risk" population. We have also confirmed the Impression of many 
others that selected symptoms like warmth, nausea, and vomiting are ameliorated 
by low-osmolar contrast. It should be noted that steroid or other prophylactic 
therapy was not given to patients In our randomized trial. The exclusion of 
some patients from the randomized trial did not prevent us from using these 
patients to assess risk factors as we col Jected the same data on alI patients. 
The adverse events whlch constituted our primary outcome were generally 
not long-lasting or severe but were sufficiently worrisome for 8 doctor to 
treat them. The decision to treat these reactions was taken before unbllndlng 
In virtually alI cases and therefore the difference In the n~ber of treated 
reactions Is likely to be due to a difference In toxicity. 
The frequency of reactions requiring a doctor's attention (1.6 percent) In 
those who were over 50 years of age but had no other risk factor, and who were 
I 
given high-osmolar contrast, Is comparable to the frequency of fairly similar 
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events In the I tterature. Such events occur In between 1.2 and 2 percent of 
unselected cases In prospective surveys (12 1 14-18). Thus this category of 
patients might be considered to be at average rlsk 6 at most 1 for these 
"intermediate" level reactions. 
A history of prior reaction to contrast medla 1 or al lergtes did behave as 
risk factors for "Intermediate" level adverse reactions to high-osmolar media 
In our trial. This Is similar to the general experience and the relative risks 
are comparable to those seen in the Japanese survey In relation to overal I and 
severe adverse events (5). Our multivariate analysis showed that the 
independent effect of each of these risk factors may be a I ittle lower than the 
usual univariate analyses might suggest. Despite accepted opinion (5) we were 
unable to identify asthma as a major risk factor for adverse reactions. 
Exclusion of the most severe asthmatics from the randomized trial cannot 
explain this as asthma stll I falls to act as a major risk factor when these 
excluded patients are also considered. However 1 In this study the presence or 
absence of asthma was dependent only on the patients own history and a greater 
risk associated with true atopy may have been diluted. Anxiety and other 
clinical conditions are 1 at best, weak risk factors for these "Intermediate" 
reactions. The Increase In risk associated with higher doses of high-osmolar 
contrast supports the recent literature (5). 
Non tonic 
mort a I tty (5). 
contrast for Intravenous use has not been shown to reduce 
Severe or life-threatening reactions to contrast are very rare 
and probably have the same risk factors as the less severe reactions occurring 
during our trial (5 6 6). Even these "moderate" reactions are Infrequent and do 
cluster In high risk groups. Provision of nontontc contra~t to our study 
population (about half of the total population receiving Intravenous contrast> 
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would be very expensive. Prevention of what are really quite mild reactions to 
Ionic contrast will be prohibitive In many Institutions. Provision of nonlontc 
contrast to those with a prior reaction to ionic contrast, an at lerglc history 
or asthma is more cost-effective but stll I quite expensive. This Is even more 
so ln the United States, where nonionlc contrast costs more than In Canada. 
If the cost differential did not exist, few would oppose universal use of 
nonlontc contrast. In addition to reduced use of procedures requiring contrast 
and a reduction In volume Infused, the Ideal solution to the current dilemma 
would be a reduction in the cost of nonionlc contrast. Every effort should be 
made to encourage the pharmaceutical companies to do this. The use of steroid 
prophylaxis might reduce the incidence of reactions to high-osmolar contrast by 
as much as nonlonlc contrast does (12) but we did not examine that approach In 
our trial. No direct comparison of the strategies of steroid prophylaxis 
versus use of nonlonlc contrast has been made and to do so would require a 
large trial. Steroid prophylaxis is cheap and might be a reasonable 
alternative to the use of nonlonlc contrast In many cases. In the Interim we 
feel that a policy of selective use of nonlonlc Intravenous contrast In 
patients with a history of prior reaction to contrast, at lergy or asthma can be 
justified. 
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T 18LE 11 BAS Ell NE QfARACTER I ST I CS Of lliE RAN[)(J41 ZED GROUPS 
Total 
Male 
FotentJal Risk Factors 
Prior reaction to contrast 
History of al lergles 
Asthma 
History of cardiac disease 
Renal impairment 
Diabetes 
Age > 50 years 
Age >50 years only 
Anxious 
Very II I 
Medical History 
History of Heart Failure 
Hy pert ens l ve 
History of transient 
cerebrel lschemle 
Eczema 
Rhinitis 
Hlgh-osmoler 
N = 955 
487 
26 
273 
53 
139 
94 
115 
774 
274 
254 
33 
16 
309 
46 
41 
37 
s = 100 
51 
2.7 
28.6 
5.5 
14.6 
9.8 
12.0 
81.0 
28.7 
26.6 
3.5 
1.7 
32.4 
4.8 
4.3 
3.9 
Lo.t-osmol ar 
N = 1158 % = 100 
566 48.9 
37 
332 
79 
226 
140 
143 
975 
307 
337 
32 
35 
403 
59 
54 
44 
3.2 
28.7 
6.8 
19.5 
12.1 
12.3 
84.2 
26.5 
29.1 
2.8 
3.0 
34.8 
5.1 
4.7 
3.8 
TMLE 1: BASEL liE OtARACTER I ST I CS OF lliE RANOCJ.11 ZED GROUPS ( CX>NT1 0) 
Drug History 
Digoxin 
Beta B I cx:ker 
Nitrate 
Anti-histanine 
Steroid 
Bronchodilator 
Age (years) 
Heart Rate (beats/min) 
Systolic blood pressure (mmHg) 
OJ astol ic blood pressure (mmHg> 
Contrast Volume (mls) 
Serum Creatinine (umol/1) 
High-Osmolar 
N=955 ~=100 
39 4. 1 
70 7.3 
32 3.4 
15 1.6 
32 3.4 
39 4. 1 
Mean ± SO 
59.2 .:t 14.3 
78.3 .:t 11.9 
1 35 • 9 .:t 21 • 3 
83.4 ± 11.7 
Median (Range) 
100 (40-750) 
84 (27-1823) 
Lew-osmolar 
N=1158 ~=100 
58 5.0 
100 8.6 
61 5.3 
18 1.6 
51 4.4 
65 5.6 
Mean± SO 
60.3±13.1 
78.1 ± 12.5 
137.0 ± 22.4 
82.4 ± 11.4 
Median (Range) 
50 ( 1-400) 
85 (43-991) 
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TIBLE 2a BASEliNE OiARACTER I ST I CS OF PATIENTS EXCLUDED FRCJ4 THE RAND041 ZED 
TRIAL. 
High-Osmolar LOit'-osmo I ar 
Total N = 716 % = 100 N = 338 % = 100 
Male 349 48.7 145 42.9 
Potential Risk Factors 
Prior reaction to contrast 8 1.1 136 40.2 
History of al lergles 183 25.6 171 50.6 
Asthma 37 5.2 105 31.1 
History of card! ac disease 125 17.5 57 16.9 
Renal ImpaIrment 87 12.2 39 11.5 
Diabetes 1 1 2 15.6 37 1 o. 9 
Age > 50 years 625 87.3 185 54.7 
Age > 50 years only 167 23.3 11 3.3 
Anxious 314 43.9 114 33.7 
Very II I 50 7.0 18 5.3 
Medical History 
History of Heart Failure 23 3.2 13 3.8 
HypertensIve 217 30.3 96 28.4 
History of transient 33 4.6 13 3.8 
cerebral Ischemia 
Eczema 23 3.2 36 10.7 
Rhinitis 22 3.1 51 15.1 
Tl6lE 2: BASEL It£ CHARACTERISTICS OF PATIENTS EXCLUDED 
TRI AI.. COONT'D) 
Drug History 
Digoxin 
Beta B I ocker 
Nitrate 
Anti-hIstamIne 
Steroid 
Bronchodilator 
Age (years) 
Heart Rate (beats/min) 
Systo I i c b I ood pressure ( mmHg) 
Diastolic blood pressure (mmHg) 
Contrast Volume (mls) 
Serum Creatinine Cumol/1) 
High-Osmolar 
N=716 %=100 
41 5.7 
45 6.3 
30 4.2 
19 2.7 
54 7.5 
36 5.0 
Mean ± SO 
60.4 .± 12.8 
78.9 ..± 11 • 6 
1 34.4 .± 21 • 4 
78.1 ± 11.1 
Median (Range) 
300 (26-650) 
86 (36-1375) 
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FROM THE RANDOMIZED 
Low-Osmolar 
N=338 %=100 
9 2.8 
23 6.8 
11 3.3 
13 4.0 
32 9.8 
88 26.0 
Mean± SO 
51.3 ± 17.5 
81.1 ± 13.4 
131.4 ± 21.7 
83.3 ± 12.2 
Median (Range) 
100 (20-400) 
84 (43-654) 
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TMLE 3: DES~JPTION OF ADVERSE REACTIONS TO CX>NTRAST IN THE RAN()()otiZED TRIAl. 
H 1 gh-Osmol ar 
Reactions requiring therapy 13 (1.4%> 
Reactions requiring attention 37 (3.9%> 
of a doctor 
Low-Osmolar 
6 {0.5%> 
10 (0. 9%) 
Nature of reactions requiring attention by a doctor 
Treated 
N % N N 
Urticaria alone 18 ( 1 • 9) 7 0 
Other anaphylactoid 6 (0.6) 4 3 
Angina 3 (0.3) 0 6 
Other card i ovascu Jar 2 (0.2) 0 
Neurol og i ca I 2 (0.2) 0 
Severe vcmiting 5 (0.5) 0 
Other ( o. 1) 0 0 
Subjectively severe symptans (~ 5 on a scale 0 to 10) 
Warmth 167 ( 1 7.5) 87 
Nausea 69 (7.2) 25 
Vanttlng 21 (2.2) 8 
Prur ltus 29 (3.0) 6 
Pain 13 ( 1 .4) 12 
Dyspnea 9 (0.9) 12 
Chest Pain 6 (0.6) 11 
p 
0.035 
<0.000005 
Treated 
% N 
(0) 0 
(0.3) 
(0.5) 5 
(0) 0 
( 0. 1 ) 0 
(0) 0 
(0) 0 
(7 .5) <0.000001 
(2.2) <0.000001 
(0.7) 0.0015 
(0.5) <0.000005 
( 1.0) NS 
(1 • 0) NS 
(0.9) NS 
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TABLE 4: ADVERSE EVENTS ASSOCIATED WITii OONTRAST IN PATIENTS EXQU~D FROM THE 
RAN[)(J4JZED TR I H... 
Adverse Event High-Osmolar Low-Osmolar 
Total N=716 % N=338 % 
Reaction requiring therapy 11 ( 1 • 5) (0.3) 
Reaction requiring attention 22 (3. 1 ) 5 ( 1 • 5) 
Urticaria 9 { 1 • 3) 2 (0.6) 
Angina 5 (0.7) 0 (0) 
Subjectively severe symptans {~ 5 on a scale 0 to 1 O> 
Warmth 59 {8.2) 29 (8.6) 
Nausea 37 {5. 2) 10 (3. 0) 
Vanitlng 16 {2.2) 2 {0.6) 
Prur l tus 11 ( 1 • 5) 4 { 1 • 2) 
Pain 8 ( 1 • 1 ) 4 ( 1 • 2) 
Dyspnea 7 ( 1 • 0) 4 ( 1 • 2) 
Chest Pain 8 ( 1. 1 ) (0.3) 
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TABLE 5: THE RISK, RELATIVE TO lHOSE AGED OVER 50 YEARS AND WITHOUT OllER RISK 
FACTORS, ASSOCIATED WI~ VARIOUS OiARACTERISTICS BY UNIVARIATE 
ANALYSIS. 
Characteristic 
Prior reaction to 
contrast 
History of "allergy" 
Cardiac disease 
Severe II I ness 
Renal Impartment 
Anxiety 
Diabetes Mel lltus 
Asthma 
High-Osmolar 
Rei ati ve Rl sk 
7.4 
4.4 
3.1 
3.0 
2.4 
2.2 
1.9 
1.4 
95% Cl 
2.3-24 
2.0-10 
1 .2-8 
0. 9-1 o. 1 
0.9-6.8 
0.9-5.2 
0.7-5.5 
0.3-6.6 
Low-Osmolar 
Relative Risk 95% Cl 
9.2 1.1-78 
2.5 0.3-22 
7.9 0.9-63 
6.4 0.4-100 
3.5 0.3-39 
3.5 0.4-30 
1.8 0.1-28 
1.7 0. 1-27 
TABLE 6: FACTORS ASSOCIATED Willi ADVERSE REACTIONS TO <X>NTRAST BY KJLTI-
VARIATE ANALYSIS. 
AI I PatIents 
Risk Factor 
High/Low osmolar contrast 
Prior reaction/No prior 
reaction 
AI lergy/No allergy 
Cardiac disease/No 
cardiac disease 
Odds Ratio 
2.2 
1 .a 
1.6 
1.4 
Patients given high-osmolar contrast only 
Prior reaction/No prior 
reaction 
AI lergy/No allergy 
High volume of contrast/ 
l~ vollJTle of contrast 
1.8 
1.8 
1.3 
95% Confidence Interval 
1.6-2.9 
1.2-2.7 
1.2-2.0 
1.1-1.9 
1.0-3.1 
1.4-2.3 
1.0-1.7 
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ABSTRACT 
Background: Prescription of low-osmolar contrast to prevent 
nephrotoxicity in subjects with pre-existing renal impairment is 
costly and has not been clearly shown to be effective. 
Methods: 366 subjects with a pre-contrast serum creatinine greater 
than 120 pmol/1 having cardiac catheterization or intravenous 
contrast had serum creatinine repeated 48 to 72 hours after 
contrast. 249 of these were randomized to receive high or 1 ow-
osmolar contrast. 
Results: In the randomized study the serum creatinine rose by at 
least 25 percent after contrast in 8 of 117 {6.8 percent) given 
high and in 5 of 132 (3.8 percent) given low-osmolar contrast (p 
> 0.05, 1-tailed 95 percent confidence interval for the difference 
3 to 7. 8 percent). More severe renal fai 1 ure (greater than 50 
percent increase in serum creatinine) after contrast was uncommon 
(3.4 percent with high and 1.5 percent with low-osmolar contrast). 
A rise in serum creatinine after contrast was significantly 
associated with the severity of the pre-contrast renal impairment 
and the presence of diabetes mellitus. Diabetics with a serum 
creatinine greater than 200 pmol/1 pre-contrast had the highest 
risk of deterioration in renal function after contrast. 
Conclusions: Clinically important nephrotoxicity is uncommon after 
high-osmolar contrast and is not completely prevented by low-
osmolar contrast in subjects with renal impairment. Larger studies 
I 
wi 11 be required to define the precise role of 1 ow-osmolar contrast 
for prevention of contrast nephropathy, particularly in diabetics 
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with renal impairment. 
Key words: contrast media, adverse effects, high-osmolar ionic, 
low-osmolar, kidney failure (acute), random allocation, comparative 
study. 
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IHTRODUCTOB 
Contrast nephropathy may be defined as an acute toxic 
nephropathy due to radiographic contrast media. There has been 
considerable confusion in the literature about the incidence of the 
condition (1). We have previously shown that it is not common with 
normal pre-existing renal function, but that it is more frequent 
in patients with renal impairment, especially when due to diabetic 
nephropathy (2,3}. 
There has been difficulty in establishing an animal model of 
contrast nephropathy (4). This has hindered efforts to investigate 
it's pathogenesis and has led some to question the existence of the 
condition (5). Nevertheless, contrast has been shown to have toxic 
effects in rabbits whose kidneys have been subjected to other 
stresses {6). 
It was expected that nonionic low-osmolar contrast would be 
less nephrotoxic than ionic high-osmolar media. Some (7-9}, but 
not all studies (10,11) of contrast-induced enzymuria and 
proteinuria have suggested that 1 ow-osmolar media may be 1 ess 
nephrotoxic. A randomized trial in humans, mostly with normal renal 
function, did not find that low-osmolar media were less nephrotoxic 
(12). In a noncomparative study, low-osmolar contrast was 
associated with a 50 percent incidence of a 25 percent rise in 
serum creatinine after cardiac catheterization in patients with 
advanced diabetic nephropathy (13). A randomized trial in patients 
I 
with pre-existing renal impairment undergoing cardiac angiography 
found a statistically significantly smaller rise in serum 
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creatinine at 24 hours after nonionic contrast than after ionic 
contrast (14). The authors of the study concluded that the nonionic 
contrast was less nephrotoxic than the ionic, although there was 
not a significant reduction in the incidence of clinically 
important episodes of nephrotoxicity and no benefit was seen in 
insulin requiring diabetics (14). 
Because low-osmolar contrast is 10-20 times more expensive 
than high-osmolar contrast and because patients with impaired renal 
function have an increased risk of contrast nephropathy, we 
performed a randomized controlled clinical trial to examine the 
relative nephrotoxicity of the two classes of contrast media in 
patients with high serum creatinine levels. 
METHODS 
Research design and study population: 
This study was one component of a large randomized trial 
comparing ionic high-osmolar to nonionic low-osmolar contrast 
( 15,16). The trial was performed over the three years prior to 
February 1991 at a university based tertiary referral centre. 
Patients having cardiac catheterization, intravenous pyelography., 
or CT scanning with contrast were eligible. All subjects entered 
in the trial had their serum creatinine measured within 24 hours 
prior to contrast administration and, if this exceeded 120 ~ol/1, 
were included in the study of nephrotoxicity. The protocol included 
repeated measurement of serum creatinine in all such subjects at 
I 
48 to 72 hours after contrast. 
The subjects were stratified into those having cardiac 
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angiography and those having intravenous contrast before 
randomization. No attempt was made to stratify for other factors 
related to nephrotoxicity. 
Some subjects were excluded from the randomized trial (15,16). 
No subject was excluded because of a perceived risk of 
nephrotoxicity. To all ow recognition of bias we followed all 
subjects irrespective of randomization status. Table 1 shows the 
number of subjects who were eligible fo·r entry to this portion of 
the study, along with the number of subjects who had a second 
measurement of serum creatinine after contrast. 
Many subjects were outpatients and were not seen by a 
nephrologist prior to contrast. No routine prophylactic measures 
against nephrotoxic! ty were employed before or after imaging. 
Before randomization, details of demographic, clinical (including 
any renal or cardiac disease and diabetes mellitus), and medication 
history were recorded by the research nurse. Subjects who had a 50 
percent or greater rise in serum creatinine were seen by a 
nephrologist after imaging. The medical records of all subjects 
with at least a 25 percent increase in serum creatinine were 
reviewed by a nephrologist, blind to the contrast administered, to 
determine whether contrast was likely to have caused the increase. 
Outcomes: 
Serum creatinine was measured by autoanalyser in several 
different laboratories, as outpatient subjects attended their local 
' 
hospitals for follow-up. We defined a case of contrast nephropathy 
as the unexplained occurrence of a 25 percent or greater increment 
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in serum creatinine at 48 hour~ after contrast. We also report more 
severe degrees of deterioration in renal function. To facilitate 
comparison with other studies ( 12,14), we report the number who had 
a rise of at least 44 pmol/1 in serum creatinine, and the mean 
change in serum creatinine after each type of contrast. 
Statistics and sample size: 
Incidence rates, means and standard deviations, medians and 
ranges are used as appropriate to describe the data. The frequency 
of events in the groups receiving high- and low-osmolar contrast 
was compared by Chi-squared tests or Fisher's exact tests for 2 by 
2 tables. Means were compared by t-tests for unpaired data, while 
medians were compared by Mann-Whi tney-U t .ests. We used a 1 tai 1 ed 
Q of 0.05 to declare significance and we report one tailed 95 
percent confidence intervals for differences between the randomized 
groups. We used multiple logistic (BMDP LR program, 1988) and 
multiple linear regression (SPSS-X, 1988) models to examine, and 
adjust for, the effect of covariates on the outcomes. Crossovers 
were handled by intention-to-treat analysis, but only one 
randomized subject received both types of contrast and had a 
subsequent rise in serum creatinine. 
Before the study we estimated that the incidence of a 25 
percent rise in serum creatinine after high-osmolar contrast would 
be 10 percent (2). To detect a 50 percent reduction in this 
incidence with low-osmolar contrast, with a 1 tailed Q of 0.05 and 
a ~ of 0.2, we required to randomly assign 332 subjects to each 
type of contrast. However, enrollment in this component of the 
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study was stopped when the objectives of the two associated trials 
were achieved {15,16). Although the size of the sample that could 
be analysed was less than anticipated, and thus prone to type II 
error, we felt that the data collected on these 366 subjects with 
renal impairment should be reported now. 
RESULTS 
Baseline comparison: 
Table 2 shows the baseline characteristics of the randomized 
subjects who had a measurement of serum creatinine after contrast. 
By chance more diabetics were given low-osmolar contrast, while 
cardiac angiography was the investigation performed in a greater 
proportion of those given high-osmolar contrast. 
Table 3 shows the same profile of baseline characteristics for 
the subjects who were not entered in the randomized trial, but who 
did have a second determination of serum creatinine. In the early 
part of our study infusable low-osmolar contrast was not available 
for CT of the body (16). These patients were more likely to have 
diseases associated with renal impairment. The profile of the 
subjects who had low-osmolar contrast reflects the fact that a 
majority had severe cardiac disease and had cardiac angiography. 
Therefore it is not surprising that both groups had higher serum 
creatinine levels than the corresponding randomized groups. 
We examined the characteristics of those subjects who failed 
to have a second serum creatinine determination. In the randomized 
study these subjects differed from those having follow up in that 
a greater proportion had intravenous contrast (76.2 percent), and 
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were outpatients, while a lesser proportion (7.1 percent) had a 
serum creatinine greater than 200 ~ol/1. 
Outcome of the trial: 
The difference between the two randomized groups, in terms of 
any of the outcome events, failed to reach statistical significance 
(Table 4). Although the incidence of minor changes in renal 
function after contrast was greater in the subjects who were not 
randomized, more severe acute renal failure was not significantly 
more common in these subjects (Table 4). 
Following review of the records, it was felt that contrast was 
unlikely to have been responsible for the 25 percent rise in serum 
creatinine after contrast in one subject randomized to high-
osmolar contrast, in two subjects nonrandomly receiving high-
osmolar contrast, and in one subject nonrandomly given low-osmolar 
contrast. When these cases were excluded, the incidence of a 25 
percent increment in creatinine was 6 percent (95 percent CI 2.4-
11.9) in those randomized to high-osmolar, and 3.8 percent (95 
percent CI 1.2-8.6) in those randomized to low-osmolar contrast. 
The corresponding figures for the non-randomized groups were 18.6 
percent {95 percent CI 8.4-33.4) with high-osmolar and 9.5 percent 
(95 percent CI 3.9-18.5) with low-osmolar contrast. 
The mean change in serum creatinine by 48 to 72 hours after 
contrast was 3.5 pmol/1 in those randomized to high-osmolar and 
-1.5 pmol/1 in those randomized to low-osmolar contrast (95 percent 
confidence interval [CI] for the difference -6.1 to 16.1). The 
corresponding figures for . the non-randomized groups were 17 pmol/1 
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in the high-osmolar and 4 pmol/1 in the low-osmolar group. Because 
serum creatinine is not linearly related to glomerular filtration 
rate, we also compared the response to the two types of contrast 
after inverse and 1 ogari thmic transformation of the data. This 
analysis also failed to reveal · any statistically significant 
difference between the high- and low-osmolar media. 
Multivariate analysis of the effect of contrast: 
Given the lack of statistically significant benefit with low-
osmolar contrast, and the difference in the randomized groups at 
baseline which might have contributed to this situation, we 
analysed the randomized subjects by multiple 1 inear regression 
analysis. The change in serum creatinine after contrast served as 
the dependant. The independent variables used were the type and 
route of administration of contrast, presence of diabetes, and the 
pre-contrast serum creatinine. The type of contrast did not not 
significantly predict the change in serum creatinine in these 
models. 
Risk factors for contrast nephropathy: 
In order to identify factors which might predispose to 
contrast nephropathy and to examine the effect of low-osmolar 
contrast in various risk groups we stratified the randomized 
subjects into four groups: those with a pre-contrast serum 
creatinine between 120 and 200 pmol/1 with and without diabetes, 
and those with a pre-contrast serum creatinine greater than 200 
pmol/1 with and without diabetes. The incidence of contrast 
nephropathy, as defined by a 25 percent increment in serum 
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creatinine after high- or 1 ow-osmolar contrast, in each of the 
strata is shown in table 5. These results suggest that those with 
more severe renal impairment, especially when due to diabetic 
nephropathy, are at the highest risk of contrast nephropathy. There 
is not a consistent trend to a lower incidence of contrast 
nephropathy with low-osmolar contrast across the strata but the 
lower incidence with low-osmolar contrast in the group with 
advanced diabetic nephropathy is interesting given the results of 
another recent trial (14). 
When the data for all subjects, irrespective of randomization 
or type of contrast prescribed, was stratified and analysed in the 
same fashion as for the randomized patients the results suggested 
even more strongly that the degree of renal impairment, especially 
in diabetics, is predictive of the risk for contrast nephropathy. 
The serum creatinine rose by more than 25 percent after contrast 
in 16 of 266 ( 6 percent) with a serum creatinine 1 ess than 200 
pmol/1 without diabetes, in 4 of 36 (11 percent) diabetics with a 
serum creatinine less than 200 pmol/1, in 8 of 48 (16.7 percent} 
of those with a serum creatinine greater than 200 pmol/1 without 
diabetes, and in 5 of 15 (33.3 percent) diabetics with a serum 
creatinine greater than 200 pmol/1. 
In a series of multiple linear and logistic regression models 
the only variables which were statistically significantly 
associated with a rise in serum creatinine after contrast were the 
severity of the pre-existing renal impairment and the presence of 
diabetes. In these models the type, volume, and route of 
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administration of contrast did not add to the prediction of 
contrast nephropathy. 
DISCUSSION 
This study shows that the level of renal impairment, 
especially in diabetic patients is the most significant predictor ) 
of contrast nephropathy and that the incidence of clinically severe 
contrast nephropathy (greater than 50 percent rise in serum 
creatinine) is low whether high- or low-osmolar contrast is 
prescribed. 
The randomized study failed to confirm a clinically important 
role for low-osmolar contrast in prevention of contras: nephropathy 
in subjects with renal impairment. This is compatible with the 
results of an earlier study which largely examined subjects with 
normal renal function (12). However, as the overall incidence of 
contrast nephropathy was lower than we had predicted, this study 
does not have sufficient power to exclude a 50 percent reduction 
in the incidence of contrast nephropathy, as assessed by any 
outcome, with low-osmolar contrast. Given the results, we would 
have required a sample size of over 1300 subjects per group to 
exclude such a benefit, using a rise of 25 percent in serum 
creatinine to diagnose a case of contrast nephropathy (17). The 
study did have a power of greater than 0. 8 to detect a true 
difference of at least 10 pmol/1 in the change in serum creatinine 
after contrast between high- and low-osmolar media, and no such 
, 
difference was found. This is contrary to the findings of another 
recent trial (14). 
256 
Although the data suggest that low-osmolar media may have some 
benefit, we cannot conclude that low-osmolar contrast prevents 
contrast nephropathy in subjects with impaired renal function. If 
the point estimates of incidence in our randomized trial are 
correct one would need to treat 53 subjects of the type in our 
randomized trial with low-osmolar contrast at a marginal cost of 
Can $4770 to prevent one case having a 50 percent rise in serum 
creatinine after contrast. If low-osmolar contrast was reserved for 
those with a pre-contrast serum creatinine of greater than 200 
~ol/1 with or without diabetes one would only need to treat 8 such 
subjects at a marginal cost of Can $720 to prevent one such event. 
It is of interest that the incidence of contrast nephropathy 
was low in our subjects who did not receive any prophylactic 
treatment. In fact, our results are similar to those of others who 
employed a prophylactic fluid loading regimen (12). While avoidance 
of dehydration is desirable the benefits of intentional fluid 
loading or any other prophylactic measure need to be established 
by adequate randomized controlled trials before routine use can be 
reconvnended. 
We chose to use serum creatinine to measure outcome, even 
though it is an insensitive measure of renal function, as it has 
the advantages of being easy to measure and of being able to detect 
clinically important changes in renal · function. Others have used 
enzy~uria to compare the nephrotoxicity of high- and low-osmolar 
I 
contrast, but the results have not been consistent and were often 
of dubious clinical relevance (7-11). 
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We conclude that the incidence of clinically important 
contrast nephropathy is low after both high and low-osmolar 
contrast media in subjects with moderate pre-existing renal 
impairment. Larger studies will be required to define the precise 
role of low-osmolar media for prevention of contrast nephropathy 
in subjects with more severe impairment of renal function. Since 
those with diabetic nephropathy seem to be at greatest risk (13), 
it would make most sense to conduct any further trials in such 
patients. 
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REFERENCES 
1. Barrett BJ, Parfrey PS. Clinical aspects of acute renal failure 
following use of radiocontrast agents . In: Solez K, Racusen LC. 
Eds. Acute renal failure: diagnosis, treatment, and prevention. 
Marcel Dekker Inc. New York, 1991:481-500. 
2. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers 
J, Farid N, McManamon P. Radiocontrast induced renal failure 
in diabetes mellitus and in patients with pre-existing renal 
failure: a prospective controlled study. N Engl J Med 
1989;320:143-9. 
3. Cramer BC, Parfrey PS, Hutchinson TA M et al. Renal function 
following infusion of radiologic con t rast material: a 
prospective controlled study. Arch I n t ern Med 1985;145:87-9. 
4. Vaamonde CA, Bier RT, Papendick R, Al pert H, Gouvea W, Owens 
B, Pardo V. Acute and chronic renal effects of radiocontrast 
in diabetic rats: role of anesthesia and risk factors. Invest 
Radiol 1989;24:206-18. 
5. Katzberq RW. What do we really know about contrast medium-
induced acute renal failure? Invest Radiol 1989;24:219-20. 
6. Vari RC, Natarajan LA, Whitescarver SA, Jackson BA, Ott CE. 
Induction, prevention and mechanisms o f contrast media-induced 
acute renal failure. Kidney Int 1988; 33:699-707. 
7. Tornquist C, Holtas S. Renal angiogra phy with iohexol and 
metrizoate. Radiology 1984;150:331-4. 
' 
8. Cavaliere G, Arrigo G, D'Amico G, Ber nasconi P, Schiavina G, 
Dellafiore L, Vernaghi D. Tubular nep rotoxicity after 
259 
intravenous urography with ionic high-osmolal and nonionic low-
osmolal contrast media in patients with chronic renal 
insufficiency. Nephron 1987;46:128-33. 
9. Skovgaard N, Holm J, Hemmingsen L, Skaarup P. Urinary protein 
excretion following intravenously administered ionic and non-
ionic contrast media in man. Acta Radiologica 1989;30:517-9. 
10. Gale ME, Robbins AH, Hamburger RJ, Widrich WC. Renal toxicity 
of contrast agents: iopamidol, iothalamate, and diatrizoate. 
AJR 1984;142:333-5. 
11. Donadio C, Tramonti G, Giordani R, Lucchetti A, Calderazzi A, 
Sbragia P, Bianchi C. Effects of contrast media on renal 
hemodynamics and tubular function: comparison between 
diatrizoate and iopamidol. Adv Exp Med Bioi 1989;252:257-64. 
12. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, 
Skelton TN, Bashore TN. Contrast nephrotoxicity: a randomized 
controlled trial of a nonionic and an ionic radiographic 
contrast agent. N Engl J Med 1989;320:149-53. 
13. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy 
in azotemic diabetic patients undergoing coronary angiography. 
Am J Med 1990;89:615-20. 
14. Taliercio CP, Vlietstra RE, Ilstrup DM, et al. A randomized 
comparison of the nephrotoxicity of iopamidol and diatrizoate 
in high risk patients undergoing cardiac angiography. JACC 
1991;17:384~90. 
15. Barrett BJ, .Parfrey PS, Vavasour HM, O'Dea F, Kent G, Stone E. 
A comparison of nonionic low-osmolar with ionic high-osmolar 
radiocontrast agents during cardiac catheterization. 
(submitted}. 
260 
16. Barrett BJ, Parfrey PS, McDonald J, Hefferton D, Reddy R, 
McManamon P. A randomized trial of nonionic low-osmolar versus 
ionic high-osmolar radiocontrast for intravenous use in 
patients perceived to be at high risk. (submitted}. 
17. Detsky AS, Sackett DL. When was a 'negative' clinical trial big 
enough? Arch Intern Med 1985;145:709-712. 
261 
TABLE 1. Patients with pre-contrast serum creatinine greater than 
120 ~ol/1 who underwent cardiac angiography or had a 
procedure requiring intravenous contrast. 
Randomized 
Cardiac 
Eligible 153 
Serum creatinine 123 
repeated after (80%) 
contrast 
IV 
222 
126 
Total 
375 
249 
(57\) {66\) 
Non-randomized 
Cardiac 
57 
50 
(88%) 
IV 
105 
67 
Total 
162 
117 
(64%) (72\) 
,. 
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TABLE 2. Baseline comparison of the randomized groups with post-
contrast serum creatinine avai 1 able. . 
High-osmolar 
Total: N=117 \ 
Male 99 86.6 
Diabetic 12 10.3 
Creatinine > 200 pmol/1 17 14.5 
History of cardiac failure 18 15.4 
Hypertensive 61 52.1 
Bed bound in hospital 11 9.4 
ACE inhibitor 13 11.1 
Calcium channel blocker 49 41.9 
Nonsteroidal 15 12.8 
anti-inflammatory 
Diuretic 
. 
Type of investigation: 
Cardiac catheterization 
Intravenous pyel ogram 
Computed tomography 
Age (years} 
Systolic blood 
pressure (mmBg} 
Diastolic blood 
pressure (nunBg} 
30 25.6 
64 54.7 
19 16.2 
34 29.1 
Mean ± SO 
64.3 ± 10.7 
140.6 ± 26.5 
75.9 ± 12.1 
Low-osmolar 
N=132 \ 
92 69.7 
24 18.2 
18 13.6 
20 15.2 
77 58.3 
14 10. 6 
15 11.4 
48 36.4 
15 11.4 
31 23.5 
59 44.7 
34 25.8 
39 29.5 
Mean ± SD 
64.0 ± 12.3 
142.8 ± 23.6 
78.2 ± 13.0 
• 
TABLE 2. continued. 
High-osmolar 
Median (range) 
Serum creatinine (pmol/1) 138 (120-685) 
Serum urea (mmol/1) 9.8 (4-47) 
Contrast volume (rnls) 120 {50-400} 
r 
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Low-osmolar 
Median (range) 
138 (120-572) 
9.9 (4.7-44) 
100 {40-400) 
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TABLE 3. Baseline characteristics of the non-randomized groups with 
post-contrast serum creatinine available. 
High-osmolar Low-osmolar 
Total: N=43 
Male 36 
Diabetic 4 
Creatinine > 200 pmol/1 13 
History of cardiac failure 8 
Hypertensive 20 
Bed bound in hospital 5 
ACE inhibitor 3 
Calcium channel blocker 5 
Nonsteroidal 9 
anti-inflammatory 
Diuretic 13 
Type of investigation: 
Cardiac catheterization 1 
Intravenous pyelogram 2 
Computed tomography 40 
Mean 
Age (years) 66.4 
Systolic blood 136.0 
pressure (mmHg) 
\ 
83.7 
9.3 
30.2 
18.6 
46.5 
11.6 
7.0 
11.6 
20.9 
30.2 
2.3 
4.6 
93.1 
± SD 
± 11.4 
± 20.1 
Diastolic blood 
pressure (mmHg) 
79.0 ± 11.7 
N=74 
47 
11 
15 
25 
51 
22 
12 
32 
10 
29 
49 
9 
16 
Mean 
67.0 
142.0 
\ 
63.5 
14.9 
20.2 
33.8 
68.9 
29.7 
16.2 
43.2 
13.5 
39.2 
66.2 
12.2 
21.6 
± SD 
± 11.8 
± 29.5 
75.0 ± 15.3 
~ ,, 
TABLE 3. continued. 
High-osmolar 
Median (range) 
Serum creatinine (pmol/1) 159 (120-502) 
Serum urea (mmol/1) 11.8 (6-32) 
Contrast volume (mls) 300 (50-400) 
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Low-osmolar 
Median (range) 
141 (120-654) 
10.3 (5-66) 
122.5 (45-400) 
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TABLE 4. The incidence of outcome events in the trial before 
removal of cases where contrast was not felt to be the 
cause of the acute renal failure. 
Randomized subjects: 
High-osmolar Low-osmolar 95\ CI For The 
N = 117 \ N = 132 \ Reduction With 
Low-osmolar (\) 
Scr rise of ~ 25\ 8 6.8 5 3.8 3.0 to 7.8 
Scr rise of ~ 50\ 4 3.4 2 1.5 1.9 to 5.2 
Scr rise of ~ 44 J.lmOl/1 7 6.0 7 5.3 0.7 to 5.6 
Dialysis required 1 0.8 0 0.8 to 2.1 
Non-randomized subjects: 
High-osmolar Low-osmolar 
N = 43 \ N = 74 \ 
Scr rise of ~ 25\ 10 23.3 8 10.8 
Scr rise of ~ 50\ 2 4.7 3 4.1 
Scr rise of ~ 44 pmol/1 7 16.3 8 10.8 
Dialysis required 0 2 2.7 
Scr = serum creatinine. Note that the 95 percent confidence 
intervals for the differences between the randomized groups are one 
tailed. 
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TABLE 5. The incidence of a 25 percent rise in serum creatinine 
with high- or low-osmolar contrast in the randomized 
trial after stratification by serum creatinine and the 
presence of diabetes mellitus. 
Stratum High-osmolar Low-osmolar 
N \ N \ 
Nondiabetic with serum 3/91 3.3 1/97 1.0 
creatinine < 200 pmol/1 
Diabetic with serum 0/18 2/17 11.8 
creatinine < 200 pmo1/1 
Nondiabetic with serum 1/13 7.6 1/11 9.1 
creatinine > 200 pmol/1 
Diabetic with serum 3/4 75.0 1/7 14.3 
creatinine > 200 pmo1/1 
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CONSENT TO PARTICIPATE IN BIOMEDICAL RESEAROi 
TITI.E: The side effects of 
contrast medt um 
non-tonic compared to tonic 
INVESTIGATORS: Dr.'s Parfrey, P. McManamon, E. Stone 
You are going to have an Imaging procedure which requires injection of 
contrast material Into your blood vessels. You are being asked to 
participate In a research trial of 2 different types of constrast 
material. Participation In this study Is entirely voluntary. You may 
decide not to participate or may withdraw from the study at any time 
without affecting your normal treatment. 
Confidentiality of Information concerning participants wll I be maintained 
by the Investigators. An Investigator wt I I be available during the study 
at I times should you have any problems or questions about the study. 
1. Purpose of study: To determine whether the non-Ionic contrast 
medium Is safer than the usually prescribed Ionic contrast material. 
2. Description of procedures and tests: You wt I I be given either non-
Ionic or Ionic contrast and neither you or your doctor wll I be 
aware which one It Is. You wl I I complete a short questionnaire 
before and after your test. At the time a needle Is Inserted to 
give the contrast, a blood test may be taken and this wl I I be 
repeated 2 days later, If the Initial test shows abnormal kidney 
function. 
3. Duration of subjects participation: Ten minutes before and thirty 
minutes Immediately after your Imaging test, and 5 minutes 2 days 
later. 
4. Foreseeable risks, discomforts, or Inconveniences: As the first 
blood sample wit I be taken at the time a needle Is Inserted to give 
contrast, no extra discomforts should arise other than those usually 
associated with having the Imaging test. The new contrast medium Is 
likely to be at least as safe than the regularly used medium. If 
your Jntttal blood test shows abnormal kidney function than a 
second blood sample wll I be taken 2 days after your Imaging test 
and may leave a smal I bruise. 
5. Benefits which the subject may receive: The new non-tonic contrast 
may produce less discomfort than the regularly used tonic contrast. 
6. Alternative procedures or treatment for those not entering the 
study: Your Imaging test wit I be undertaken using the regularly 
used ,Jontc contrast. 
7. Any other relevant Information: As the newer medium Is 10-15 times 
more expensive we want to be sure that It wit I be safer than the 
regularly used Ionic contrast. 
I , 
--------------------------------------' the undersigned, agree to 
(my child's, relative's or ward's·---------------------------------
participation In the research study described above. 
I acknowledge that a copy of this form has been offered to me. 
understand that there Is no guarantee that participation wl I I be 
beneficial. 
(Signature of Participant) <Date) 
(Signature of Witness, optional) 
To be signed by lnyestlgator; 
To the best of my ability I have fully explained to the subject the 
nature of this research study. I have Invited questions and provided 
answers. I believe that the subject fully understand the Implications 
and voluntary nature of the study. 
(Signature of Investigator) <Date) 
If appropriate: 
(Signature of Minor Participant> 
Relationship to participant named above------------------------------
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